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Background: Advances in neuroscience have led to a deeper understanding of 
the neuro-circuitry associated with eating disorders (ED). There is however, a 
lack of brain-directed treatment options. Neuromodulatory techniques have 
therapeutic efficacy in other psychiatric disorders and evidence in ED is 
promising. There is a need for further studies of neuromodulation in ED, to 
probe disease mechanisms and to develop novel treatments. The aim of this 
research is to explore the use of neuromodulation in ED and specifically assess 
the utility of repetitive transcranial magnetic stimulation (rTMS) in anorexia 
nervosa (AN).  
Methods: An overview of ED and their neurocircuitry underpinnings is 
presented. A systematic review of the literature regarding the effects of 
neuromodulation on eating related outcomes was also conducted. The effects of 
neuronavigated (MRI-guided) rTMS in AN is explored in a single-session 
randomised control trial (RCT) and in a 20-session therapeutic case series.  
Results: The systematic review supports further research on neuromodulation 
in ED. The single-session RCT of real versus sham rTMS in 51 individuals with 
AN demonstrated that following real rTMS, individuals report reduced AN 
symptoms and an increased liking of specific foods. Real/sham rTMS did not 
alter salivary cortisol concentrations and levels of cortical excitability were 
associated with AN symptomatology. Lastly, rTMS proved to be safe, tolerable 
and acceptable in people with AN. A neurocognitive measure of intertemporal 
choice showed that rTMS encourages prudent decision making in AN: this may 
underlie the effects of rTMS on AN symptoms. Whilst a therapeutic case series 
of five individuals with enduring AN did not lead to weight gain, significant 
improvements in ED and general psychopathology were reported and 
sustained.  
Conclusions: rTMS has the ability to improve core symptomatology in AN and 
alter decision making processes. Therefore, neuromodulation may be a viable 
treatment adjunct for people with an ED.  
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MRI magnetic resonance imaging 
PFC prefrontal cortex 
RCT randomised control trial 
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SD standard deviation 
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TD/DD temporal/delay discounting 
tDCS transcranial direct current stimulation 
VAS visual analogue scale 
VNS vagus nerve stimulation 
 5 
Table of contents 
Abstract ................................................................................................................................ 2 
Acknowledgments............................................................................................................. 3 
Abbreviations used throughout the thesis ............................................................... 4 
Table of contents ............................................................................................................... 5 
List of tables ........................................................................................................................ 8 
List of figures ................................................................................................................... 10 
Papers associated with thesis .................................................................................... 12 
Conference and research presentations associated with thesis ................... 13 
Declaration of candidate’s role ................................................................................. 14 
Chapter 1. General introduction ............................................................................ 16 
Eating disorders: an overview ................................................................................................ 17 
Eating disorders and the brain ............................................................................................... 28 
The neurocircuitry of eating disorders ............................................................................... 37 
Neuromodulation techniques ................................................................................................. 44 
Summary ......................................................................................................................................... 47 
Aims and hypotheses .................................................................................................... 47 
Thesis map ........................................................................................................................ 48 
Chapter 2. A systematic review of the effects of neuromodulation on 
eating and body weight; evidence from human and animal studies............ 50 
Introduction ................................................................................................................................... 51 
Methods ........................................................................................................................................... 52 
Results .............................................................................................................................................. 54 
Discussion ....................................................................................................................................... 61 
Chapter 3. A randomised single-session sham-controlled trial of 
repetitive transcranial magnetic stimulation in anorexia nervosa ............. 83 
Introduction ................................................................................................................................... 84 
Chapter 3.1 Repetitive Transcranial Magnetic Stimulation ............................ 86 
Mechanisms ................................................................................................................................... 87 
Terminology .................................................................................................................................. 89 
The use of repetitive transcranial magnetic stimulation within psychiatry ........ 93 
 6 
Chapter 3.2 Outline of the study ............................................................................... 94 
Participants .................................................................................................................................... 94 
Randomisation and blinding ................................................................................................... 95 
Protocol ........................................................................................................................................... 97 
Procedures ...................................................................................................................................100 
Chapter 3.3 The effect of repetitive transcranial magnetic stimulation on 




Chapter 3.4 The effects of repetitive transcranial magnetic stimulation on 




Chapter 3.5 The effects of repetitive transcranial magnetic stimulation on 








Chapter 3.7 Cardiac safety, tolerability and acceptability of repetitive 




Chapter 3.8 Overall Summary .................................................................................. 172 
Chapter 4. The effects of repetitive transcranial magnetic stimulation on 






Chapter 5. A therapeutic case series of repetitive transcranial magnetic 





Chapter 6. General overview ................................................................................ 229 
Hypotheses tested .....................................................................................................................230 
Summary of findings ................................................................................................................230 
Strengths .......................................................................................................................................232 
Limitations ...................................................................................................................................232 
Implications of this research .................................................................................................235 
Directions for future research and clinical implications ............................................238 
Conclusions ..................................................................................................................................240 
References ...................................................................................................................... 241 
Appendices ..................................................................................................................... 287 
List of Appendices .....................................................................................................................288 
 8 
List of tables 
Table 1.1 Common neuromodulation techniques........................................................... 44 
Table 2.1 Neuromodulation studies in healthy participants and people with 
frequent food cravings ............................................................................................................... 68 
Table 2.2 Neuromodulation studies in people with bulimia nervosa and in obese 
individuals ...................................................................................................................................... 70 
Table 2.3 Neuromodulation studies in people with anorexia nervosa ................... 72 
Table 2.4 Neuromodulation studies assessing eating behaviours and/or body 
weight in other psychiatric and neurological disorders .............................................. 74 
Table 2.5 Neuromodulation studies assessing food intake and/or weight in 
animals ............................................................................................................................................. 77 
Table 3.1 Study protocol for the RCT of rTMS in AN. .................................................... 98 
Table 3.2 Baseline characteristics; demographic information, psychiatric history 
and current psychopathology. Mean ± SD reported ....................................................112 
Table 3.3 Composite outcomes and individual VAS before and after the first FCT.  
Mean ± SD reported. .................................................................................................................115 
Table 3.4 Mixed ANOVA results of the composite outcomes following real/sham 
rTMS. Mean ± SD reported. ....................................................................................................117 
Table 3.5 Mixed ANOVA results of the ‘initial’ VAS following real/sham rTMS. 
Mean ± SD reported. .................................................................................................................118 
Table 3.6 Mixed ANOVA results of the ‘additional’ VAS following real/sham 
rTMS.  Mean ± SD reported. ...................................................................................................120 
Table 3.7  Mixed ANOVA results of the composite ‘liking of food’ outcomes 
following real/sham rTMS. Mean ± SD reported. ..........................................................136 
Table 3.8 Mixed ANOVA results of the ‘appearance’ of each food type following 
real/sham rTMS.  Mean ± SD reported. .............................................................................137 
Table 3.9 Mixed ANOVA results of the perceived ‘smell’ of each food type 
following real/sham rTMS.  Mean ± SD reported..........................................................138 
 9 
Table 3.10 Mixed ANOVA results of the perceived ‘taste’ of each food type 
following real/sham rTMS. Mean ± SD reported. ..........................................................139 
Table 3.11 Mixed ANOVA results of the ‘urge to eat’ each food type following 
real/sham rTMS. Mean ± SD reported. ..............................................................................140 
Table 3.12 Techniques used to measure cortical inhibition and excitability. ....155 
Table 3.13 Mixed ANOVA results of blood pressure and pulse following 
real/sham rTMS. Mean ± SD reported. ..............................................................................168 
Table 4.1 Studies investigating temporal discounting in relation to disordered 
eating ..............................................................................................................................................179 
Table 4.2 Studies investigating the effects of neuromodulation on temporal 
discounting ...................................................................................................................................186 
Table 5.1 Protocol for the 20 rTMS sessions and follow-ups ...................................208 
Table 5.2 Timeline for the 20 rTMS sessions and follow-ups. .................................212 
Table 5.3 Demographic and clinical information for each participant prior to 20 
rTMS sessions. ............................................................................................................................212 
Table 5.4 Individual weight, BMI, EDE-Q global and DASS-21 total scores. .......218 




List of figures 
Figure 1.1 Brain areas implicated in eating disorders .................................................. 39 
Figure 1.2 A schematic representation of the underlying neurocircuitry of self-
regulation difficulties and resulting phenotypic behaviours in eating disorders
............................................................................................................................................................. 43 
Figure 2.1 PRISMA flow chart of literature search and reviewed studies ............. 54 
Figure 2.2 Brain areas targeted with neuromodulation in reviewed studies ...... 55 
Figure 3.1 Diagram of the (a) application and (b) magnetic fields of TMS ........... 88 
Figure 3.2 Examples of rTMS protocols .............................................................................. 90 
Figure 3.3 CONSORT diagram of recruitment and randomisation procedures .. 96 
Figure 3.4 Number of participants who correctly or incorrectly guessed 
stimulation type .........................................................................................................................123 
Figure 3.5 The frequency of researchers correctly or incorrectly guessing 
stimulation type allocated to participants .......................................................................123 
Figure 3.6 Amount of smoothie consumed after real/sham rTMS. Mean ± SD 
reported.........................................................................................................................................142 
Figure 3.7 Amount of food eaten during the 24 hours following real/sham rTMS. 
Mean ± SD reported. .................................................................................................................142 
Figure 3.8 Salivary cortisol concentrations for each of the real/sham group. 
Median ± IQR reported ............................................................................................................151 
Figure 3.9 Level of discomfort reported following real/sham rTMS. Mean ± SD 
reported.........................................................................................................................................169 
Figure 4.1 Schematic representation of temporal discounting and its 
measurement ..............................................................................................................................175 
Figure 4.2 Impaired interoceptive and reward processing in AN and the effects 
on short-term/long-term decision making .....................................................................189 
Figure 4.3 Calculation of area under the curve. .............................................................192 
 11 
Figure 4.4 Area under the curve pre and post real/sham rTMS. Mean + SD 
reported.........................................................................................................................................196 
Figure 4.5 Subjective value of reward over time pre and post real rTMS. ..........196 
Figure 4.6 Subjective value of reward over time pre and post sham rTMS ........197 
Figure 4.7 Area under the curve for each AN subtype pre and post real/sham 
rTMS. Mean + SD reported. ....................................................................................................197 
Figure 5.1 Levels of stress; mean VAS scores pre and post each rTMS session.
...........................................................................................................................................................213 
Figure 5.2 Urge to restrict; mean VAS scores pre and post each rTMS session.
...........................................................................................................................................................213 
Figure 5.3 Levels of anxiety; mean VAS scores pre and post each rTMS session.
...........................................................................................................................................................214 
Figure 5.4 Urge to exercise; mean VAS scores pre and post each rTMS session.
...........................................................................................................................................................214 
Figure 5.5 Levels of feeling full; mean VAS scores pre and post each rTMS 
session. ...........................................................................................................................................215 
Figure 5.6 Levels of feeling fat; mean VAS scores pre and post each rTMS 
session. ...........................................................................................................................................215 
Figure 5.7 Mean EDE-Q subscale scores pre and post the 20 rTMS sessions and 
at 1 and 6 month follow-up. ..................................................................................................220 
Figure 5.8 Mean DASS-21 subscale scores pre and post the 20 rTMS sessions 
and at 1 and 6 month follow-up ...........................................................................................220 
Figure 5.9 Area under the curve pre and post the 20 rTMS sessions for each 
participant. ...................................................................................................................................221 
Figure 6.1 An amended version of the figure presented in Chapter 1 that 
incorporates the findings from this research. ................................................................237 
 
 12 
Papers associated with thesis 
This paper forms the basis of Chapter 2:  
McClelland, J., Bozhilova, N., Campbell, I.C. & Schmidt, U. (2013). A systematic 
review of the effects of neuromodulation on eating and body weight: 
evidence from human and animal studies. European Eating Disorders 
Review, 21 (6), 436-455 (A copy of this paper is included in Appendix A.1). 
This paper forms the basis of Chapters 3 and 4:  
McClelland, J., Kekic, M., Bozhilova, N., Nestler, S., Van Den Eynde, F., David, A., 
Rubia, K., Campbell, I.C. & Schmidt, U. (submitted). A randomized 
controlled trial of neuronavigated repetitive transcranial magnetic 
stimulation in anorexia nervosa.  
These papers form the basis of Chapter 5:  
McClelland, J., Bozhilova, N., Nestler, S., Campbell, I.C., Jacob, S., Johnson-Sabine, 
E. & Schmidt, U. (2013) Improvements in symptoms following 
neuronavigated repetitive transcranial magnetic stimulation in severe and 
enduring anorexia nervosa; findings from two case studies. European 
Eating Disorders Review, 21 (6), 500-506. (A copy of this paper is included 
in Appendix A.2). 
McClelland, J., Kekic., M., Campbell, I.C. & Schmidt, U. (submitted). Therapeutic 
repetitive transcranial magnetic stimulation in five cases of enduring 
anorexia nervosa.  
  
 13 
Conference and research presentations associated with thesis 
Conference presentations: 
McClelland, J. (2015, accepted) A randomised single-session sham-controlled 
trial of neuronavigated repetitive transcranial magnetic stimulation in 
anorexia nervosa. Oral presentation at the International Conference on 
Eating Disorders (ICED) in Boston, U.S.A. 
McClelland, J. (2015, accepted) A therapeutic case series of neuronavigated 
repetitive transcranial magnetic stimulation in enduring anorexia nervosa. 
Oral presentation at the International Conference on Eating Disorders 
(ICED) in Boston, U.S.A.  
McClelland, J. (2014) Neuromodulation in eating disorders: where we are and 
where we are going. Oral presentation at the Eating Disorders 
International Conference (EDIC) in London, U.K. 
McClelland, J. (2013). A systematic review of the effects of neuromodulation on 
eating behaviour: Implications for brain directed treatments in eating 
disorders. Oral presentation at the Australia and New Zealand Academy 
for Eating Disorders (ANZAED) conference in Melbourne, Australia.  
McClelland, J. (2012). Transcranial magnetic stimulation in eating disorders. 
Oral presentation at the European conference for eating disorders in Lyon, 
France. 
Research presentations:  
The research included within this thesis has been presented at departmental 
meetings at the Institute of Psychiatry, Psychology and Neuroscience, King’s 
College London (chaired by Prof Ulrike Schmidt, Prof Janet Treasure and Prof 
Iain Campbell) and hospitals/clinical teams within London; e.g. the Phoenix 
Wing of St Ann’s Hospital, Tottenham and Chase Farm Hospital, Enfield. 
 14 
Declaration of candidate’s role 
Chapter 1: General introduction. 
All work is the candidate’s own. 
Chapter 2: A systematic review of the effects of neuromodulation on eating 
and body weight; evidence from human and animal studies 
The candidate was the main contributor to the development and process of the 
systematic review conducted on the potential of neuromodulation techniques 
for the treatment of ED. This work was done in close collaboration with an 
undergraduate student, Ms Natali Bozhilova who was on a one-year placement 
at the Section of Eating Disorders under the supervision of the candidate, Prof 
Schmidt and Prof Campbell.  
Chapter 3: A randomised single-session sham-controlled trial of repetitive 
transcranial magnetic stimulation in anorexia nervosa 
This study involved 51 people with AN. Recruitment, the administration of 
real/sham rTMS and data analysis was done by the candidate. The candidate 
was the main contributor to the data collection and data entry, in collaboration 
with Ms Natali Bozhilova. Due to the double blinded nature of the trial, three 
individuals were needed at each session – one to administer the rTMS 
(candidate), one to help with the rTMS neuronavigation equipment (primarily 
Mr Steffen Nestler) and one to do the pre- and post-assessments (primarily 
either Ms Natali Bozhilova or Ms Maria Kekic). Occasionally, other members of 
the Section of Eating Disorders assisted when the above-mentioned individuals 
were not available.  
 15 
Chapter 4: The effects of repetitive transcranial magnetic stimulation on 
temporal discounting in anorexia nervosa  
As the data for this study was collected within the RCT of Chapter 3, the role of 
the candidate is much the same as mentioned above. The administration of 
real/sham rTMS was done by the candidate, whilst the primary outcome – the 
administration of the temporal discounting (TD) task was done by the blinded 
researcher conducting the pre- and post-assessments (primarily Ms Natali 
Bozholiva or Ms Maria Kekic). Data entry and analysis was done by the 
candidate.  
Chapter 5: A therapeutic case series of repetitive transcranial magnetic 
stimulation in five cases of enduring anorexia nervosa 
This study involved the delivery of approximately twenty sessions of rTMS in 
five individuals with enduring forms of AN. Recruitment, data collection and 
analyses were done by the candidate. The candidate delivered all of the rTMS 
sessions and was assisted by one other person at each appointment. This was 
typically Ms Natali Bozhilova, Ms Maria Kekic or Mr Steffen Nestler.  
Chapter 6: General overview. 
All work is the candidate’s own. 
 16 
Chapter 1. General introduction 
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A recent initiative by The National Institute of Mental Health (NIMH) in the 
United States, the Research Domain Criteria, emphasises the importance of 
modern neuroscience tools in improving the diagnosis and treatment of 
psychiatric illnesses (Cuthbert, 2014; Insel et al., 2010). The growing 
understanding of eating disorders (ED) as brain-based mental illnesses 
supports the notion that research utilising neuroscience technologies will be of 
most use in elucidating the pathogenesis of disease and developing novel 
treatment approaches (Chavez & Insel, 2007; Schmidt & Campbell, 2013; van 
Elburg & Treasure, 2013).  
This chapter summarises the history, diagnoses, epidemiology, pathogenesis, 
and current treatment approaches to ED. Following this, a summary of current 
neuroscience data is presented leading to a neurocircuit model of ED. Finally, 
common neuromodulation techniques with the ability to alter cortical activity 
are introduced to provide an understanding of their relevance and potential 
within ED.  
Eating disorders: an overview 
History 
Cross-cultural descriptions of religious fasting, neurotic self-starvation and 
binge/purge behaviours date back to the medieval period (Bemporad, 1996; 
Keel & Klump, 2003; Miller & Pumariega, 2001). However, the first medically 
reported case of an ED was in 1689 when the physician Richard Morton 
described an 18-year old female with anorexic symptoms (Pearce, 2004). It was 
not until much later that Sir William Gull coined the term Anorexia Nervosa 
(AN) (Gull, 1874) and in 1979 that Prof. Gerald Russell first published a 
description of Bulimia Nervosa (BN) (Russell, 1979). By 1980 both AN and BN 
were diagnosable, psychiatric illnesses as defined in the third edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM; A.P.A, 1980). Since 
then, ED have become widely researched and more thoroughly understood as 
serious, debilitating psychiatric disorders with a large degree of heterogeneity.  
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Diagnostic criteria 
A number of diagnostic tools are employed in the classification, diagnosis and 
treatment of ED. The World Health Organisation’s International Statistical 
Classification of Disease and Related Health Problems (ICD-10) is an established 
diagnostic tool (WHO, 1992). However, despite criticisms for its symptom-based 
categorisation (Insel, 2013), the DSM is the most extensively used nomenclature 
by clinicians and researchers for psychiatric diagnoses. In May 2013, almost a 
decade after the fourth edition (A.P.A., 1994), the DSM-5 was published and 
included a number of important changes to the diagnosis of three distinct ED1 
(A.P.A., 2013). 
Characterised by significantly low weight and a disturbance in the perception of 
one’s body, the diagnosis of AN was marginally revised in DSM-5. Most notably, 
given the growing understanding that amenorrhea (a previous criterion of AN) 
reflects nutritional state rather than illness severity and that this diagnostic 
requirement is irrelevant in men and for females taking oral contraception, 
amenorrhea was removed as a diagnostic criterion for AN in DSM-5 (Attia & 
Roberto, 2009). Additionally, rigid terminology relating to the overt refusal of 
weight maintenance, and fear of weight gain were clarified in the fifth edition of 
DSM. The two previously defined subtypes of AN, restricting and binge-
eating/purging remain.   
Binge-eating episodes, recurrent compensatory behaviours (e.g. self-induced 
vomiting) and an undue influence of body weight/shape on self-evaluation 
characterises BN. In DSM-5, the frequency of binge/purge behaviours required 
to meet BN diagnosis was reduced from twice weekly, to once a week over the 
past three months. Similarly, this lower binge frequency threshold was also 
applied to Binge Eating Disorder (BED), in which binge-eating causes marked 
distress however is not associated with inappropriate compensatory 
behaviours. In DSM-IV, BED was not a formal diagnosis; rather it was mentioned 
                                                        
1 Four other DSM-5 feeding and ED categories are beyond the scope of this 
thesis; avoidant/restrictive food intake disorders, elimination disorder, pica and 
rumination disorder.  
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in the appendix as requiring further research. Recent evidence for the validity 
and clinical utility of BED (Wonderlich, Gordon, Mitchell, Crosby, & Engel, 2009) 
led to it being recognised as a separate diagnostic entity in DSM-5.  
By relaxing the criteria of AN and BN, and including BED as a separate diagnosis, 
the DSM-5 aims to reduce numbers in the most common DSM-IV category, 
Eating Disorders Not Otherwise Specified (EDNOS; Call, Walsh, & Attia, 2013). 
Reportedly the diagnosis for up to 60% of ED cases (Fairburn & Bohn, 2005), 
EDNOS was renamed Other Specified Feeding or Eating Disorders (OSFED) in 
DSM-5 and incorporates a number of smaller sub-diagnoses (Fairweather‐
Schmidt & Wade, 2014). For example, OSFED includes conditions that do not 
meet full criteria of other ED such as atypical AN (weight within normal range), 
sub-threshold BN (binge eating and compensatory behaviours occur less than 
once a week), purging disorder (recurrent purging behaviours occur in the 
absence of bingeing) and night eating syndrome (regular episode of night 
eating). These sub-diagnoses are more homogeneous than EDNOS and aim to 
provide greater clinical utility. Importantly, the ED differ from other psychiatric 
disorders in that diagnoses are relatively unstable. Diagnostic flux is common, 
supporting the notion of shared underlying mechanisms and trans-diagnostic 
models of ED (Eddy et al., 2008; Milos, Spindler, Schnyder, & Fairburn, 2005). 
Psychiatric comorbidity 
ED rarely occur in isolation, commonly having other psychiatric comorbidities. 
Approximately 80% of ED sufferers have at least one other psychiatric 
comorbidity, with depression, anxiety and substance misuse the most common 
diagnoses (Braun, Sunday, & Halmi, 1994; Hudson, Hiripi, Pope, & Kessler, 2007; 
von Lojewski, Boyd, Abraham, & Russell, 2012). Additionally, personality 
disorders (Rosenvinge, Martinussen, & Ostensen, 2000) and developmental 
disorders such as autism and attention-deficit hyperactive disorder (ADHD) are 
more prevalent in individuals with ED (Bleck & DeBate, 2013; Huke, Turk, 
Saeidi, Kent, & Morgan, 2013; Råstam et al., 2013). Whether or not ED typically 
precede other psychiatric conditions or are in fact subsequent comorbidities 
themselves requires further clarification. Similarly, it is difficult to establish the 
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time of onset of co-morbid personality and developmental disorders when these 
conditions are assessed in people with an ED.  
Epidemiology 
The majority of existing ED epidemiological research is based on the DSM-IV 
criteria and therefore primarily investigates AN or BN. Although future research 
utilising DSM-5 will complicate comparisons to the existing literature, it should 
provide more accurate representations of the incidence and prevalence rates of 
ED, including those of BED and OSFED.  
Incidence 
The term incidence refers to the number of new cases in a population in a given 
year. In their review Hoek and van Hoeken (2003) suggest incidence rates of 8 
and 12 cases per 100,000 persons per year for AN and BN respectively. More 
recent community studies report much higher incidence rates of AN and BN in 
adolescent groups (Smink, van Hoeken, & Hoek, 2012). Such community rates 
are typically much higher than those derived from medical settings, reflecting 
the large number of people who do not seek/or are unable to obtain treatment 
for their ED.  
Whilst some suggest that the incidence of ED is increasing (Eagles, Johnston, 
Hunter, Lobban, & Millar, 1995; Keel & Klump, 2003) others report stable rates 
(Hoek & van Hoeken, 2003). Specifically, the incidence of AN seems to be stable 
since the 1970s and whilst BN increased threefold between 1988 to 1993, rates 
have fallen since (Currin, Schmidt, Treasure, & Jick, 2005; Turnbull, Ward, 
Treasure, Jick, & Derby, 1996). In comparison there has been a rise in the 
diagnoses of EDNOS (Micali, Hagberg, Petersen, & Treasure, 2013). The 
incidence of ED is highest amongst adolescents (Smink et al., 2012) and varies 
enormously between the genders (Currin et al., 2005).  
Prevalence 
The number of cases in a population at any given time is referred to as the 
prevalence of a disorder. The lifetime prevalence, that is the proportion of 
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people who have had an ED at any point in their life, for AN, BN and BED (based 
on the DSM-IV) are estimated at 0.9%, 1.5%, 3.5% for women and 0.3%, 0.5% 
and 2.0% for men respectively (Hudson et al., 2007). A more recent review 
reports similar rates ranging from 1.2-2.2% in AN and 1-2.9% for BN (Smink et 
al., 2012). Despite only recently being recognised as a separate diagnostic entity, 
BED is reportedly more common than both AN and BN (Hay, Mond, Buttner, & 
Darby, 2008).  
Prognosis 
Evidence suggests that the onset of an ED during adolescence has a better 
prognosis than in adulthood (Fisher, 2003; Goddard et al., 2013). There is 
currently insufficient data to assess long-term outcomes of both EDNOS and 
BED (Ben-Tovim et al., 2001; Berkman, Lohr, & Bulik, 2007) whilst remission 
rates of around 70% at up to 10 years follow-up have been reported in BN (Ben-
Tovim et al., 2001; Keel, Mitchell, Miller, Davis, & Crow, 1999; Keski-Rahkonen 
et al., 2009). Outcomes for AN are the worst of the ED – less than half of 
sufferers recover, demonstrating either a full or partial ED at follow-up, whilst 
20% remain chronically ill (Goddard et al., 2013; Keski-Rahkonen et al., 2007; 
Steinhausen, 2009; Steinhausen, 2002).  
Mortality 
All ED have elevated mortality risks, with AN suggested to have the highest 
mortality rate of all psychiatric illnesses (Arcelus, Mitchell, Wales, & Nielsen, 
2011; Harris & Barraclough, 1998). In a longitudinal study, crude mortality 
rates of 4.0%, 3.9% and 5.2% were reported for AN, BN and EDNOS 
respectively. All-cause and suicide standardised mortality ratios (SMRs; ratio of 
observed to expected deaths) were also elevated across the ED and more so in 
BN and BED than had previously been reported (Crow et al., 2009). In 
comparison, a recent systematic review and meta-analysis identified overall 
SMRs of 5.86 for AN, 1.93 for BN and 1.92 for EDNOS (Arcelus et al., 2011). 
Mortality rates for the DSM-IV criteria EDNOS were identified as higher than 
those in AN by Crow et al. (2009) and equivalent to BN (Arcelus et al., 2011), 
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whilst a 12 year follow-up of inpatient BED patients yielded a mortality rate of 
2.9% (Fichter, Quadflieg, & Hedlund, 2008). 
Aetiopathogenesis 
As has been outlined, ED are prevalent, serious and life-threatening illnesses. 
Significant attempts have been made to identify factors that contribute to the 
onset and maintenance of ED. In their seminal paper, Jacobi, Hayward, De 
Zwaan, Kraemer, and Agras (2004) identified gender, ethnicity, early 
eating/gastrointestinal problems, body image concerns and adverse 
experiences as risk factors for ED. Evidently, a number of factors from within a 
biopsychosocial framework are pertinent to the aetiopathogenesis of ED.  
Psychological factors 
Early explanations of ED were predominantly psychologically grounded. 
Initially, psychodynamic theories suggested ED to be a defence mechanism 
against sexual desires (Freud, 1961), a mother-centric objection to normal 
female development (Palazzoli, 1974) or an attempt to gain psychological 
independence and control (Bruch, 1974). Later, family-wide systemic theories 
were proposed (Minuchin et al., 1975), however they lacked complete empirical 
validation (Kog, Vertommen, & Vandereycken, 1987; Strober & Humphrey, 
1987). More recently, research has diverged from familial theories of ED, and 
instead family collaboration is now seen as central in the successful treatment 
and recovery of ED in young people (Eisler, 1995).  
Cognitive behavioural models of ED have also been proposed. Whilst Garner and 
Bemis (1982) suggest that the overvaluation of weight and shape is a central 
maintaining factor of ED, the need for control (Slade, 1982), extreme dietary 
restraint (Polivy & Herman, 1985) and escape from negative affect (Heatherton 
& Baumeister, 1991) have also been implicated. Fairburn, Shafran, and Cooper 
(1999) incorporated these concepts into a CBT model of AN and later into a 
trans-diagnostic approach (Fairburn, Cooper, & Shafran, 2003). More recently, 
Schmidt and Treasure (2006) proposed a cognitive-interpersonal maintenance 
model of AN that is not culture-bound by the undue influence of weight and 
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shape concerns. Within such models, personality factors such as perfectionism 
(Bastiani, Rao, Weltzin, & Kaye, 1995) and obsessive-compulsive traits in AN 
(Anderluh, Tchanturia, Rabe-Hesketh, & Treasure, 2003), and impulsivity 
(Claes, Vandereycken, & Vertommen, 2002) or sensation-seeking (Rossier, 
Bolognini, Plancherel, & Halfon, 2000) in BN and BED (Cassin & von Ranson, 
2005) have also been proposed to drive ED.  
Sociocultural factors 
Despite being reported throughout medical history (Brumberg, 1988) and 
cross-culturally (Gordon, 2001; Keel & Klump, 2003) ED are often misconceived 
as a modern, sociocultural phenomenon. The ED cannot be explained by 
external factors alone, however a number of cultural, environmental and social 
factors have been proposed to contribute to their onset and maintenance. 
Contemporary western culture explicitly promotes female thinness and a lean, 
muscular physique in males; furthermore research suggests that these ideals 
are becoming increasingly unrealistic and unattainable (Pope, Olivardia, Gruber, 
& Borowiecki, 1999; Spitzer, Henderson, & Zivian, 1999). Exposure to media 
images of such body ideals has been linked to body dissatisfaction and 
depression (see reviews Groesz, Levine, & Murnen, 2002; Hausenblas et al., 
2013). Furthermore, groups of individuals where aesthetics and body weight is 
particularly important, such as dancers, gymnasts and models, and athletes in 
weight class sports such as rowing and boxing, demonstrate elevated body 
dissatisfaction and rates of ED (Arcelus, Witcomb, & Mitchell, 2014; Goltz, 
Stenzel, & Schneider, 2013).  
Peer and parental relationships influence dieting behaviours, body 
dissatisfaction and ED related symptoms in adolescents (Arcelus et al., 2014). 
Similarly, Stice (2002) identified that a family or personal history of obesity, 
along with weight, shape or eating related criticisms are risk factors for BN. 
However, whilst such evidence for the potency of cultural body ideals, sport-
specific pressures and social environments in the aetiopathogenesis of ED exist, 




The majority of biological research within ED has focused on the role of 
neurobiological dysfunctions (which will be discussed in depth later) and 
genetic predispositions. Familial aggregation and twin studies have contributed 
to understanding ED as complex, heritable and polygenic diseases (Jacobi et al., 
2004; Trace, Baker, Penas-Lledo, & Bulik, 2013). Heritability estimates range 
from 22-74% and 52-83% for broad AN and BN respectively, and one study 
reports BED heritability as 57% (Bulik, Sullivan, Wade, & Kendler, 2000; Javaras 
et al., 2008). Additionally, higher rates of psychiatric disorders in relatives of ED 
probands when compared to healthy controls (HC) have been reported 
(Lilenfeld et al., 1998; Lilenfeld, Ringham, Kalarchian, & Marcus, 2008; Smith, 
Brandt, & Jimerson, 1989). Given that first-degree relatives and twins typically 
share genetic and environmental elements, and adoption studies in ED are 
scarce, differentiating between genetic and environmental factors is inherently 
difficult.   
Two common approaches for elucidating genetic traits are pre-selecting a 
candidate gene based on evidence for its involvement in ED, and genome-wide 
screenings that aim to identify relevant genes with no priori hypotheses (see 
reviews Hinney & Volckmar, 2013; Jacobi et al., 2004; Trace, Baker, Peñas-Lledó, 
& Bulik, 2013). Candidate gene studies within ED have demonstrated the role of 
genes in serotonergic (Brewerton & Jimerson, 1996) and dopaminergic systems 
in AN (Bergen et al., 2005). The leptin gene has been implicated during weight 
fluctuations from acute to weight restored AN (Hebebrand et al., 1997), whilst 
brain derived neurotrophic factor (BDNF), essential for the growth and survival 
of neurones, has been implicated in restrictive AN (Ribasés et al., 2005). Also, 
early genome-wide association studies identified an association of chromosome 
1 in AN (Grice et al., 2002). Whilst these associations have been recently 
confirmed across the spectrum of ED, studies remain underpowered to reach 
genome wide significance levels (Boraska et al., 2012; Boraska et al., 2014; 
Wade et al., 2013; Wang, Zhang, et al., 2011). Larger, international 
collaborations and meta-analyses are needed to overcome this (Boraska et al., 
2014). 
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Gene-environment interactions and epigenetics  
Environmental and biological mechanisms, such as those previously mentioned, 
interact and are therefore often inseparable, particularly in the case of 
psychiatry. The presence of certain genetic traits vulnerable to influences from 
specific environmental factors, otherwise known as gene x environment (G x E) 
interactions, may increase the risk of developing an ED. For example, Karwautz 
et al. (2011) suggest evidence for an interaction between several environmental 
factors and the serotonin transporter gene in AN. Furthermore, early physical 
environmental effects have the ability to alter genetic expression via epigenetic 
processes. Although research into epigenetic mechanisms within ED is scarce, 
interactions involving stress during pregnancy, perinatal complications and 
nutrition (both over and under feeding) have been proposed to alter the risk of 
ED related behaviours via epigenetic processes (Campbell, Mill, Uher, & 
Schmidt, 2011; Pjetri, Schmidt, Kas, & Campbell, 2012).  
Current treatments 
Given their complicated aetiopathogenesis, optimal treatment choices for ED, in 
particular for AN, remain largely undetermined. The current NICE (2004) 
guidelines recommend guided self-help (GSH) programs and cognitive 
behavioural therapy (CBT) for adults with BN and BED, family based therapy 
(FBT) for adolescent AN, yet there is still no treatment of choice for adult AN 
(NICE, 2004; Watson & Bulik, 2012). Whilst talking therapies have been the 
most widely researched and disseminated within the field of ED, there is also 
some suggested value in drug therapies (Tortorella, Fabrazzo, Monteleone, 
Steardo, & Monteleone, 2014). The efficacy of existing psychological and 
pharmacological interventions are discussed below. 
Psychotherapy 
Transdiagnostic treatment approaches for ED have been developed by Fairburn 
et al. (2009). These comprise of two forms of CBT which address ED specific 
psychopathology, and broader, general domains such as affect, perfectionism, 
low self esteem and interpersonal skills. At 15 months follow-up, a 53% 
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reduction in ED symptoms in EDNOS and BN patients was reported following 
this approach (Fairburn et al., 2009).  
Other psychotherapies are designed for specific ED diagnoses. In adolescent BN, 
a more rapid reduction in bingeing behaviours occurred with CBT based GSH 
when compared to FBT (Schmidt et al., 2007) whilst FBT proved more effective 
than supportive psychotherapy (Le Grange, Crosby, Rathouz, & Leventhal, 
2007). In the case of adult BN, GSH has proven efficacy and given its low cost, is 
recommended as a first-line treatment approach (Banasiak, Paxton, & Hay, 
2005; Cooper, Coker, & Fleming, 1996). A number of studies have compared 
CBT to interpersonal therapy (IPT) and demonstrated a more rapid decrease in 
binge eating, vomiting and restraint and a greater chance of remission with CBT 
(Agras, Walsh, Fairburn, Wilson, & Kraemer, 2000; Fairburn et al., 1991). 
However, when comparing treatment approaches for BN at follow-up, CBT and 
IPT are equally effective (Hay, Bacaltchuk, Stefano, & Kashyap, 2009; Wilson, 
Grilo, & Vitousek, 2007). Moreover, CBT and IPT have similar efficacy in BED 
(Wilfley et al., 2002). Whilst an adapted form of CBT is recommended by NICE 
(2004) for BED, CBT based GSH has proved beneficial in BED and should also be 
considered as a first choice of treatment (Grilo & Masheb, 2005).   
Family based interventions have the strongest evidence base for the successful 
treatment and long-term outcome of adolescent AN (Eisler, Simic, Russell, & 
Dare, 2007; Lock, 2011; Lock, Couturier, & Agras, 2006; Robin et al., 1999; 
Strober, Morrell, Burroughs, Salkin, & Jacobs, 1985). There is no gold-standard, 
first-line treatment for adult AN and only a small number of randomised control 
trials (RCT) have compared the efficacy of different psychotherapies with mixed 
findings. Specialised supportive clinical management (SSCM) is reportely 
superior to both CBT and IPT (McIntosh et al., 2005). Whilst at 12 month follow-
up psychodynamic therapy was advantageous to both enhanced CBT and 
treatment as usual (TAU), however enhanced CBT demonstrates quicker rates 
of weight gain and ED psychopathology improvements (Zipfel et al., 2014). 
Recently, indifferences between SSCM to the Maudsley model of anorexia 
nervosa (MANTRA) have also been reported, however MANTRA is more 
acceptable than SSCM and works better in severe cases (Schmidt et al., 2012; 
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Schmidt et al., submitted). Similarly, SSCM and CBT-AN for severe and enduring 
AN have also been reported as similarly effective (Touyz et al., 2013).  
Such varied results add to the difficulty in determining an optimal treatment for 
adult AN; there is little evidence that differentiates treatments such as CBT, 
focal psychodynamic, SSCM and MANTRA from one another. Whilst novel 
approaches such as cognitive remediation therapy (CRT) have been trialled, the 
evidence for their efficacy is mixed. In the only first-line study of CRT treatment 
for AN, CRT proved no more effective than CBT (Lock et al., 2013). Relapse 
prevention studies sugest that CRT alters neurocognitive outcomes 
(Brockmeyer, Ingenerf, et al., 2014), may be beneficial alongside TAU in 
severe/enduring AN (Dingemans et al., 2014), however is inferior to exposure 
based treatments (Steinglass et al., 2014). Therefore, the evidence for CRT is 
inconclusive and more data are required (Genders & Tchanturia, 2010; 
Tchanturia, Davies, & Campbell, 2007). Furthermore, evidence for the efficacy of  
both psychotherapy and pharmacotherapy in severe and enduring forms of AN 
is also significantly lacking and requires research (Andries, Frystyk, Flyvbjerg, & 
Stoving, 2014; Hay, Touyz, & Sud, 2012; Touyz et al., 2013).  
Pharmacotherapy 
Given the serious nature of ED, the limited efficacy of psychotherapy and the 
evidence for a neurobiological basis to ED, a number of drug therapies have 
been considered as treatment adjuncts. A recent review by Tortorella et al. 
(2014) considers the current data on pharmacological treatments for AN and 
BN. The efficacy of fluoxetine in reducing BN symptoms was demonstrated in 
nine out of twelve RCT, whilst tricylic antidepressants, a range of monoamine 
oxidase inhibitors and the anticonvulsant topiramate also led to a reduction in 
symptoms when compared to placebo (Tortorella et al., 2014). In addition, 
topiramate lead to a reduction in binge frequency and BMI in obese individuals 
with BED (McElroy et al., 2003).  
Research into drug therapies for AN is inconclusive – the efficacy of fluoxetine 
was not supported by Walsh et al. (2006), whilst the antipsychotic olanzapine 
lead to weight gain and/or reductions in ED psychopathology in four of seven 
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RCT (Tortorella et al., 2014). Similarly, a recent trial of dronabinol (a cannaboid 
agonist) versus placebo found small but significant weight gain in severe and 
enduring AN (Andries et al., 2014). Preliminary evidence for the use of the 
neuropeptide oxytocin in AN has also been considered and suggested as a future 
research avenue (Maguire, O'Dell, Touyz, & Russell, 2013).  
Eating disorders and the brain 
As is evident throughout the above overview, ED are multifaceted, difficult to 
treat, and often chronic mental illnesses. They can be conceptualised as 
biopsychosocial conditions and both researchers and clinicians should be aware 
of over simplistic approaches. Whilst psychosocial approaches have dominated 
the field to date, there has been a recent surge in biologically based ED research 
(Harris & Steele, 2014). This is likely to be a reflection of the wider 
understanding of ED as medical illnesses, the limitations of psychological 
approaches within such disorders and the on-going development of 
sophisticated neuroscience tools (e.g. functional neuroimaging), with the ability 
to delve deeper into neurobiological mechanisms. However, this rise in 
neurobiological-based ED research does not disregard earlier work; 
neuroscience has been informed by and can incorporate previous psychosocial 
findings, whilst non-biological approaches can benefit from recent advances in 
neuroscience. Interdisciplinary approaches involving clinicians and 
neuroscientists will enable a comprehensive understanding of the pathogenesis 
and effective treatment of ED (Holmes, Craske, & Graybiel, 2014) and thus, 
when considered within the wider framework, biological, brain-based empirical 
research in ED is crucial.  
Although poorly understood, the role of the brain in the vulnerability, 
development and maintenance of ED is unquestionable. Whilst organic, brain-
based differences may render an individual more susceptible to developing an 
ED, habit formation and the plasticity of the brain allow for seemingly external 
influences to become tangible. Along with a number of extensive and thorough 
reviews of the neuroscience data in ED to date (Frank, Bailer, Henry, Wagner, & 
Kaye, 2004; Jauregui-Lobera, 2012; Kaye, 2008; Kaye, Wierenga, Bailer, 
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Simmons, & Bischoff-Grethe, 2013; Lask & Frampton, 2011; Phillipou, Rossell, & 
Castle, 2014; Pietrini et al., 2011; Zhu et al., 2012), the following summary 
serves to provide a body of evidence for the brain-basis of ED.  
Brain lesion cases 
Uher and Treasure (2005) reviewed 54 cases of ED occurring in cases with 
brain lesions. They identified that hypothalamic lesions are the most common 
cause of AN-like symptoms, in particular weight loss, but rarely occur in 
conjunction with ED psychopathology. Whilst brainstem lesions have been 
associated with restrictive AN, this finding requires further substantiation. 
Interestingly, of eight cases presenting with ED psychopathology, four had 
frontal and temporal lesions, implicating the role of frontotemporal circuits. 
Similarly, complete remission of AN was demonstrated following the removal of 
a frontal brain lesion (Houy, Debono, Dechelotte, & Thibaut, 2007). More 
recently, ED related behaviours were reported following traumatic brain injury 
in four patients. Following temporal and hypothalamic lesions two patients 
presented with hyperphagia, whilst refusal of food or notable aversions to 
certain foods was associated with frontal lobe damage (Castano & Capdevila, 
2010). Although the literature on brain lesions and ED is scarce, the role of the 
hypothalamus in changes to weight/appetite, and frontal regions in ED 
psychopathology is somewhat consistent.  
Structural imaging 
Nutritional deficiencies can have detrimental effects on brain structure. For 
example, lipids are essential for the myelination of neural axons, which enables 
fast conductivity for complex cognitive processes. A significant reduction in 
levels of adipose tissue i.e. during starvation has important consequences on 
brain composition and function. Research involving structural imaging 
techniques at both the acute and recovered stages of ED is vital in 
understanding neural links to clinical characteristics and brain-based 
ramifications of ED.  
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Computerised tomography (CT) produces three-dimensional x-ray images and 
has been used to investigate brain structure and volume in ED. Studies 
employing CT scans have demonstrated dilated ventricles, enlarged sulci and 
hemispheric fissures in both AN (Artmann, Grau, Adelmann, & Schleiffer, 1985; 
Kohlmeyer, Lehmkuhl, & Poutska, 1983) and BN (Kiriike et al., 1990; Krieg, 
Lauer, & Pirke, 1989). These findings reflect overall reductions in brain volume 
and cerebral atrophy during acute stages of illness, often irrespective of 
emaciation. Furthermore, such changes have been associated with impaired 
cognitive functions such as processing speed, concentration and reaction time 
(Kohlmeyer et al., 1983; Palazidou, Robinson, & Lishman, 1990). Fortunately, 
early CT data suggest that following recovery, these structural and cognitive 
changes are reversible (Artmann et al., 1985; Kohlmeyer et al., 1983; Krieg et al., 
1989). 
Compared to CT, structural magnetic resonance imaging (MRI) has less risk of 
radiation and enables higher resolution images. As such, MRI is now more 
widely used than CT and employs magnetic fields to produce images of 
biological tissues and fluids. Early studies of MRI in ED confirm previous CT 
findings of dilated ventricles, enlarged sulci and cerebral atrophy in AN 
(Kornreich et al., 1991) and BN (Hoffman et al., 1989). More recently, two 
systematic reviews assessed the use of voxel-based morphology in ED. 
Increased grey matter (GM) volume in frontal and ventral striatal areas was 
shown in BN, whilst the opposite, reductions in GM were identified in AN (Van 
den Eynde, Suda, et al., 2012). Similarly, a reduction in GM volume in brain areas 
implicated in reward and somatosensory processing in AN patients was 
reported soon after (Titova, Hjorth, Schiöth, & Brooks, 2013). Evidence for the 
normalisation of ventricular enlargement (Golden et al., 1996; Swayze et al., 
1996) and white matter (WM) volume exists, however deficits in GM volume 
have been shown to either persist (Friederich et al., 2012; Katzman, Zipursky, 
Lambe, & Mikulis, 1997; Lambe, Katzman, Mikulis, Kennedy, & Zipursky, 1997; 
Roberto et al., 2011) or restore following weight restoration in AN (Lazaro et al., 
2013; Mainz, Schulte-Ruther, Fink, Herpertz-Dahlmann, & Konrad, 2012).  
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Functional imaging  
Whilst studying brain structure in an attempt to understand ED is important, 
the brain is a highly plastic, complex and interconnected organ. The 
development of a variety of neuroimaging techniques with the ability to 
examine the brain’s electrical, neurobiological and haemodynamic activity has 
led to a greater understanding of the neural basis of ED. 
Providing far higher temporal resolution than other forms of functional imaging, 
electroencephalography (EEG) enables a direct measure of neuronal electrical 
activity. Current EEG data in relation to ED suggest both sleep abnormalities, 
including increased awakening and wakefulness, and differences in event 
related potential in AN patients (see review Jauregui-Lobera, 2012). Such 
aberrations are most pronounced in underweight AN individuals, supporting 
the relationship between impaired nutritional state and EEG abnormalities. 
Whether or not these differences reduce with treatment and/or weight 
restoration remains controversial (Bradley et al., 1997; Crisp, Stonehill, & 
Fenton, 1971; Hatch et al., 2011). Examinations of neural activity in response to 
ED related stimuli have also been examined with EEG and findings are in 
accordance with those found with other neuroimaging modalities. For example, 
compared to obese women without BED, elevated frontal beta activity has been 
reported in response to food cues in obese women with BED. Moreover, beta 
activity was associated with eating related disinhibition and thus implicates the 
role of frontal activity in the sensitivity and response to salient cues in BED 
(Tammela et al., 2010). In response to such findings, the use of EEG 
neurofeedback has been suggested as a means of targeting these alterations in 
ED patients (Bartholdy, Musiat, Campbell, & Schmidt, 2013).  
Positron emission tomography (PET) is a method of imaging designed to study 
the function of the brain via the relationship between energy consumption and 
neural activity. A PET image is created by injecting a radioactive isotope into the 
blood and it travelling to metabolically active areas of the brain. In PET ED 
research to date, studies have investigated alterations in regional cerebral 
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glucose metabolism (rCGM) along with the role of the monoamine 
neurotransmitters serotonin (5-hydroxytryptamine; 5-HT) and dopamine. 
A body of PET literature investigating rCGM in ED exists. Hypermetabolism in 
the caudate nuclei (Delvenne, Goldman, De Maertelaer, & Lotstra, 1999; 
Delvenne et al., 1996; Herholz et al., 1987; Krieg, Holthoff, Schreiber, Pirke, & 
Herholz, 1991) and medial temporal regions (Gordon et al., 2001) has been 
found in AN. In contrast, global and regional hypometabolism, in particular 
throughout frontal and parietal areas, has also been reported in both AN and BN 
(Delvenne, Goldman, Biver, et al., 1997; Delvenne et al., 1999; Delvenne et al., 
1996; Delvenne, Goldman, Simon, De Maertelaer, & Lotstra, 1997; Delvenne et 
al., 1995). Such rCGM alterations have been suggested to normalise after weight 
gain (Delvenne et al., 1996; Frank et al., 2007; Herholz et al., 1987).  
Along with investigations into rCGM, PET studies have examined the role of 
serotonergic function in ED, focussing mainly on the binding receptors 5-HT1A 
and 5-HT2A. Increased binding potential of 5-HT1A in both AN and BN (when 
compared to HC) has been reported (Bailer et al., 2007; Bailer et al., 2005; 
Galusca et al., 2008; Kaye, 2008; Tiihonen et al., 2004) whilst a reduction in 
binding of 5-HT2A (Audenaert et al., 2003) has been shown to persist in both 
recovered AN (Bailer et al., 2004; Frank et al., 2002) and BN individuals (Kaye et 
al., 2001). Moreover, Bailer et al. (2007) report that ED subtypes can be 
distinguished via their differences in serotonin receptor activity.  
Altered dopamine activity in ED has also been established via PET, 
demonstrating a reduction in striatal neurotransmission in both BN (Broft et al., 
2012) and recovered AN (Frank et al., 2005). Furthermore, a direct relationship 
between the interaction of serotonin transporter and striatal dopamine activity 
has recently been associated with harm avoidance behaviours in both AN and 
BN (Bailer et al., 2013). Whilst the implications of these abnormalities in 
serotonergic and dopaminergic function are discussed later, it is likely that they 
contribute to a number of ED characteristics such as altered satiety signals, 
impulsivity abnormalities, diminished reward sensitivity and aversive food-
motivation drives.  
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Single-photon emission computed tomography (SPECT) enables the 
visualisation of brain function by measuring the rate of regional cerebral blood 
flow (rCBF) through different areas of the brain. The interpretation of SPECT 
research relies on the premise that active brain areas require more oxygen and 
thus demonstrate increased rCBF. In part agreement with PET research, AN has 
been associated with hypoperfusion in frontal, parietal and temporal regions 
(Chowdhury et al., 2003; Gordon, Lask, Bryant-Waugh, Christie, & Timimi, 1997; 
Kuruoglu et al., 1998; Nozoe et al., 1995; Råstam et al., 2001; Takano et al., 
2001) and areas including the anterior cingulate cortex (ACC; Naruo et al., 2001; 
Takano et al., 2001) and amygdala (Chowdhury et al., 2003). However, there is 
some evidence that BN is associated with frontotemporal hyperperfusion 
(Nozoe et al., 1995). Despite reported differences regarding whether or not 
rCBF alterations normalise (Frank et al., 2007; Kojima et al., 2005; Kuruoglu et 
al., 1998) or persist in recovered individuals (Frampton, Watkins, Gordon, & 
Lask, 2011), temporal hypoperfusion during the acute stages of an ED has been 
correlated with long-term outcome and may therefore have prognostic value 
(Jimenez-Bonilla et al., 2009).   
Similarly to SPECT, functional MRI (fMRI) enables investigations into how 
different parts of the brain function and interact with each other. Since active 
brain areas require oxygen, as blood passes through functionally active brain 
tissue and oxygen levels are depleted, blood oxygen level detection (BOLD) 
signals can be used to identify networks of brain activity. Numerous fMRI 
studies have compared recovered and chronic ED patients to HC in their brain 
responses to salient stimuli (see Zhu et al., 2012 for a thorough review). When 
viewing foods images, individuals with ED demonstrate altered activation of 
limbic regions such as the insula and amygdala (Ellison et al., 1998; Holsen et al., 
2012; Joos, Saum, van Elst, et al., 2011; Kim, Ku, Lee, Lee, & Jung, 2012). 
Moreover, prefrontal responses to food images have differentiated both AN and 
BN individuals from their healthy counterparts (Brooks et al., 2011; Joos, Saum, 
Zeeck, et al., 2011; Uher et al., 2004). Interestingly, when compared to both HC 
and currently ill individuals, recovered AN individuals demonstrate heightened 
neural responses to both rewarding and aversive food stimuli (Cowdrey, Park, 
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Harmer, & McCabe, 2011) and persisting hyperactivity of the ACC and medial 
prefrontal cortex (MPFC) (Uher et al., 2003). These findings are incorporated 
and explored within the succeeding neurocircuit model of ED; involving the 
over-representation of limbic responses (i.e. diminished reward sensitivity 
and/or heightened emotional responses) in conjunction with impaired and/or 
exaggerated cognitive control.   
Response to food images during satiated and hungry states has also been 
examined in order to understand state related effects on neural networks. 
Increased activation to high-calorie foods in areas such as the amygdala and 
insula has been demonstrated in fasted HC (Gizewski et al., 2010; Goldstone et 
al., 2009). In contrast, both weight-restored and currently ill AN samples 
showed hypoactivations when fasted, which persist in the insula of satiated, 
acute AN individuals (Holsen et al., 2012; Santel, Baving, Krauel, Munte, & Rotte, 
2006). These findings highlight limbic activation differences between AN and 
HC in response to ED salient stimuli, as well as the importance of considering 
state related neural effects. Similarly, supporting the notion that food reactivity 
is modulated by internal motivational states Uher, Treasure, Heining, Brammer, 
and Campbell (2006) also identified heightened reactions to fasting in females, 
providing a neural basis to the gender-related susceptibility to ED.  
More recently Van den Eynde, Giampietro, et al. (2013) suggest that BN 
individuals do not differ from HC in their processing of food related images, 
however, when comparing their own bodies to slim ideals, people with BN 
engage limbic structures (in particular the insula) less than their healthy 
counterparts. Similarly, women with ED demonstrate reduced activity in the 
insula and aversive responses (e.g. heightened anxiety) when viewing images of 
themselves (Sachdev, Mondraty, Wen, & Gulliford, 2008). Likewise, reduced 
activation of the lateral fusiform gyrus and parietal cortex in response to line 
drawings of female bodies (Uher, Murphy, et al., 2005), and the right fusiform 
gyrus and MPFC when engaging in body checking actions (Suda et al., 2013) 
differentiates people with ED from HC. In contrast, Friederich et al. (2010) 
demonstrated insula hyperactivity during body comparisons and others suggest 
that the neural correlates of two distinct body image components (attitudes 
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towards one’s body and body size estimation) can be identified in both AN and 
BN (Mohr et al., 2011; Mohr et al., 2010). These findings implicate brain regions 
central to somatosensory processing and may account for the characteristic 
body image disturbance and dissatisfaction apparent within ED.  
Arguably a more potent and realistic method of symptom provocation, the 
administration of food substances during fMRI have been investigated in a small 
number of ED studies. Research involving the administration of glucose/sucrose 
in both recovered AN and BN has demonstrated reduced neural activation 
(compared to HC) in areas including the insula (Wagner, Aizenstein, et al., 2008) 
and ACC (Frank et al., 2006). Furthermore, the receipt of chocolate milkshake in 
BN was associated with hypoactivation of the insula (Bohon & Stice, 2011). 
More recently the neural effects of sucrose were found to be different in AN and 
BN having significantly diminished and elevated insula activation responses 
respectively (Oberndorfer et al., 2013). In general, this evidence for diminished 
reward sensitivity is thought to reduce the palatable and hedonic nature of food 
for ED patients, potentially contributing to the reduced motivation to eat in AN, 
and the need to binge eat to achieve satiety in BN.  
Along with using symptom provocation tasks, the administration of 
neuropsychological assessments whilst undergoing fMRI has proven useful in 
exploring the neurocognitive profile of ED. It is well documented that the ED are 
associated with a number of neuropsychological traits including cognitive 
inflexibility (Tchanturia et al., 2012), altered sensitivity to rewards (Harrison, 
O'Brien, Lopez, & Treasure, 2010) and disturbances in impulsivity (Rosval et al., 
2006). fMRI studies have produced data on the potential neural correlates of 
these characteristics. For example, impaired behavioural response shifting in 
AN has been associated with hypoactivation in the thalamus, ventral striatum, 
ACC and cerebellum in conjunction with predominant frontoparietal activation 
(Zastrow et al., 2009). Moreover, tempoparietal hyperactivation has been 
associated with working memory tasks in acute AN which returned to normal 
following treatment (Castro-Fornieles et al., 2010). Interestingly, during an ED 
salient Stroop task, thin and fat words were associated with hypoactivation of 
limbic structures and prefrontal cortex (PFC) dominance respectively 
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(Redgrave et al., 2008). This finding further supports the notion of reduced 
limbic processing of ‘rewarding’ cues and the over-activation of cognitive 
control circuits in response to aversive cues. Others also suggest a deficiency in 
the processing of positive and negative valence in the anterior ventral striatum 
in both AN and BN (Wagner et al., 2010; Wagner et al., 2007). Such findings 
indicate difficulties in identifying the emotional significance of stimuli across 
the ED. Moreover, a failure to engage frontal-striatal networks has been 
associated with reward processing in BED patients (Balodis et al., 2014), 
implicit learning in sub-threshold BN (Celone, Thompson-Brenner, Ross, Pratt, 
& Stern, 2011) and inhibitory control in both AN and BN (Lock, Garrett, 
Beenhakker, & Reiss, 2011; Marsh et al., 2011; Marsh, Steinglass, et al., 2009; 
Oberndorfer, Kaye, Simmons, Strigo, & Matthews, 2011). These findings suggest 
shared disturbances in the processing of emotional salience, reward and 
inhibitory control.  
More recently, fMRI studies of resting state functional connectivity, i.e. neural 
activity in the absence of cue or task administration, have been conducted. Such 
investigations allow for an examination of the default mode network (DMN), 
which is typically more active at rest than during attention-demanding tasks 
(Park, Godier, & Cowdrey, 2014). Compared to controls, individuals recovered 
from AN demonstrate increased temporal coherence (i.e. spontaneous 
coactivation) in the DMN, and between the DMN and areas such as the 
dorsolateral prefrontal cortex (DLPFC) (Cowdrey, Filippini, Park, Smith, & 
McCabe, 2014). Similarly, individuals with acute AN (compared to controls) 
demonstrate increased functional connectivity within areas of the fronto-
parietal network and in the anterior insula which is associated with poor 
interoceptive awareness (Boehm et al., 2014). These abnormalities in resting 
state networks suggest dysfunction in self-referential and cognitive control 
processes and further support the notion of altered neural circuitry 
underpinnings to ED.  
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The neurocircuitry of eating disorders 
As has been outlined, numerous brain regions have been implicated in the 
aetiology and symptomatology of ED. Drawing on such evidence, a number of 
conceptual, neuroscience-based models of ED have been proposed. 
Neurodevelopmental models of ED have been suggested (Connan, Campbell, 
Katzman, Lightman, & Treasure, 2003; Southgate, Tchanturia, & Treasure, 2005) 
along with cognitive neuroscience AN-specific models centered around learning 
and habit formation (Steinglass & Walsh, 2006) or the pronounced role of the 
insula (Nunn, Frampton, Gordon, & Lask, 2008). Whilst these models identify 
fundamental neural substrates and cognitive processes in the development of 
ED, recent neurocircuit models provide more comprehensive accounts of the 
important functional and effective connectivity between cortical and subcortical 
regions (Friederich, Wu, Simon, & Herzog, 2013; Hatch et al., 2010; Kaye, Fudge, 
& Paulus, 2009; Kaye, Wagner, Fudge, & Paulus, 2011; Kaye et al., 2013; 
Lipsman, Woodside, & Lozano, 2014; Marsh, Maia, & Peterson, 2009). Such 
existing hypotheses of ED have informed and been incorporated within the 
following model and rationale to this thesis.  
Neurocircuitry and self-regulation in eating disorders 
As has been discussed previously, the ED are biopsychosocial disorders, arising 
from a combination of predisposing biological, psychological and personality 
factors, modified by epigenetic processes and exacerbated by potent 
sociocultural pressures. These factors are particularly pertinent during 
adolescence, a time of hormonal fluctuations, brain developmental changes and 
a heightened need for social acceptance. Furthermore, adolescence is a key 
period in the maturation of important neural circuitry and the subsequent 
development of self-regulation abilities (Marsh, Maia, et al., 2009).  
Affective regulation 
Adequate development of neural circuitry is central to the effective regulation of 
emotional responses. Firstly, the ventral circuit, including the amygdala, nucleus 
accumbens and insula, is important in the identification and coding of 
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emotionally salient stimuli. Secondly, the dorsal circuit, incorporating areas 
such as the PFC, parietal regions and the cingulate cortex, is responsible for 
responding to ventral signals via cognitive control/executive functions such as 
decision making, selective attention, planning and modulating emotional 
responses (Ochsner & Gross, 2007; Phillips, Drevets, Rauch, & Lane, 2003). 
These and other models of emotion regulation propose that ‘bottom-up’ 
emotion generation arises from subcortical, limbic neural structures whilst 
dorsal, prefrontal regions exert  ‘top-down’ cognitive control.  
Disturbances within such circuitry are proposed to underlie emotion 
dysregulation across various psychiatric disorders (Ochsner, 2008; Phillips, 
Ladouceur, & Drevets, 2008). Specifically, in relation to ED, key components of 
the neural circuitry proposed to underlie emotion dysregulation models have 
been implicated in neuroimaging data (see Figure 1.1). Moreover, emotion 
dysregulation and alexithymia is well documented across the spectrum of ED 
(Brockmeyer, Skunde, et al., 2014; Gilboa-Schechtman, Avnon, Zubery, & 
Jeczmien) and therefore, alterations in the neural networks that subserve 
emotion and mood regulation are highly pertinent to ED.  
Appetite regulation 
Similar components of the neural circuitry proposed to be involved in emotion 
regulation difficulties are also implicated in appetite disturbance. For example, a 
recent study found that modulation of the amygdala lead to loss of appetite in 
rats (Cai, Haubensak, Anthony, & Anderson, 2014) and such ventral circuit 
structures are proposed to play a key role in the hedonic aspects of eating such 
as pleasure and motivation (Koh, Wilkins, & Bernstein, 2003). Thus, the well-
documented alterations in mesolimbic activity in ED sufferers is likely to 
contribute to the heightened emotionality and/or diminished motivation 
towards food and eating. In response, dorsal circuitry is engaged during 
decisions regarding the approach or avoidance of food and aberrant activity 
may be an attempt to reduce dysphoric mood (e.g. heightened fear/anxiety) 
(Kaye et al., 2009; Kaye et al., 2011). Therefore, the integrated nature of the 
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neurocircuitry underling affect and appetite control is highly relevant to the 
manifestation of self-regulatory control difficulties seen in ED.  
The ventral/limbic circuit, including areas such as the insula, nucleus accumbens 
(NuAcc), amygdala and anterior cingulate cortex (ACC), is important in the 
identification and coding of emotional salience and therefore responsible for 
generating ‘bottom-up’ emotional responses. The dorsal/cognitive circuitry, 
including areas such as the dorsolateral prefrontal cortex (DLPFC) and parietal 
regions, is engaged in response to such emotive signals and modulates executive 
functions (e.g. decision making) and ‘top-down’ cognitive control.  
  
Self-regulatory control 
In response to emotion dysregulation and appetite disturbances, fronto-striatal 
circuitry has also been suggested as a unanimous neural substrate of the self-
regulatory control difficulties seen in ED (Brooks, Rask-Andersen, Benedict, & 
Schioth, 2012; Marsh, Maia, et al., 2009). For example, disturbances in the 
neural circuitry that regulate reward sensitivity and inhibitory control are 
 
Figure 1.1 Brain areas implicated in eating disorders 
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central to BN. Directional differences of reward circuitry activity in BN differs 
between studies (Brooks et al., 2011; Kim et al., 2012; Oberndorfer et al., 2013) 
however, evidence suggests that the hypoactivity of mesolimbic circuitry 
underlies diminished responsiveness to the palatable nature of food (Bohon & 
Stice, 2011; Frank, Reynolds, Shott, & O'Reilly, 2011; Frank et al., 2006). 
Moreover, a reduction in striatal dopamine neurotransmission further supports 
the notion of impaired mesolimbic circuitry in BN (Broft et al., 2012) and binge-
eating behaviour may be an attempt to compensate for this diminished reward 
sensitivity.  
The concurrent failure to engage frontal, cognitive control areas when 
presented with relevant stimuli (Joos, Saum, Zeeck, et al., 2011; Uher et al., 
2004) and during inhibitory control tasks (Balodis et al., 2014; Lock et al., 2011) 
may underlie the impulsive traits of BN. This diminished cognitive control, 
coupled with the over-evaluation of weight and shape may underlie the binge 
and purging behaviours characteristic of BN. Interestingly, preliminary evidence 
suggests opposite brain activation patterns in BED. Specifically, enhanced 
reward sensitivity and medial orbitofrontal PFC activity (Schienle, Schafer, 
Hermann, & Vaitl, 2009) coupled with increased striatal dopamine levels (Wang, 
Geliebter, et al., 2011) have been found in BED. These findings suggest that 
compared to the diminished reward sensitivity and impaired cognitive control 
of BN, BED may be characterised on a neural level by heightened anticipatory 
reward.  
Mesolimbic structures critical to affect regulation and nutritional homeostasis 
have long been implicated in the aetiology of AN (Lipsman et al., 2014; Nunn et 
al., 2008). Similarly to BN, the exact direction of altered mesolimbic activity 
requires further substantiation, however Friederich et al. (2013) suggest a 
combined over-representation of reward and fear related neural circuitry in AN.  
For example, hyperactivity in limbic areas such as the insula in response to 
symptom provocation (Cowdrey et al., 2011) may represent enhanced aversive 
motivation, whilst diminished responses may demonstrate impaired processing 
of the hedonic nature of food (Oberndorfer et al., 2013). Concurrent 
hyperactivity of the amygdala (Ellison et al., 1998; Joos, Saum, van Elst, et al., 
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2011), a central structure in the formation of fear responses, is likely to 
contribute to the heightened food related anxiety experienced in AN and the 
consolidation of learned fear responses. Moreover, diminished dopaminergic 
drives in recovered AN (Frank et al., 2005) suggest a trait related disturbance in 
reward circuitry, whilst altered serotonergic activity may explain altered satiety 
signals, heightened aversive arousal and harm avoidance strategies such as food 
restriction (Bailer et al., 2013; Friederich et al., 2013).  
In response to over-represented mesolimbic drives, exaggerated frontal activity 
(Brooks et al., 2011; Uher et al., 2003; Zhu et al., 2012) may facilitate the 
pathological rigidity and self-control typical of AN. This trait is demonstrated in 
the unique ability of individuals with AN to resist immediate gratification in 
favour of later, more desirable rewards i.e. food restriction in the pursuit of 
weight loss (Steinglass et al., 2012). Furthermore, predominant fronto-parietal 
activity has been associated with poor cognitive flexibility in AN (Zastrow et al., 
2009). Such heightened PFC activity during cognitive control tasks and food 
exposure (Brooks et al., 2011; Uher et al., 2003) is thought to reflect dominant 
top-down processing in an attempt to modulate aberrant mesolimbic signals 
and resulting dysphoric mood. Moreover, alterations in the resting functional 
connectivity of interoceptive and cognitive control networks have been 
demonstrated in AN and support the notion of impaired neural circuitry 
(Boehm et al., 2014; Cowdrey et al., 2014). 
Symptom/diagnostic commonalities 
Whilst evidence for ED subtype-specific neural activation patterns exist, Brooks 
et al. (2012) suggest that commonalties represent trans-diagnostic sporadic 
dominance of either top-down or bottom-up processing. Moreover, in the 
context of variable environmental challenges, temperamental dominance is 
suggested to dictate ED phenotype. In response to heightened fear and anxiety 
responses, dominant cognitive activity and therefore heightened self-regulatory 
control typifies restrictive AN, whilst impaired dorsal circuitry in response to 
diminished reward sensitivity and mood instability manifests in the poor 
inhibitory control symptoms of BN. Importantly, intermittent dominance of the 
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opposite system may often occur and thus account for symptom or diagnostic 
flux within ED (Brooks et al., 2012).  
Chronicity 
These neural network based disturbances that manifest in altered emotionality, 
appetite drives and self-regulatory control symptoms are then further 
maintained by the biopsychosocial factors that instigated them, positive 
reinforcement, temporary emotional respite and the consolidation of ED related 
coping mechanisms. With repetition, these conscious behaviours become 
ritualised, automatic and often compulsive habits that are increasingly difficult 
to unlearn and resistant to change (Godier & Park, 2014; Park et al., 2014; 
Steinglass & Walsh, 2006). This shift from active behaviours, to habitual and/or 
compulsive responses relies on neuroplasticity, the brain’s ability to change in 
response to environmental stimuli and learning processes. Neuroplasticity has 
been implicated in other impulse control disorders (Muresanu, Stan, & 
Buzoianu, 2012) and may explain the deep-rooted and treatment resistant 
nature of ED with increasing illness duration. This model suggests that unless 
identified early, before the brain adapts to maladaptive behaviours, ED may 
require brain-directed treatment adjuncts in an attempt to restore underlying 
dysfunctional neurocircuitry and alleviate symptomatology.  
The neurocircuit approach to ED outlined emphasises the importance of 
considering ED within a biopsychosocial framework. The neurodevelopmental 
role of altered fronto-striatal circuitry is central to explaining the self-regulation 
difficulties such as emotional processing, appetite disturbances and inhibitory 
control aberrations found in ED. The manifestation of these neural alterations 
into the phenotypic ED subtypes is explored, whilst commonalities and 
symptom/diagnosis crossover are also accounted for. Finally, the neural basis of 
learning and habit formation is the last, yet significant stage of this model, 
explaining how ED can become ingrained on a neural level and develop into 
chronic, treatment-resistant and life-threatening illnesses. This proposed model 
of dysfunctional neurocircuitry and resulting self-regulation difficulties in ED is 








Perfectionism, impulsivity, emotionality 
SOCIOCULTURAL 









































Figure 1.2 A schematic representation of the underlying neurocircuitry of self-regulation difficulties and resulting phenotypic 
behaviours in eating disorders
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On the basis of extensive neuroimaging literature, comprehensive 
neurobiological models and the limited efficacy of existing therapies, there is an 
indisputable need for novel, brain-directed treatment adjuncts to ED. This is 
further supported by the NIMH recognition of ED as brain based mental 
disorders and the subsequent development of the Research Domain Criteria 
(Chavez & Insel, 2007; Insel et al., 2010). Significant scope exists for 
investigations into neuromodulation techniques, which have the ability to 
directly, focally and implicitly influence the cortical and sub-cortical processes 
proposed to underlie ED. Therefore, neuromodulation techniques offer potential 
in probing disease mechanisms and exploring novel treatments for ED.  
Four common neuromodulation techniques are relevant to this thesis, in 
particular the subsequent review (Chapter 2). They range from relatively non-
invasive procedures, such as Transcranial Magnetic Stimulation (TMS) and 
transcranial Direct Current Stimulation (tDCS), to more invasive procedures 
requiring surgery, such as Vagus Nerve Stimulation (VNS) and Deep Brain 
Stimulation (DBS). Such techniques are advantageous compared to older brain 
directed treatment approaches, such as Electroconvulsive Therapy (ECT), as 
they are non-lesional, adjustable and most are without severe side effects. 
Those investigated most widely and relevant to this thesis are summarised in 
Table 1.1.  
 
Table 1.1 Common neuromodulation techniques 
Type Mechanism of action 
Transcranial Magnetic 
Stimulation (TMS) 
Electromagnetic induction modulates neural 
activity in the underlying cortex. 
Transcranial Direct Current 
Stimulation (tDCS) 
Weak current alters neuronal excitability. 
Neural effects depend on direction of 
current. 
Vagus Nerve Stimulation (VNS) Electrical stimulation of vagus nerve 
conveyed to other areas of the brain.  
Deep Brain Stimulation (DBS)  Electrical pulses delivered to specific brain 
area central to symptom/condition.  
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Repetitive transcranial magnetic stimulation 
TMS works on the principle of electromagnetic induction – the electrical current 
that is run through a TMS coil produces a magnetic field that can induce a 
secondary current in a nearby conductor. When a TMS coil is held up against the 
head, the electromagnetic field modulates neural activity in the underlying 
cerebral cortex. Initially, single pulse TMS was developed in order to investigate 
and demonstrate motor cortex excitability (Barker, Jalinous, & Freeston, 1985). 
However, the development of the ability to deliver of multiple pulses over a 
short period of time, known as repetitive TMS (rTMS), enabled longer lasting 
neural effects and investigations into behavioural and psychological conditions. 
When applied at a low frequency (LF; < 5Hz), rTMS suppresses cortical activity, 
whilst high frequency rTMS (HF; 5Hz or above) enhances cortical activity 
(Rossi, Hallett, Rossini, & Pascual-Leone, 2009; Rossini et al., 1994). Recent 
evidence suggests that HF rTMS applied to the left DLPFC has therapeutic 
efficacy in depression (Gaynes et al., 2014). As such, rTMS is approved by the 
Food and Drug Administration (FDA) in the United States as a second-line 
treatment for depression.  
Transcranial direct current stimulation  
tDCS applies a weak direct current from one electrode (excitatory; anode) to 
another (inhibitory; cathode). In comparison to rTMS, the mechanism by which 
tDCS works enables multiple stimulation designs; switching the position of the 
electrodes enables alternating excitation/inhibition between the right and left 
hemispheres. In comparison to rTMS, tDCS is safer, cheaper and easier to 
administer, however has not yet been as widely investigated. However, interest 
in tDCS is growing, having shown promising therapeutic effects in both 
Parkinson’s Disease (Benninger et al., 2010; Boggio et al., 2006; Fregni et al., 
2006) and Alzheimer’s disease (Ferrucci et al., 2008) and more recently, in 
major depression (Ferrucci et al., 2009; Kalu, Sexton, Loo, & Ebmeier, 2012; Loo 
et al., 2012; Loo et al., 2010; Nitsche, Boggio, Fregni, & Pascual-Leone, 2009). 
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Vagus nerve stimulation  
VNS involves the implantation of a stimulator device; the generator is placed 
under the clavicle in the chest and is connected to electrodes wrapped around 
the vagus nerve (Connor, Nixon, Nanda, & Guthikonda, 2012; Meneses et al., 
2013). The vagus nerve, one of 12 cranial nerves, relays information to and from 
the brain to major organs including the heart, stomach and lungs. Electrical 
stimulation via VNS results in activation/inhibition of brainstem structures, 
which is then conveyed to other areas of the brain including the thalamus, 
frontal cortex, hypothalamus and limbic lobe (Chae et al., 2003). The use of VNS 
is FDA approved for the treatment of intractable epilepsy and depression, yet its 
therapeutic efficacy in depression is argued to require further substantiation in 
high quality controlled trials (Martin & Martin-Sanchez, 2012).  
Deep brain stimulation 
Finally, DBS is a technique that has been used for more than 25 years to 
modulate dysfunctional neurocircuitry. It involves the implantation of 
electrodes in a defined brain target deemed to be central to the clinical problem. 
Similarly to VNS, the electrodes are connected to a generator implanted in the 
body, which sends electrical pulses to the region of interest. Marked 
improvements in the major motor symptoms of Parkinson’s disease have been 
found after DBS typically of either the globus pallidus, sub-thalamic nucleus or 
other thalamic targets (DeLong & Wichmann, 2012). Use of DBS now extends 
into psychiatric disorders for which there are neural based aetiological models. 
For example, promising therapeutic effects have been reported following DBS of 
the subgenual cingulate gyrus or the ventral internal capsule/ventral striatum 
in major depression (Taghva, Malone, & Rezai, 2012), the nucleus accumbens in 
obsessive compulsive disorder  (de Koning et al., 2013; Greenberg et al., 2006) 
and the hypothalamus in Alzheimer’s Disease (Laxton et al., 2010).  
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Summary  
ED are complex, prevalent and debilitating mental disorders. Research has 
significantly advanced our understanding of their aetiopathogenesis and aided 
the development of important psychosocial and pharmacological interventions. 
However, remission rates remain unsatisfactory. Given the increasing volume of 
neuroscience data and resulting brain-based aetiological models, the utilisation 
of modern and sophisticated neuroscience tools, such as neuromodulation, will 
be of use in elucidating the neural basis of ED and for developing brain-directed 
treatment adjuncts to existing therapies.   
Aims and hypotheses 
The aim of this research was to investigate the potential of neuromodulation 
techniques in the treatment of ED, focusing specifically on the effects of rTMS in 
AN. Four major hypotheses were tested: 
Hypothesis 1. Existing literature demonstrates that in human and animal 
populations, neuromodulation techniques have the ability to alter feeding and 
eating behaviour, body weight and ED related symptoms, and therefore have 
potential in the treatment of ED (Chapter 2). 
Hypothesis 2. In patients with AN, core symptoms of AN will be reduced 
immediately and 24 hours after a single-session of real (as opposed to 
sham/placebo) HF rTMS to the left DLPFC (Chapter 3). 
Hypothesis 3. Excessive cognitive control in AN will be reduced following real (as 
opposed to sham/placebo) HF rTMS to the left DLPFC (Chapter 4). 
Hypothesis 4. In patients with enduring AN, ED and related psychopathology 
(e.g. mood) and weight will be improved immediately following therapeutic (20 




This thesis examines the potential of neuromodulation techniques for the 
treatment of ED. Specifically it focuses on an examination of the effects of rTMS 
in AN.  
Chapter 1: Introduction  
This chapter provides the background and rationale for this research. A 
summary of the existing research on the diagnosis, severity and treatment 
options for ED is provided. Relevant neuroscience data are presented, the 
neurocircuitry associated with ED is discussed and existing neuromodulation 
techniques are introduced. 
Chapter 2: A systematic review of the effects of neuromodulation on eating 
and body weight; evidence from human and animal studies 
A systematic review of the literature on neuromodulation techniques in relation 
to ED symptoms, eating/feeding behaviours and body weight examines the 
literature in this field. Evidence is assessed in relation to the potential use of 
neuromodulation for the treatment of ED.  
Chapter 3: A randomised single-session sham-controlled trial of repetitive 
transcranial magnetic stimulation in anorexia nervosa 
This chapter includes an in depth introduction to rTMS as a technique, together 
with a detailed description of the methods and design of the single-session, real 
versus sham rTMS, RCT that was conducted. The rationale and findings 
regarding the effects of HF rTMS to the left DLPFC on symptoms of AN are 
reported followed by data on its effects on food preferences and consumption. 
The effects of rTMS on stress levels (salivary cortisol) in AN are then presented 
and data on cortical excitability, the safety, tolerability and acceptability of rTMS 
in AN are reported. In each of the relevant sections, there is a discussion of the 
findings and their implications.  
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Chapter 4: The effects of repetitive transcranial magnetic stimulation on 
temporal discounting in anorexia nervosa 
In this chapter, an introduction to the concept of temporal discounting (TD; the 
preference to choose smaller, immediate over larger later rewards) is presented 
and its association with choice impulsivity/controlled decision making is 
discussed. Literature on the use of TD tasks in relation to disordered eating and 
the effects of neuromodulation on TD is also reviewed. Using the same AN 
sample and RCT design described in Chapter 3, the results of the effects of rTMS 
on TD behaviour in AN are presented. These findings and their implications are 
discussed.  
Chapter 5: A therapeutic case series of repetitive transcranial magnetic 
stimulation in enduring anorexia nervosa 
A case series of five individuals with enduring AN treated with ~20 sessions of 
rTMS is presented. Within session data regarding ED experiences pre and post 
each rTMS session are then presented. One and six month follow-up data on 
weight, ED and general psychopathology are reported. Finally, qualitative 
information from both the participants and a third-party/significant other is 
presented. The results of these five cases are discussed together with the 
implications for the use of rTMS in the treatment of AN.  
Chapter 6: General discussion 
In this final chapter, the main findings are summarised in light of the strengths 
and weaknesses of this research. Directions for future research are suggested 
combined with a discussion of the clinical significance of this work.  
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Chapter 2.  A systematic review of the effects of 
neuromodulation on eating and body weight; evidence from 














The ED are serious illnesses with often devastating consequences. Various 
forms of psychotherapy, often alongside medication, are currently the only 
treatment options available. Although these treatments work for some, dropout 
and relapse rates are high and a significant number of people do not respond to 
any of the treatment options currently available (Dejong, Broadbent, & Schmidt, 
2012; Schmidt et al., 2012). Talking psychotherapies for ED target explicit 
cognitive processes teaching patients to employ effortful and conscious 
strategies to divert attention from anxiety-provoking thoughts. Given the 
psychological components to ED, there is an indubitable need for such 
approaches within the field. However, given the neuroscience data and 
neurobiological models of ED summarised previously, there is a strong need for 
brain-directed treatment adjuncts to complement existing therapies in order to 
improve outcomes. Despite this, and the development of sophisticated 
neuroscience technologies, research into novel ED treatment options has 
remained relatively ‘brainless’.  
The four neuromodulatory techniques introduced previously are used in both 
research and clinical settings to probe, understand and alter neural activity in 
other disorders. The non-invasive techniques rTMS and tDCS have been most 
widely investigated in relation to depression (Berlim, Van den Eynde, & 
Daskalakis, 2012, 2013; Gaynes et al., 2014; Kalu et al., 2012; Nitsche, Boggio, et 
al., 2009; Shiozawa et al., 2014; Slotema, Blom, Hoek, & Sommer, 2010) whilst 
VNS and DBS, despite being more invasive, have shown potential in the 
treatment of depression, OCD, epilepsy and Parkinson’s disease (DeLong & 
Wichmann, 2012; Holtzheimer & Mayberg, 2011; Kohl et al., 2014; Martin & 
Martin-Sanchez, 2012; Meneses et al., 2013). These forms of neuromodulation 
are widely accepted as safe and useful techniques that are highly relevant to 
investigations in circuit-based disorders such as ED. 
In an attempt to understand the potential of neuromodulation in the treatment 
of ED, we have systematically reviewed the effects of rTMS, tDCS, VNS and DBS 
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on ED symptoms and related behaviours e.g. food intake and body weight. As 
has been outlined, the need for this review arises from a) the limited efficacy of 
existing treatments for ED, in particular enduring AN, b) the growing number of 
neural based models of ED, c) the variety of neuromodulation techniques being 
used in research and in clinical settings, d) recent studies which have applied 
neuromodulatory procedures in ED patients, and e) a perceived need to help 
direct the field of brain-directed interventions in ED. 
Methods 
A systematic review was conducted, following the recommendations outlined in 
the PRISMA guidance (Moher, Liberati, Tetzlaff, & Altman, 2009). The literature 
search was conducted independently by two investigators and then compared. 
Any disagreements were resolved by further examination of the full text and via 
consensus. Relevant studies were identified using online databases Pubmed, 
PsychInfo and Web of Knowledge. Key search terms are included below in the 
search strategy used in Pubmed:  
((brain stimulation [Title/Abstract] OR “TMS” [Title/Abstract] OR 
transcranial magnetic stimulation [Mesh Terms] OR “tDCS” 
[Title/Abstract] OR “transcranial direct current stimulation” 
[Title/Abstract] OR transcranial stimulation [Title/Abstract] OR 
vagus stimulation [Title/Abstract] AND (food[MeSH Terms] OR 
food [Title/Abstract] OR eating [MeSH Terms] OR body [MeSH 
Terms] OR anorexia [MeSH Terms] OR anorexi* [Title/Abstract] 
OR bulimia [MeSH Terms] OR bulimi* [Title/Abstract] OR obesity 
[MeSH Terms] OR obes* [Title/Abstract] OR binge eat* 
[Title/Abstract])) 
Searches using Web of Knowledge and PsychInfo were conducted by organising 
key search terms into two groups. The first group related to neuromodulation 
techniques for example (“brain” AND “stimulation”), “TMS”, “tDCS”, 
(“transcranial” AND “stimulation”), “VNS”, (“vagus” AND “stimulation”), whilst 
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the second group consisted of eating disorder salient words including “food”, 
“eating”, “body”, “anorexia”, “bulimia”, “obesity”, “binge eat”. The first group of 
neuromodulation terms was crossed with each eating disorder salient word. 
Initially, all of the identified articles were screened and included on the basis of 
relevance to the topic via inspection of their title and abstract. Publications 
were then cross-referenced, published review articles were examined for 
additional relevant studies and experts in the field were contacted in order to 
source any additional relevant literature. The full text versions of the remaining 
articles were then assessed in more detail. An overview of the literature search 
is shown in Figure 2.1.  
Inclusion/exclusion criteria 
We included articles in English (and German), dated from the earliest date 
available up until January 2013, that explored the effects of a form of 
neuromodulation on eating related outcomes e.g. ED symptoms, food cravings, 
eating behaviours, food intake, weight, BMI. We included studies on healthy 
participants (HP), people with ED, people with other psychiatric or neurological 
disorders and studies in animals. In addition to RCT, clinical studies, case series 
and case reports were included.  
Several studies were excluded on the basis that their focus was not on changes 
to eating behaviours or body weight as a result of neuromodulation (e.g. motor 
excitability in Parkinson’s disease). In other cases, studies were excluded that 
looked primarily at the use of neuromodulation techniques as a conditioned 
response rather than a neuromodulatory tool. A number of other studies were 
excluded as they focused on the effects of neuromodulation on bodily 
form/perception. Whilst this is relevant to ED, it was deemed that this fell out of 
the scope of the present review. Finally, papers reporting on non-eating related 
outcomes and safety issues in ED patients (e.g. cortisol concentrations and 
cardiac safety), and those using an uncommon method of neuromodulation (e.g. 





We identified 60 studies that met the inclusion criteria for this review. Five of 
these were conducted in HP, six were in bulimic or obese individuals, six were 
in AN patients, 18 were in individuals with other psychiatric or neurological 
disorders and 25 were animal studies. The studies that were included report 
effects on ED symptoms, eating behaviours, food intake and changes to body 
weight associated with the application of neuromodulation techniques to a 
number of different brain regions/structures illustrated in Figure 2.2.  
 
Figure 2.1 PRISMA flow chart of literature search and reviewed studies 
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Areas targeted with rTMS and tDCS (blue) are the dorsomedial prefrontal cortex 
(DMPFC) and the dorsolateral prefrontal cortex (DLPFC); DBS targets (purple) 
include the subgenual cingulate cortex (SCC), nucleus accumbens (NuAcc), ventral 
capsule/striatum (VC/VS), hypothalamus (Hyp), sub-thalamic nucleus (STN), 
globus pallidus (GP); and the vagus nerve (VN: in orange) is targeted in VNS. 
 
Studies in healthy participants and people with frequent food cravings 
Five studies in HP were identified, with four of these using individuals who 
reported frequent food cravings (Table 2.1). The study involving a non-food 
craving group, reported that compared to control conditions, active LF (1Hz) 
rTMS to the right DLPFC, decreased the value assigned to food (Camus et al., 
2009). Given this, it is arguable that rTMS to the right DLPFC may reduce food 
cravings. However, following reports of a reduction in the urge to smoke 
(Johann et al., 2003) and cigarette consumption (Eichhammer et al., 2003) 
following HF (10 Hz) rTMS to the left DLPFC, two studies used a similar protocol 
to investigate effects on food cravings (Barth et al., 2011; Uher, Yoganathan, et 
 
Figure 2.2 Brain areas targeted with neuromodulation in reviewed studies 
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al., 2005). In an RCT of 28 individuals, food cravings during exposure to food 
remained stable after real rTMS and increased after sham (placebo) stimulation 
(Uher, Yoganathan, et al., 2005). In contrast, a cross over study with an 
‘improved’ sham condition in ten food cravers reported that real rTMS was no 
better than sham in reducing cravings (Barth et al., 2011).  
Building on the above studies, Fregni et al. (2008) compared both tDCS 
protocols; anode right/cathode left, anode left/cathode right to sham 
stimulation and found that food cravings reduced, remained stable or increased 
in these conditions respectively. Goldman et al. (2011) compared a single tDCS 
condition, anode right/cathode left to sham and found food cravings reduced in 
both conditions; however, the percentage change was greater following the 
active tDCS. 
Studies in people with bulimia nervosa, binge eating disorder and obesity 
Six studies were identified (Table 2.2) five of which investigated the effects of 
rTMS in patients with BN. Two single case studies of patients with BN and 
comorbid depression applied rTMS either to the left DLPFC (Hausmann et al., 
2004) or both sides of the DMPFC (Downar, Sankar, Giacobbe, Woodside, & 
Colton, 2012). Both case studies reported complete recovery from binge/purge 
symptoms.  
Three studies that involved larger samples (two are RCT) applied rTMS to the 
left DLPFC. A therapeutic trial of 15 sessions of HF, neuronavigated (guided by 
structural MRI scans) real/sham rTMS in 14 people with BN, reported 
improvements in binge/purge behaviours in both groups, however no 
difference between conditions (Walpoth et al., 2008). In a larger sample of 38 
bulimic individuals, our group found that compared to sham, a single session of 
real HF rTMS (combined with cue exposure to food) significantly reduced right-
handed patients’ urge to eat and binge eating episodes over the 24 hours 
following stimulation: however, mood deteriorated in a series of left-handed 




Only one study has examined neuromodulatory effects in obesity and no study 
was found in BED. Montenegro et al. (2012) conducted a small crossover study 
of anode left/cathode right tDCS versus sham stimulation, isolated or combined 
with aerobic exercise in nine obese individuals. Although this used an opposing 
stimulation protocol to studies that have reported a reduction in food cravings 
(anode right/cathode left tDCS), participants’ desire to eat decreased after 
active tDCS in comparison to sham, with a greater decrease being seen when 
tDCS was combined with aerobic exercise.  
Studies in people with anorexia nervosa 
Six studies investigating the effects of neuromodulation in patients with AN 
were identified (Table 2.3). In a case of AN with comorbid depression, ten 
sessions of HF rTMS to the left DPLPFC were initially administered as a 
treatment for depression (Kamolz, Richter, Schmidtke, & Fallgatter, 2008). As 
improvements in both depression and AN symptoms (including weight gain) 
were observed, a further 31 sessions were administered (inclusive of 
maintenance sessions): this resulted in a continuous improvement in both the 
depressive and AN symptoms. Since then, a pilot study by our group, examined 
the effect of a single session of real rTMS applied to the left DLPFC in 10 cases 
with AN and reported a reduction in levels of feeling full, feeling fat and anxiety 
(Van den Eynde, Guillaume, Broadbent, Campbell, & Schmidt, 2013). 
Four studies were identified that used DBS to treat AN. Two cases of AN were 
treated with DBS for different comorbidities. In the first, there was complete 
remission of AN in a patient treated with DBS targeting the subgenual cingulate 
cortex (SCC) for co-morbid depression (Israel, Steiger, Kolivakis, McGregor, & 
Sadikot, 2010). Similar reductions in AN symptoms, and the maintenance of a 
healthy BMI was observed in another patient who underwent DBS (targeting 
the ventral capsule/striatum) for co-morbid OCD (McLaughlin et al., 2013).  
Since these promising case reports, two groups have conducted small case 
series’ of DBS in AN. In four acutely ill adolescent AN patients, DBS to the 
nucleus accumbens resulted in an average weight increase of 65% and in all 
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patients no longer meeting diagnostic criteria for the illness (Wu et al., 2013). A 
recent study applied DBS to the SCC in six treatment resistant AN patients 
(Lipsman et al., 2013). Nine months after DBS surgery, three patients (50%) 
increased and maintained their BMI greater than their historical baseline, whilst 
four saw improvements in AN related obsessions, mood, anxiety and affective 
regulation. Along with these clinical improvements, reversals in the 
abnormalities seen in the anterior cingulate cortex, insula and parietal lobe 
were accompanied by changes in cerebral glucose metabolism.  
Studies assessing eating behaviours and weight in people with other 
psychiatric or neurological disorders 
Eighteen studies applied neuromodulation to patients with other psychiatric or 
neurological disorders and found concurrent changes to food cravings, eating 
behaviours, weight and/or BMI. Findings in patients with OCD, depression and 
epilepsy are presented in Table 2.4, followed by studies in Parkinson’s disease.  
In a single case report of DBS for OCD (targeting the nucleus accumbens) the 
patient’s weight increased by 8kg in the first few months of treatment 
(Mantione, van de Brink, Schuurman, & Denys, 2010). Following the initial 
weight increase this patient weighed 115kg and made a conscious decision to 
lose weight and successfully lost 44kg. 
Three papers (relating to two studies) report effects of VNS on food cravings 
and weight changes in depressed patients. Compared to controls, significant 
changes to cravings of sweet foods (in both directions) between VNS on/off 
conditions in depressed participants were reported (Bodenlos, Kose, Borckardt, 
Nahas, Shaw, O'Neil, & George, 2007; Bodenlos, Kose, Borckardt, Nahas, Shaw, 
O'Neil, Pagoto, et al., 2007). In contrast, Pardo et al. (2007) examined the effects 
of VNS in depressed, obese patients and found significant, effortless weight loss 
proportional to BMI.  
Three studies of VNS in patients with epilepsy retrospectively examined 
changes in weight/BMI following surgery. One study reported a significant 
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weight loss following VNS e.g. in 17/27 (63%) patients (Burneo, Faught, 
Knowlton, Morawetz, & Kuzniecky, 2002), whilst the remaining two studies 
reported no significant weight change following VNS for epilepsy in both adults 
(Koren & Holmes, 2006) and children (Kansagra, Ataya, Lewis, Gallentine, & 
Mikati, 2010; Koren & Holmes, 2006). 
The remaining studies report (many retrospectively) changes to eating 
behaviours and body weight following DBS to either the sub-thalamic nucleus or 
globus pallidus for the treatment of Parkinson’s disease. All eleven studies 
report either over-eating and/or increases in cravings, weight gain and 
increases in BMI following DBS (Bannier et al., 2009; Locke et al., 2011; Macia et 
al., 2004; Montaurier et al., 2007; Novakova et al., 2011; Novakova et al., 2007; 
Sauleau et al., 2009; Strowd et al., 2010; Tuite et al., 2005; Walker et al., 2009; 
Zahodne et al., 2011).  
Studies assessing food intake and weight in animals 
Table 2.5 summarises the 25 animal studies that investigated the effects of 
neuromodulation on food intake and/or body weight. Three examined the 
feasibility of DBS as a potential treatment for ED, specifically AN. Lacan et al. 
(2008) implanted the ventromedial hypothalamus of two monkeys and 
reported significant increases in food intake with active HF DBS compared to 
inactive DBS. Despite this, there was no change in body weight during the four 
month study period. The remaining two studies investigated the effects of DBS 
(sometimes referred to as electrical brain stimulation; EBS) of the lateral 
hypothalamus (Welkenhuysen, Van Kuyck, Das, Sciot, & Nuttin, 2008) and 
nucleus accumbens (van der Plasse, Schrama, van Seters, Vanderschuren, & 
Westenberg, 2012) in rats. The first found no significant changes to food intake 
but the latter reported that DBS of the medial shell of the nucleus accumbens 
(but not to the core or lateral shell) increased food intake by up to 250% (van 
der Plasse et al., 2012).  
Eight studies examine the effects of VNS and DBS in binge eating/obesity animal 
models. Three RCT demonstrate decreased food consumption and/or lowered 
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weight gain in pigs following active VNS (Sobocki, Fourtanier, Estany, & Otal, 
2006; Val-Laillet, Biraben, Randuineau, & Malbert, 2010) and rats (Bugajski et 
al., 2007). 
Four studies applied DBS to the hypothalamus in rats (Sani, Jobe, Smith, 
Kordower, & Bakay, 2007; Torres, Chabardes, & Benabid, 2012) monkeys 
(Torres, Chabardes, Piallat, Devergnas, & Benabid, 2012) and pigs (Melega, 
Lacan, Gorgulho, Behnke, & De Salles, 2012). High-frequency DBS to the lateral 
hypothalamus in rats resulted in sustained weight loss (Sani et al., 2007) whilst 
DBS to the ventromedial hypothalamus produced mixed findings. Torres, 
Chabardes, and Benabid (2012) found that compared to inactive DBS, HF 
(130Hz) DBS increased food intake, whilst LF (30Hz) DBS reduced food intake 
in 27 rats. In contrast, Torres, Chabardes, Piallat, et al. (2012) found 8 hours of 
HF (80Hz) DBS decreased food intake in all five monkeys after fasting, and 
reduced body weight/BMI in three (of four) monkeys after 8 weeks of 
stimulation. Melega et al. (2012) administered LF DBS to the ventromedial 
hypothalamus in eight mini pigs given double their amount of daily food for a 
two month period. All animals consumed the food given, however those who 
received active DBS showed lower cumulative weight gain than the non-
stimulated group. 
As far as we are aware, only one animal study has investigated the effects of DBS 
on binge eating behaviours. Halpern et al. (2013) demonstrated that short term 
(1hr) DBS to the nucleus accumbens (but not the dorsal striatum) reduced binge 
eating in mice and chronic stimulation to the nucleus accumbens over four days 
led to a reduction in caloric intake and induced weight loss.  
Four studies report changes in food intake and/or body weight in rats following 
VNS. These studies applied VNS for a period of 15 – 42 days. All four found a 
reduction in food intake, body weight/fat and/or weight gain following VNS 
(Banni et al., 2012; Gil, Bugajski, & Thor, 2011; Laskiewicz et al., 2003; Ziomber 
et al., 2009). 
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Finally, ten studies suggest changes in food intake and weight as a result of DBS 
to two areas of the hypothalamus. In general, stimulation of the lateral 
hypothalamus induced food intake in both cats and rats (Delgado & Anand, 
1953; Halperin, Gatchalian, Adachi, Carter, & Leibowitz, 1983; Mogenson, 1971; 
Schallert, 1977; Stephan, Valenstein, & Zucker, 1971). However a number 
employed complex protocols involving comparisons with copulatory behaviours 
(Stephan et al., 1971) or DBS/EBS in conjunction with food deprivation 
(Schallert, 1977) or adrenergic interventions (Halperin et al., 1983) so their 
findings lack comparability. DBS/EBS to the ventromedial hypothalamus 
consistently reduced food intake and/or reduced weight gain (Bielajew, Stenger, 
& Schindler, 1994; Brown, Fessler, Rachlin, & Mullan, 1984; Lehmkuhle, Mayes, 
& Kipke, 2010; Ruffin & Nicolaidis, 1999). 
Discussion 
This review provides evidence that neuromodulation has potential for altering 
disordered eating behaviours, food intake and body weight. Non-invasive 
neuromodulation techniques (rTMS, tDCS) have been shown to prevent and 
reduce cravings in individuals who report frequent food cravings and rTMS 
applied to the PFC also has shown promise for reducing BN symptoms. In AN, 
the data also demonstrate potential for symptom improvement including 
weight gain, following both rTMS and DBS. Furthermore, reports of significant 
weight gain following DBS for Parkinson’s disease and in animal models provide 
grounds for investigating the use of DBS in AN, whilst evidence suggests that 
VNS may have potential as an alternative bariatric intervention. 
Methodological considerations 
Findings reported in this review must be interpreted in the context of the 
varying methodologies considered. Four different techniques, rTMS, tDCS, VNS 
and DBS have been reviewed and within each exists the potential for a wide 
range of protocols. Each technique has the ability to suppress/enhance neural 
activity via a number of different parameters - frequency, duration, intensity, 
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number of pulses, number of sessions and stimulation sites. Such differences 
may help explain why some studies report no changes in ED symptoms or 
weight following neuromodulation (Barth et al., 2011; Kansagra et al., 2010; 
Koren & Holmes, 2006; Walpoth et al., 2008). The degree to which studies vary 
from one another methodologically, also limits their comparability and hence 
the generalisability of these findings. On the other hand, the number of 
neuromodulatory techniques available and the wide range of protocol options 
possible within each, means that the field is advancing along a broad front.  
Further studies on the neural effects of neuromodulation are needed to optimise 
protocols: these are likely to arise from research involving online 
neuroimaging/neuromodulation. Data from animal models are also important, 
but must be interpreted with caution as factors such as the ratio of 
neuromodulation device (e.g. TMS coil size) to head size, coil orientation, 
anaesthesia and mechanical restraint are just a few elements that need to be 
considered when findings are extrapolated to humans (Vahabzadeh-Hagh, 
Muller, Gersner, Zangen, & Rotenberg, 2012). Finally, although limited by issues 
of stimulation focality and differences between animal and human brains, 
animal models are likely to provide important information on the mechanisms 
of neuromodulation and their potential for use in the treatment of ED.  
Repetitive Transcranial Magnetic Stimulation 
rTMS has been investigated in healthy individuals, those reporting frequent 
food cravings, and in patients with BN and AN. Most of this work has involved 
HF (excitatory) rTMS to the left PFC. The studies demonstrate its promise in 
stabilising food cravings during food exposure, and reducing both BN and AN 
symptoms. Arguably, this may result from restoring altered ‘top-down’ cognitive 
control in relation to emotional and other self-regulation processes. Given the 
demonstrated ability of rTMS to modulate food cravings and binge eating 
episodes, in addition to its non-invasive, safe and relatively tolerable nature it is 
perhaps surprising that no studies have investigated its potential in BED or 
obesity. Lastly, given the chronic and life-threatening nature of AN and the 
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promising data on rTMS in AN, larger, sham controlled studies are needed (see 
Chapter 3).  
The use of neuroimaging techniques in ED is likely to increase knowledge of the 
neural correlates of disordered eating and this will enable refinement and 
optimisation of rTMS protocols for treating specific ED. In particular, the role of 
right fronto-temporal circuits in ED as outlined in a review of brain lesions in 
ED (Uher & Treasure, 2005) and reports of ED resolution following right 
temporal lobe injuries (Levine, Lipson, & Devinsky, 2003) suggest that right 
sided rTMS may be equally, if not more effective than the predominately left 
sided rTMS protocols.  
Transcranial Direct Current Stimulation 
Increased knowledge on the role of hemispheric lateralisation in ED, together 
with improvements in the design of neuromodulation protocols is likely to 
emerge from studies involving tDCS. To date, most tDCS research has been in 
relation to food cravings and has shown that excitation of the right/inhibition of 
the left PFC reduces cravings during cue exposure. Stabilisation of cravings 
during exposure was observed with the opposite tDCS protocol, which is 
somewhat consistent with the rTMS literature. The idea that increasing activity 
in the right PFC may decrease cravings/appetite and re-establish control over 
eating is also consistent with the right brain hypothesis of obesity (Alonso-
Alonso & Pascual-Leone, 2007). It is possible that there is some type of inter-
hemispheric imbalance in conditions involving cravings and over eating, but 
more neuroimaging based evidence is required. 
In comparison, the idea of right hemispheric dominance in AN, specifically 
hyperactivity in the right frontal regions, is somewhat established, and it is 
possible that anodal left/cathodal right tDCS may aid in altering/resetting inter-
hemispheric balance (Hecht, 2010). This is consistent with the TMS literature in 
AN, which shows symptom reduction following excitation of the left DLPFC. By 
comparing the two possible tDCS designs to sham tDCS in AN, the possible role 
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of hemispheric lateralisation in the illness may be elucidated. As in the case of 
rTMS, there is a need for more investigations of tDCS within ED populations.  
Vagus Nerve Stimulation 
Evidence from the use of VNS in other psychiatric and neurological disorders 
and in animal studies supports the argument for more investigations in ED, 
especially obesity. Whilst VNS seems to have induced weight loss in a 
proportion of participants with depression, obesity or epilepsy, VNS in animals 
has consistently been associated with reductions in food intake and/or weight 
loss.  
The vagus nerve is the major neural pathway carrying information to the 
gastrointestinal tract. In the current review, VNS has been associated with 
changes in food intake and resulting body weight suggesting that vagal 
stimulation mediates satiety signals. Given the increasing prevalence, high 
morbidity and mortality of obesity, VNS has potential as an alternative to more 
invasive treatments for morbid obesity, which are often associated with severe 
side-effects and unsustainable weight loss. 
Deep Brain Stimulation 
DBS has been used in a number of treatment studies of AN, in part as a result of 
emerging neural based models of AN. The results are promising – two case 
reports resulting in remission of the illness, and two case series resulting in 
increases in body weight and reductions in symptoms in most patients. 
Furthermore, the reviewed cases have demonstrated DBS to be a safe procedure 
with minor side effects. Existing studies of DBS in AN have targeted a variety of 
different brain structures and thus more research is needed in order to 
establish optimal DBS targets. Moreover, larger controlled trials are needed to 
establish the long term efficacy of DBS in this difficult to treat population. 
Weight gain following DBS for Parkinson’s disease has implications for the use 
of DBS in AN. Although the reduction in motor activity (e.g. tremors) as a result 
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of DBS may contribute to resulting weight gain, two studies found no correlation 
between weight gain and reduced motor activity following DBS (Locke et al., 
2011; Montaurier et al., 2007). A number of explanations have been proposed 
including the suggestion that the DBS current may spread to the hypothalamic 
satiety centres. In support of this, a number of animal studies report increases 
in food intake and/or body weight following DBS to the lateral hypothalamus. In 
contrast, stimulation to the ventromedial hypothalamus shows the opposite, 
particularly when applied at lower frequencies. Interestingly, two studies 
showed lower rates of weight gain in stimulated animals despite no changes in 
the amount of food consumed, suggesting that DBS may alter metabolic rate 
(Lehmkuhle et al., 2010; Melega et al., 2012).  
Considerations for neuromodulation in eating disorders 
ED are complex, multifaceted mental illnesses, associated with altered thinking 
and beliefs, heightened fear and anxiety responses, mood disturbances and a 
myriad of other symptoms. The ED are therefore not simply about eating. 
Although this review reports solely on the effects of neuromodulation on eating 
related behaviours and resulting weight gain/loss, such changes are likely to 
arise as a result of effects to some of the underlying cognitive, emotional and 
self-regulatory aspects of ED, such as cognitive rigidity, impaired decision 
making, poor inhibition and altered self-control. Such traits are proposed to be 
caused by the same dysfunctional fronto-subcortical circuits (Celone et al., 
2011; Marsh et al., 2011; Marsh, Maia, et al., 2009; Marsh, Steinglass, et al., 2009; 
Sato et al., 2013). Neuromodulation is likely to alter such neurocognitive 
impairments in ED, however further investigations employing 
neuropsychological outcomes are required (see Chapter 4).  
Changes in neuropsychological aspects of ED following neuromodulation may 
also result from alterations associated with neuroplasticity. Studies in animals 
have demonstrated that repeated sessions of HF rTMS induce long-lasting 
effects in neuroplasticity (Gersner, Kravetz, Feil, Pell, & Zangen, 2011). Such 
findings have implications for intractable, neuro-circuit disorders such as AN. 
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Changes in neuroplasticity highlight the potential of including exposure 
therapies with neuromodulation protocols in ED, to facilitate extinction learning 
(Koskina, Campbell, & Schmidt, 2013). In rats, HF rTMS paired with exposure to 
a conditioned stimulus facilitated fear extinction up to 24 hours post 
stimulation (Baek, Chae, & Jeong, 2012). Whilst a number of studies reviewed 
here include exposure to highly palatable foods immediately before and after 
neuromodulation, online approaches applying neuromodulation during 
exposure tasks may bolster outcomes. 
Similarly, individual differences in cortical plasticity have been shown to 
modulate the behavioural effect of neuromodulation (Plewnia et al., 2013). 
Research into individual neural patterns will enable more precise, personalised 
protocols for rTMS, tDCS, VNS and DBS. Altering neuromodulation parameters 
such as stimulation site and frequency (excitatory/inhibitory) as a result of a 
better understanding of hemispheric lateralisation and hyper- or hypo-activity 
of certain brain regions is one likely possibility. In addition, brain imaging could 
be used to identify biomarkers of treatment response and thus individualised 
neuromodulation foci. 
Such neural targets may include the insula and other sub-cortical structures 
involved in emotional responses and reward processing, and implicated in brain 
imaging ED research. However, the neural effects of common non-invasive 
neuromodulation techniques such as rTMS and tDCS are thought to be limited to 
the outer cerebral cortex. Continuing innovation within the neuromodulation 
domain has led to the development of tools with both improved focality and a 
greater depth of modulatory effects. Deep TMS operates on the same principle 
of electromagnetic induction as standard TMS. However, the standard TMS 
figure-of-eight coil alters cortical excitability up to a depth of 1.5-2.5cm. In 
comparison, the most widely used and safety tested deep TMS coil – the H-coil – 
exerts neuromodulatory effects up to 6cm from the scalp (Bersani et al., 2013). 
Early evidence suggests that patients with treatment resistant depression who 
are also ECT non-responders may benefit from deep TMS (Rosenberg, Zangen, 
Stryjer, Kotler, & Dannon, 2010). Deep TMS may therefore have a place in future 
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ED neuromodulation applications. Modulation of both the cerebral cortex and 
limbic neural circuits that deep TMS may induce could enable changes to both 
the dysfunctional ‘top-down’ dorsal circuits as well as the ‘bottom-up’ ventral 
systems proposed to underlie ED. Similarly, building on advances from TMS 
research, magnetic seizure therapy (MST) induces a seizure via HF rTMS. 
Despite the same final outcome as ECT i.e. a ‘therapeutic’ seizure – increased 
stimulation focality, lessened side effects in conjunction with similar 
antidepressant response rates to ECT, have been found in the early stage of MST 
investigations, indicating that this a preferable alternative (Hoy et al., 2013). 
Overall summary 
Increasing knowledge of the neural underpinnings of ED, and the evidence 
emerging from neuromodulation studies indicates that treatments for ED 
should not remain ‘brainless’. Although neuromodulation treatments are 
unlikely to be stand-alone treatments for ED or obesity, this review 
demonstrates the potential of rTMS, tDCS, VNS or DBS to improve outcomes. In 
particular, reducing problematic eating behaviours and promoting weight gain 
in enduring and chronic cases of AN seems feasible via the use of 
neuromodulation techniques. 
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HP: healthy participants; rTMS: repetitive transcranial magnetic stimulation; RCT: randomised control trial; DLPFC; dorsolateral prefrontal 
cortex; Hz: Hertz; min: minutes; MT: motor threshold 
  
Table 2.1 Neuromodulation studies in healthy participants and people with frequent food cravings 
 N 
 
Sample Type Design Area Protocol Findings Comments 





rTMS RCT  
parallel, 
blinded  
i) real to right 
DLPFC,   
2 controls: ii) 
real to vertex 





1Hz, 15min   
50% output  
900 pulses 
1 session  
Neuronavigated 
Compared to control conditions, real 
rTMS to right DLPFC decreased the 
























5cm anterior method 
Food cravings with food exposure 
remained stable after real rTMS & 
increased after sham rTMS. 
 

















1 session of each 
condition 
5cm anterior method 
Real rTMS reduced cravings no better 
than sham. 
Improved sham 




HP: healthy participants; tDCS: transcranial direct current stimulation; RCT: randomised control trial; DLPFC: dorsolateral prefrontal 
cortex; mA: milliamps; min: minutes; EEG: electroencephalography 
Table 2.1 (continued) Neuromodulation studies in healthy participants and people with frequent food cravings 
 N 
 
Sample Type Design Area Protocol Findings Comments 















vs. iii) sham 
DLPFC 2mA, 20min 
1 session of each 
condition 
10-20 EEG system (F3 
for left DLPFC, F4 for 
right DLPFC) 
Cravings decreased with anode 
right/cathode left, remained stable 
with anode left/cathode right & 
increased after sham. Subjects fixated 
(eye-tracking) on food-related pictures 
less after anode right/cathode left. 
Subjects consumed less food after both 
types of active stimulation. 
 









crossover, blinded   
i) anode 
right/cathode left, 
vs. ii) sham 
DLPFC 2mA, 20min 
1 session of each 
condition 
10-20 EEG system (F3 
for left DLPFC, F4 for 
right DLPFC) 
Food cravings reduced in both 
conditions; percentage change 
significantly greater in active tDCS. 
Active tDCS reduced cravings for sweet 
foods & carbohydrates more than sham. 
No difference between groups in 
amount of food ingested. 
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BN: bulimia nervosa; DP: depression; rTMS: repetitive transcranial magnetic stimulation; RCT: randomised control trial; DLPFC: 
dorsolateral prefrontal cortex; HZ: Hertz; min: minutes; MT: motor threshold; OCD: obsessive compulsive disorder; hrs: hours  
  
Table 2.2 Neuromodulation studies in people with bulimia nervosa and in obese individuals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Hausmann et 
al (2004) 
1 BN/DP rTMS Case report Left-
DLPFC 
20Hz, ~12min,  
80% MT 
10 sessions; 2 per weekday 
for 2 weeks 
Neuronavigated 
Complete recovery from 
binge/purge symptoms & 
~50% decrease in depression 
scores.  
 
Walpoth et al 
(2009) 
14 BN rTMS RCT  
parallel 
double blind 






Total of 30000 pulses 2000 
pulses per/session 
15 sessions; 1 per weekday 
for 3 weeks 
Neuronavigated 
Improvement in self-reported 
binge/purge behaviours, 
depressive & OCD symptoms in 
both groups. No difference 
between real & sham groups. 
 
Van den 












10Hz, 20min, 110% MT 
1000 pulses 
1 session 
5cm anterior method 
Compared to sham, real rTMS 
was associated with a decrease 
in self-reported urge to eat & 










rTMS Case series 
All received real 
despite being 
told they might 
receive real or 
sham. Compared 




10Hz, 20min, 110%MT 
1000 pulses 
1 session 
5cm anterior method 
Left-handed group: decrease in 
reported cravings whilst urge 
to eat remained stable. Mood 
deteriorated in the left-handed 
group yet improved in the right 
handed group. No difference 
between right & left handed 
groups in urge to eat, urge to 
binge, tension or hunger.  
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BN: bulimia nervosa; DP: depression; OB: obese; rTMS: repetitive transcranial magnetic stimulation; tDCS: transcranial direct current 
stimulation; RCT: randomised control trial; DMPFC: dorsomedial prefrontal cortex; DLPFC: dorsolateral prefrontal cortex; Hz: Hertz; min: 
minutes; MT: motor threshold; mA: milliamps; EEG: electroencephalography; ED: eating disorder 
Table 2.2 (continued) Neuromodulation studies in people with bulimia nervosa and in obese individuals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Downar et al 
(2012) 
1 BN/DP rTMS Case report DMPFC 
(both) 
10Hz, 15min, 120% MT 
3000 pulses 
40 sessions in total 
Neuronavigated 
a) 20sessions; 1 per 
weekday for 4 weeks 
b) Repeat second course 
requested (20) 
a) Full remission of 
binge/purge episodes & 
depression for more than 2 
months post treatment 
completion. 
b) After significant life stressor, 
requested repeat course. 
Remained in remission from ED 
and depression. 
Full remission for 
64 days. Three 
single 
binge/purge 




to repeat course. 
Montenegro et 
al (2012) 
9 OB tDCS RCT crossover, 
blinded 
i)sham/anodal 
left DLPFC, ii) 
sham/anodal left 
DLPFC+ exercise  
DLPFC 2mA, 20min, 
1 session of each condition 
10-20 EEG system (F3 for 
left DLPFC) 
Compared to sham, active 
anodal left DLPFC tDCS 
decreased desire to eat. Anodal 
left tDCS + aerobic exercise led 
to greater suppression of desire 
to eat than tDCS/exercise alone.  
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AN: anorexia nervosa; DP: depression; rTMS: repetitive transcranial magnetic stimulation; DBS: deep brain stimulation; DLPFC: dorsolateral 
prefrontal cortex; SCC: subgenual cingulate cortex; Hz: Hertz; min: minutes; MT: motor threshold; EEG: electroencephalography; mA: 
milliamps; µS: microseconds; ED: eating disorder; BMI: body mass index 
  
Table 2.3 Neuromodulation studies in people with anorexia nervosa 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Kamolz et al 
(2008) 
1 AN/DP rTMS Case report Left-
DLPFC 
10Hz, 20min, 110% MT 
2000 pulses 
41 sessions in total 
10-20 EEG system (F3) 
a) 10 sessions/16 days 
b) deterioration 10 days 
post treatment; 6 more 
sessions 
c) requested third course of 
10 sessions 
d) maintenance; 15 
sessions, 2 p/week for 8 
weeks 
a) Improvement in depressive & 
ED symptoms e.g. 
uncomplicated food intake and 
weight gain.  
b) Reduction in depressive 
symptoms 
c) Significant reduction in 
depressive symptoms and 
eating programme effective 
after these ten sessions. 
d) Continuous improvement of 
depression and ED symptoms.  
Maintenance 
sessions required 
to reduce the 
chance of a second 
relapse. 
Van den 





rTMS Case series 
All received 
real despite 






10Hz, 20min, 110% MT  
1000 pulses 
1 session 
5cm anterior method 
Real rTMS resulted in reduced 
levels of feeling full, fat, and 
anxiety. Trend towards a 
decrease in urge to exercise. No 
difference in urge to restrict, 
urge to eat, mood, tension and 
hunger. 
 
Israel et al 
(2010) 
1 AN/DP DBS Case report SCC 
Bilateral 
Right-sided intermittent,  
2min on/1min off  
130Hz, 5mA, 91µS  
Remission of ED, no relapse and 
maintained average BMI of 19.1. 








AN: anorexia nervosa; OCD: obsessive compulsive disorder; DBS: deep brain stimulation; NuAcc: nucleus accumbens; VC/VS: ventral 
capsule/striatum; SCC: subgenual cingulate cortex; Hz: Hertz; V: volts; µS: microseconds; BMI: body mass index 
Table 2.3 (continued) Neuromodulation studies in people with anorexia nervosa 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Wu et al 
(2012) 




Average of 65% increase in body 
weight at 38 month follow-up. All 
patients weighed >85% of expected 
body weight, menstruation 
restored & no longer meet the AN 
diagnostic criteria. Depression & 
OCD symptoms improved. 
Patients age 16-17 
years, duration of 
illness 13-28 months. 




1 AN/OCD DBS Case report VC/VS  
Bilateral 
120Hz, 7.5V, 120µS 
Monopolar 
There was reduction in food/eating 
related concerns. Food intake, food 
variety & body weight were 
increased. BMI maintained 
between 18.9 – 19.6 
Symptoms worsened 
when cathode 
electrode added.  
Lipsman et al 
(2013) 
6 AN DBS Prospective 
case series 
SCC 130Hz, 5-7V, 90µS 
 
At 9 month follow-up, 3 patients 
(50%) increased & maintained BMI 
greater than their historical 
baseline. Improvement in 
food/weight preoccupations, 
mood, anxiety, affect regulation & 
quality of life. Changes in cerebral 
glucose metabolism & reversal of 
abnormalities in variety brain 
regions.  
Patients age 20-60 
years, treatment 
resistant. Side effects 
include: panic attacks, 
nausea, air embolus, 
pain and seizure (1 
patient only). 
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OCD: obsessive compulsive disorder; DP: depression; OB: obesity; EP: epilepsy; DBS: deep brain stimulation; VNS: vagus nerve stimulation; 
HC: healthy controls; NuAcc: nucleus accumbens; VN: vagus nerve; Hz: Hertz; V: volts; µS: microseconds; mA: milliamps; sec: seconds; min: 
minutes; BMI: body mass index; HC: healthy controls 




Sample Type Design Area Protocol Findings Comments 
Mantione et 
al (2010) 
1 OCD DBS Case report NuAcc 185 Hz, 3.5V, 
90µs 
Monopolar 
First few months’ post-surgery 
weight gain of 8kg. Then after 
conscious decision to lose weight 
(weighing 115kg), 10 months after 
dieting was at target weight of 
71kg (BMI = 25). Maintained 





al (2007a, b) 
33 DP VNS a) Between groups 
comparison:                     
i) depression VNS,            
ii) depression non-VNS, 
iii) HC 
b) Within VNS group: 
crossover, blinded VNS 
i) on versus ii) off 
Left VN 20Hz, 1.25mA 
0.5-84 months 
1 session 
Groups did not differ in mean food 
cravings & their ability to resist 
food. Between viewing food 
images, cravings for sweet foods 
differed between groups: 
depressed-VNS had higher change 
scores for craving of sweets than 
depression non-VNS and HC.  
 
In VNS group 
cravings for sweets 
changed in both 
directions. 
Decrease in six 
participants, 
increase in five.   
Pardo et al 
(2007) 
14 DP/OB VNS  Left VN 30Hz, 0.25-
1.5mA, 
250 or 500µs  
30sec on/ 5 
min off 
24 months 
Significant, effortless weight loss 
proportional to initial BMI. 
Stimulation parameters had no 
effect on weight changes.  
 
Burneo et al 
(2002) 
27 EP VNS Retrospective Left VN - Significant weight loss (>5%) in 17 
patients. Remaining patients had 
no significant change in weight. 
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Sample Type Design Area Protocol Findings Comments 
Koren et al 
(2006) 
21 EP VNS Retrospective Left VN 30Hz, 1.25-
3mA, 500µs 
30sec on & 
5sec off 
24 months 
No significant change in weight 
within 2 years following VNS 
implantation. 
 
Kansagra et al 
(2010) 
23 EP(c) VNS Retrospective Left VN - No significant changes in BMI at 1 
year and final time point (mean 
4.2 years) following VNS 
implantation. 
 
Macia et al 
(2004) 
33 PD DBS Retrospective 
PD DBS (n=19) vs. PD 
non-DBS (n=14) 
STN 130Hz, 1.5-3V, 
90µs 
Monopolar 
18/19 DBS patients had 
significant weight gain and 
increase in BMI. Significant 
reduction in resting EE, no 
change in daily EE 
 
Tuite et al 
(2005) 
27 PD DBS Retrospective STN - Significant weight gain up to 12 
months after surgery.  
 
Novakova et al 
(2007) 
25 PD DBS Retrospective STN 
Bilateral 
- Average weight gain of 9.4kg 
during first follow-up at 1-45 
months post- implantation. One 
year later, decrease in 12 
patients, increase in 6 & 3 
remained stable. 
 






DBS Prospective  STN 
Bilateral 
148.0Hz, 2.7-
2.8V, 69µs  
Increase in body weight & fat 




EE and weight 
gain 
EP: epilepsy; EP(c): children with epilepsy; PD: Parkinson’s disease; VNS: vagus nerve stimulation; DBS: deep brain stimulation; VN: vagus 
nerve; STN: sub-thalamic nucleus; Hz: Hertz; mA: milliamps; µS: microseconds; sec: seconds; V: volts; BMI: body mass index; EE: energy 
expenditure; kg: kilograms 
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PD: Parkinson’s disease; DBS: deep brain stimulation; STN: sub-thalamic nucleus; GP, globus pallidous; VIM: ventralis intermedius nucleus; 
Hz: Hertz; µS: microseconds; kg: kilograms  




Sample Type Design Area Protocol Findings Comments 
Walker et al 
(2009) 
39 PD DBS Retrospective STN 
Unilateral 
- Compared to preoperative 
baseline, weight increased by mean 
of 4.3kg 1 year following surgery. 
 
Bannier et al 
(2009) 
22 PD DBS  STN  68% patients overweight/obese 3 
months post-surgery, increased to 
82% at 16 months post-surgery. 
 
Sauleau et al 
(2009) 
46 PD DBS DBS to STN (n=32) 
versus DBS to GPi 
(n=14) 
STN/GP 130Hz, 60µs  
 
Significantly higher increase in BMI 
in STN DBS patients. 
 






- Significant weight gain up to 24 
months post-surgery, not predicted 
by stimulation target. 
 
Novakova et al 
(2011) 
27 PD DBS  STN - Significant weight gain during 12 
month post-implantation. 
 
Locke et al 
(2011) 
52 PD DBS Retrospective STN/GP 
Unilateral 
- Significant weight gain following 
surgery, no significant difference in 





motor scores & 
weight gain.  
Zahodne et al 
(2011) 
100 PD DBS Prospective STN/GP - DBS implantation predicted over 




DBS/EBS: deep/electrical brain stimulation; vmH: ventromedial hypothalamus; Hypoth: hypothalamus; NuAcc: nucleus accumbens; Hz: 
Hertz; V: volts; µS: microseconds; msec: milliseconds; BMI: body mass index; EE: energy expenditure.  
Table 2.5 Neuromodulation studies assessing food intake and/or weight in animals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Animal models of anorexia nervosa 
 
Lacan et al 
(2008) 
2 Monkeys DBS 2 cycles of 
stimulation a) 8 
days of active, 2 
days of inactive, 
b) 3 days active, 
3 days inactive. 
vmH 
Bilateral 
a) 185Hz, 2.5V, 
90µsec 
b) 185 Hz, 3.5V, 90 
µsec 
Significant increase in food intake 
during active stimulation. There was 




26 Rats EBS 
(DBS) 










a) 100 Hz, 0.06 
msec, 3.5hrs 0, 






a) Decrease in the number of wheel 
rotations (lower activity levels), but 
no impact on food intake. b) No 
effect on wheel rotations, or amount 
of food consumed. 
 
Van der Plasse et 
al (2012) 
8 Rats DBS Comparison of 
DBS to 3 areas of 
NAcc i) core, ii) 
lateral shell 










DBS to core had no effect on 
response to sucrose or food intake, 
to lShell reduced motivation to 
respond for sucrose, no effect on 
food intake. DBS to mShell 
profoundly increased food intake 
(250% of baseline). 
Implications for 
medial shell of 
NAcc as target 




VNS: vagus nerve stimulation; RCT: randomised control trial; VN, vagus nerve; Hypoth: hypothalamus; Hz: Hertz; V: volts; msec; milliseconds; 
mV: millivolts; mA: milliamps; µS: microseconds; sec: seconds; min: minutes  
Table 2.5 (continued) Neuromodulation studies assessing food intake and/or weight in animals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Animal models of binge eating and obesity 
  
Sobocki et al 
(2006) 
8 Pigs VNS RCT crossover 
design 
i) 4weeks on vs. 




every 3-4 hours for 
24hours 
In both groups, cumulative body weight 
gain was lower during stimulation 
period compared to the control period. 
 
Metabolic rate not 
affected.  
Bugajski et al 
(2007) 
18 Rats VNS RCT 
3 groups i) active 
VNS, ii) inactive 
VNS, iii) no VNS  
Left VN 
Unipolar 
0.05Hz, 200mV,  
10ms pulses  
100 days 
Significant decrease in meal size, fat 
weight and weight gain in VNS rats 
compared to controls. 
 
Val-Laillet et al 
(2010) 
8 Mini Pigs VNS RCT 
i) real vs. ii) sham 
VN 30Hz,2mA, 500µS 
30sec on/5min off 
14 weeks 
VNS implantation resulted in animals’ 
weight remaining stable, decreased 
food consumption & sweet food 
cravings compared to animals with 
sham implants. 
 
Sani et al 
(2007) 
16 Rats DBS RCT 
i) active 
continuous 





180-200 Hz,2.0 V, 
100msec pulse 
width, ~31 days 
Significant decrease in weight gain in 




DBS: deep brain stimulation; HF: high frequency; LF: low frequency; Hz: Hertz; hr(s): hour(s); vmH, ventromedial hypothalamus; Hypoth: 
hypothalamus; ms: milliseconds; µA: microamps; µS: microseconds; mA: milliamps; min: minutes  
Table 2.5 (continued) Neuromodulation studies assessing food intake and/or weight in animals 
 N Sample Type Design Area Protocol Findings Comments 
Torres et al 
(2011) 
27 Rats DBS Unilateral 
continuous, bipolar 
stimulation 
a) Acute: HF 
(130Hz) vs. LF 
(30Hz) b) Chronic: 
long term effects of 
HF  
vmH 30-130Hz, 60ms, 
222±103µA 
a) 30min 
b) 16 days, 
4hrs/day, 5 
days/wk, 3 weeks 
a) Acute HF increased food intake 
compared to sham. Acute LF reduced 
food intake compared to sham.  
b) Chronic stimulation (130Hz) 
slowed down body weight intake 
compared to sham.  
 
Torres et al 
(2012) 
5 Monkeys DBS a) Acute: various 
DBS parameters 
post 24hr fasting, 
vs. inactive, b) 
Chronic: 8 week 
trial of 3 protocols 
Hypoth. a) 30-130Hz, 8hrs  
b) 30Hz, 80Hz, 
130Hz continuous 
stimulation 
day/night for 8 
weeks. 
a) Decreased food intake for all MK at 
80Hz 
b) Significant decrease in body weight 
and BMI at 80Hz. Skinfolds reduced at 
80Hz yet increased at 130Hz. Sham 
MK increased their weight. 
Intraventricular 
approach 
Melega et al 
(2012) 
8 Mini Pigs DBS 2 groups: 








All animals ate the same amount of 
food, yet those that received active 
DBS had less cumulative weight gain 
than non-stimulated animals. 




Halpern et al 
(2013) 
73 Mice DBS Randomised design 
a) binge eating: 
surgical and non-
surgical mice 
b) acute DBS to 
NAcc shell or dorsal 
striatum 




a) 160Hz, 150µA,  
60µS pulses, 1hr 
b) 160Hz,150µA, 
60µS pulses for 4 
days 
DBS to NAcc shell reduced binge 
eating and increased c-Fos levels in 
this area (measure of neuronal 
activity). Dopamine receptor D2 
attenuated action of DBS. DBS to 
dorsal striatum had no influence on 
binge eating. Chronic DBS to obese 









DBS: deep brain stimulation; VNS; vagus nerve stimulation; NuAcc: nucleus accumbens; VN: vagus nerve; Hz: Hertz; µA: microamps; µS: 
microseconds; hr: hour; V: volts; sec: seconds  
Table 2.5 (continued) Neuromodulation studies assessing food intake and/or weight in animals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Other studies in animals 
 
Laskiewicz et al 
(2003) 
60 Rats VNS 5 conditions: i) left 
vagal (0.5Hz), ii) both 
vagal nerves (0.5Hz), 
iii) left vagal (0.1Hz), 
iv) both vagal nerves 
in obese rats (0.1Hz), 





0.05 and 0.1 Hz, 
0.55 V, 0.1sec for 
27days  
Body weight and total food intake 
decreased in all conditions. Effects of 
both vagal nerves stimulation on final 
body weight & food intake 
significantly more effective than only 
one single nerve. 
 
Ziomber et al 
(2010) 
78 Rats VNS 
 
 
3 conditions i) active 
in the magnetic field 
exposure (MFE), vs.2 
control groups with 
inactive solenoid 
without electrodes ii) 
in the MFE iii) outside 
the MFE 
Left VN 0.1, 0.2, 0.5 and 
1.0Hz 50, 100, 150 
and 200mV 
Stimulation 
changed every 3 
days for 15 days 
Rats with solenoid electrodes 
significantly decreased their food 
intake, weight gain & serum leptin 





Gil et al (2011) 24 Rats VNS Randomised into 3 
groups: i) active  
ii) inactive and iii) 
non-operated 
controls 
Left VN 10Hz, 200mV, 
10ms  
12hrs/day, 42 days 
Active VNS stimulation reduced daily 
and total food intake, body weight 
and body fat compared to both 
inactive & control group. No 
difference in food intake or body fat 
between inactive & control condition. 
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VNS: vagus nerve stimulation; DBS/EBS: deep/electrical brain stimulation; hr; hour; VN: vagus nerve; Hypoth: hypothalamus; Hz: Hertz; mA: 
milliamps; sec: seconds; min: minutes; µS: microseconds; V: volts; sec: seconds; hr: hour; µA: microamps; msec; milliseconds 
Table 2.5 (continued) Neuromodulation studies assessing food intake and/or weight in animals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Banni et al 
(2012) 
10 Rats VNS 2 naïve, 4 sham, 4 
VNS rats compared 
across a) acute 
(3hr) & b) chronic 
(4 weeks)  
Left VN 30Hz, 1.50mA 
30sec on/5 min off 
 
Compared to sham, chronic VNS reduced 
food intake, body weight gain & amount 
of adipose tissue. 
 
 
Delgado et al 
(1953) 
6 Cats DBS a) Control period 1-
2 weeks before 
implantation vs. b) 




60Hz, 0.2 µs, 1-5 V 
0.5sec, every 5sec, 
1hr 
5-10 days  
Daily stimulation produced increase in 
food intake. 
 
Stephan et al 
(1971) 
14 Rats EBS 
(DBS) 





0.5min on/1min off 
20 trials 












60Hz, 6-30µA, 5sec 
on/15 sec off, 
30min 
Stimulation of the lateral hypothalamic 
area induced feeding and/or drinking in 
30 rats. 
 
Schallert et al 
(1977) 
38 Rats EBS 
(DBS) 







1min on/30sec off 
Rats not attracted to food stimuli when 
undeprived, nor with stimulation alone. 
When deprived from food/water & 
stimulated became attracted to food 
stimuli.  
 
Halperin et al 
(1983) 
8 Rats EBS 
(DBS) 
4 conditions: i) 
saline, inactive EBS, 
ii) adrenergic, 
inactive EBS, iii) 







30sec on/30sec off,  
20 trials 
With combined adrenergic and EBS food 
intake was significantly greater than to 
either condition alone. 
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DBS/EBS: deep/electrical brain stimulation; RCT: randomised control trial; vmH; ventromedial hypothalamus: Hz: Hertz; µA: microamps; 
msec: V: volts; milliseconds; hr(s): hour(s); sec: seconds; µS: microseconds 
Table 2.5 (continued) Neuromodulation studies assessing food intake and/or weight in animals 
 N 
 
Sample Type Design Area Protocol Findings Comments 
Brown et al 
(1984) 
6 Dogs DBS RCT 









a) deprived food for 
24hrs, DBS for 1 
hour, repeated with 
inactive, b) 1 hr of 
DBS every 12 hours 
for 3 days 
a)dogs receiving DBS delayed their next 
meal despite food deprivation, where as 
non-stimulated dogs resumed eating 
immediately. Control subcortical white 
matter controls resumed eating 
immediately in both on/off DBS. b) 
vmH DBS decreased average daily food 
& water intake. No influence with DBS 
to subcortical white matter.  
 
Stenger et al 
(1991) 
10 Rats DBS 3 conditions: i) 
vmH stimulated, ii) 
extra vmH 
stimulated, iii) vmH 
implanted controls 
vmH 50Hz, 300µA, 100µs 
20 trains of 60sec,  
400ms on/ 600ms 
off, 12 sessions 
Significant reduction in weight gain in 




Bielajew et al 
(1994) 
49 Rats EBS 
(DBS) 
 
2 conditions: i) 
vmH,ii) adjacent 
areas of vmH 
vmH 
 
50Hz, 300µA,  
20 trains of 60s 
400ms on/600ms 
off, 3hrs duration 
3 sessions 
Stimulation bound activity associated 
with decrease in weight gain & food 
intake. Weight gain & food intake not 
affected by electrode placement. 
 
Ruffin et al 
(1999) 




i) active vs., ii) 
sham  
vmH 20-25µA, 
1ms pulse, 9ms 
interval 30sec 
on/30s off, 15min 
vmH suppressed feeding & increased 




35 Rats DBS i) chronic 
stimulation vs.  
ii) 4 control groups  
vmH 150Hz or 500Hz 
10µA, 250µs pulses  
6 weeks 
Stimulated animals gained weight at a 
lower rate than controls. No significant 







Chapter 3. A randomised single-session sham-controlled trial 




Anorexia Nervosa (AN) is a severe, difficult to treat and life-threatening 
psychiatric illness. There is no recommended treatment for adult AN (NICE, 
2004) and over 20% of individuals go on to develop severe and enduring forms 
of the illness, lasting 10-15 years (Schmidt et al., 2012; Steinhausen, 2002; 
Zipfel, Löwe, Reas, Deter, & Herzog, 2000). There is uncertainty about the 
management of these particularly chronic cases of AN (Hay et al., 2012). Talking 
therapies, which target thoughts and behaviours, have limited efficacy and there 
is a lack of evidence and acceptability of pharmacotherapy in AN (Mitchell, 
Roerig, & Steffen, 2013; Tortorella et al., 2014).   
Emerging neural models of AN suggest a neuro-circuitry underpinning the 
illness – arising from alterations in ‘bottom-up’ limbic drives responsible for 
fear and emotional responses, in conjunction with aberrant ‘top-down’ frontal 
activity central to decision making processes and self-regulatory control (see 
Chapter 1; Friederich et al., 2013; Kaye et al., 2009; Lipsman et al., 2014; Marsh, 
Maia, et al., 2009). Given the need for novel treatments and the growing 
neuroimaging data in AN, advances in the understanding and treatment of AN 
are likely to arise from investigations which utilise neuroscience technologies 
that can both probe disease mechanisms whilst also exploring the therapeutic 
efficacy of novel treatment interventions (Insel & Gogtay, 2014; Schmidt & 
Campbell, 2013).  
Neuromodulation research within psychiatric disorders is exemplary of this 
suggestion by the NIMH. The ability to alter neural activity will promote 
understanding of the neurophysiological underpinnings of mental illnesses, 
whilst also establishing the therapeutic potential of innovative treatment 
options. The therapeutic efficacy of the non-invasive neuromodulatory tool 
rTMS in other neuro-circuit psychiatric disorders such as depression, is 
relatively well established (Gaynes et al., 2014). Similarly, research into the 
biomarkers of response to rTMS has contributed to understanding the 
pathogenesis of depression, e.g. identifying the key role of substrates such BDNF 
(Fidalgo et al., 2014).  
 85 
Whilst preliminary data on the therapeutic utility of rTMS in AN are 
encouraging, further investigations in larger RCT that employ both symptom 
improvement and neurobiological outcomes are warranted. Therefore, the 
rTMS research described in this chapter assesses the effects of rTMS on some of 
the core symptoms of AN and in addition, examines the effects of rTMS on food 
preference/consumption and stress responses in AN. Moreover, issues such as 
cortical excitability in AN are discussed, along with safety and tolerability 
considerations in relation to the use of rTMS in AN.  
This chapter outlines a single-session, randomised controlled trial (RCT) of 
either real/sham (placebo) rTMS in AN and is reported according to the 
following structure; 
Background and Methods 
 Chapter 3.1 Introduction and explanation of rTMS 
 Chapter 3.2 Outline of the RCT of rTMS in AN 
Results 
 Chapter 3.3 The effects of rTMS on the core symptoms of AN 
 Chapter 3.4 The effects of rTMS on food preference and consumption in AN 
 Chapter 3.5 The effects of rTMS on salivary cortisol concentrations in AN 
 Chapter 3.6 Cortical excitability in AN 
 Chapter 3.7 Safety, tolerability and acceptability of rTMS in AN 
Summary  
 Chapter 3.8 Overall summary 
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Chapter 3.1 Repetitive Transcranial Magnetic Stimulation 
TMS is a form of non-invasive neuromodulation first developed in 1985 by 
Anthony Barker and his colleagues at the University of Sheffield. In the initial 
report, this group demonstrated the induction of a motor evoked potential 
(MEP) by applying a TMS pulse over the motor cortex and activating the 
contralateral thumb muscle (Barker et al., 1985). Most knowledge on TMS 
comes from studies on motor conductivity, given that single-pulse TMS to the 
motor cortex produces obvious, measurable effects i.e. bursts of muscular 
activity that can last for 5-10 milliseconds (Ridding & Rothwell, 2007).   
Continuing progress in the development of TMS protocols led to a number of 
ways in which TMS pulses can be applied. Paired-pulse TMS involves two 
stimuli separated by an inter-stimulus interval and can be used to measure 
intracortical facilitation/inhibition, interhemispheric inhibition and cortico-
cortical interactions (see Chapter 3.6 for more details or Rossi et al., 2009). 
Delivery of multiple single pulses, repeated within a short period, is known as 
repetitive TMS or rTMS. The ability of rTMS to induce sustained cortical effects 
(up to 30-60 minutes) that lead to physiological and cognitive effects (Pascual-
Leone et al., 1998; Pascual-Leone, Valls-Sole, Wassermann, & Hallett, 1994; 
Ridding & Rothwell, 2007) encouraged research into its therapeutic utility in a 
range of neurological and psychiatric disorders (Horvath, Perez, Forrow, Fregni, 
& Pascual-Leone, 2011).  
The first proof-of-principle study of rTMS in depression was conducted almost 
20 years ago (Kolbinger, Höflich, Hufnagel, Müller, & Kasper, 1995). Since then, 
there has been a dramatic increase in the number of published rTMS studies 
worldwide, both within healthy individuals and patients with various 
neurological and psychiatric conditions (Rossi et al., 2009). To guide such 
research, and in response to growing ethical and safety concerns, expert 
consensus groups regularly update guidelines for the use of rTMS in both 
research and clinical settings (Lefaucheur et al., 2014; Rossi et al., 2009; 
Wassermann & Lisanby, 2001). Adhering to such recommendations, rTMS has 
been established as a safe technique (Loo, McFarquhar, & Mitchell, 2008) and 
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large multi-centre controlled trials demonstrating its therapeutic efficacy have 
lead to FDA approval of rTMS as a second-line treatment for depression (Gaynes 
et al., 2014; George et al., 2010; O’Reardon et al., 2007).  
Mechanisms 
Physics 
The science underpinning TMS is based on Faraday’s law of electromagnetic 
induction. Passing an electrical current through two loops of a wire coil 
generates a time-varying magnetic field that induces a secondary electrical 
current – whose magnitude is proportional to the rate of change of the magnetic 
field – in a nearby conductor, including human tissue. In terms of TMS, as the 
electrical current passes through the coil, a magnetic field similar to that of a 
conventional MRI scanner (1.5-2.0 Tesla), but much shorter in duration, is 
produced (Rossi et al., 2009). When the TMS coil is held against an individual’s 
head, the magnetic field passes through the scalp and skull to induce a 
secondary electrical current (lasting about 200μs) in the brain (see Figure 3.1 
panel a).  
Given that the magnetic field rapidly falls off with distance from the coil, the 
stimulation is thought to primarily activate neural elements in the cortex or 
subcortical white matter. The induced electric field causes ions to flow in the 
brain and alters the electric potential of cell membranes, depolarising and 
hyperpolarising both local neurones in the cortex beneath the coil, and axons 
that project from the site of stimulation (Rossi et al., 2009). The electric field in 
the cortex is approximately 150 V/m and varies in depth and focality depending 
on the type of TMS coil used. Various physiological and behavioural effects 
result, depending on the TMS protocol used and the brain areas targeted 
(Horvath et al., 2011; Ridding & Rothwell, 2007). In summary, TMS non-
invasively stimulates the brain via electromagnetic induction, inducing 
neurophysiological changes that facilitate cognitive and behavioural changes.  
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Panel (a) demonstrates how TMS is applied, the magnetic field and secondary 
electrical current induced in the brain. Panel (b) illustrates the opposing direction 
of currents within the coil and the resulting magnetic field, which has a peak area 
of stimulation directly under the central junction of coil. Reprinted as appears in 
Ridding & Rothwell (2007) with permission from Nature Publishing Group. 
 
Coil types 
Single circular coils were the simplest and first TMS coils to be used. They 
induce a circular current flow under the coil, provide good depth of penetration 
(up to 3.5cm) but they are limited by poor focality (34cm2). When two circular 
coils are placed side by side, the induced electrical field is maximised at the 
junction of the two coils (see Figure 3.1 panel b) and this figure-of-eight coil 
design is most commonly used as it allows a good focality (5cm2) to depth 
(3.4cm) ‘trade-off’ (Deng, Lisanby, & Peterchev, 2013; Epstein, 2008). More 
recently, an H-coil has been developed that can alter neural activity up to a 
depth of 6cm and therefore may be able to modulate deeper, limbic brain 
structures. Preliminary investigations utilising the H-coil within psychiatric 
disorders, albeit predominantly to prefrontal regions, have demonstrated 
promising results (Bersani et al., 2013; Rossi et al., 2009).  
 
Figure 3.1 Diagram of the (a) application and (b) magnetic fields of TMS 
(a) (b) 
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In controlled trials of rTMS, a convincing method of placebo stimulation is 
required. Sham rTMS procedures aim to mimic the experience (i.e. appearance, 
noise, sensation) of real rTMS. Some sham procedures involve holding a real 
rTMS coil on an angle in order to reduce conductivity, however, this method still 
produces substantial stimulation (Lisanby, Gutman, Luber, Schroeder, & 
Sackeim, 2001). Therefore, specialised sham coils in which the windings are 
arranged within the coil to reduce or remove electrical current are now most 
commonly used in controlled trials. However, most sham coils do not 
adequately replicate the sensation of real rTMS. Improved designs with 
integrated scalp electrodes that produce stronger tactile responses aim to 
overcome this problem, however, they are typically cumbersome to use 
(Epstein, 2008).  
Given the difficulties in mimicking real rTMS, robust crossover designs are 
difficult to implement successfully and thus, parallel rTMS study designs are 
most common. ‘Blinding’ success, which is the ability to keep subjects and/or 
researchers unaware of the intervention administered, is crucial in interpreting 
the effects of rTMS, yet is seldom reported. However, recent reviews and meta-
analyses of those that do, suggest satisfactory rates of blinding, reporting that 
around half of participants are unable to guess whether they had real or sham 
rTMS (Berlim, Broadbent, & Van den Eynde, 2013; Broadbent et al., 2011).  
Terminology 
Motor threshold and stimulation intensity 
The intensity at which rTMS is typically applied depends on cortical excitability 
which varies between individuals. This is established by applying TMS to the 
motor cortex to establish a person’s motor threshold (MT). Typically this is the 
resting MT, i.e. when the target muscle is relaxed. The MT can be determined in 
two ways: the observed method where MT is the minimum stimulator output 
intensity required to evoke 5 out of 10 visible movements or twitches in a 
contralateral muscle, typically the thumb/finger. Alternatively, MT can be 
established using MEP whereby MT is the minimum stimulator output intensity 
required to obtain 5 out of 10 MEP greater than 50μV (Rossini et al., 1994; 
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Rothwell et al., 1999). There is a general consensus that the MEP method is a 
more accurate, conservative and safer way to assess MT, and is therefore 
preferable to the observed movement method (Anderson & George, 2009; 
Hanajima et al., 2007; Rossi et al., 2009).  
Each person’s MT should be determined prior to rTMS and stimulation 
output/intensity, i.e. the intensity of the magnetic field, is based on MT. Typical 
stimulation intensities used within psychiatric research, range between 80 – 
120% of MT (George et al., 1995; O’Reardon et al., 2007) with some evidence 
suggesting higher stimulation intensities are associated with greater treatment 
efficacy (Padberg et al., 2002). 
Pulse frequency and trains of stimulation 
In rTMS protocols, the number of pulses delivered per second is referred to as 
the frequency (Hz) of the stimulation. LF or ‘slow’ rTMS refers to protocols with 
a stimulus rate less than 5Hz, whilst HF or ‘fast’ rTMS applies pulses at a rate of 
5Hz or above (see Figure 3.2). The two types of rTMS, LF and HF, are proposed 
to have inhibitory and excitatory effects on neural activity respectively (Rossi et 
al., 2009); the neurophysiological mechanisms of which are described below. 
10 seconds of 1Hz/LF; 10 seconds of 5Hz/HF; 1 second of 10Hz/HF and 20 Hz 
rTMS delivered in 2 second train/28 second inter-train intervals. Reprinted (with 
minor amendment) as appears in Rossi et al. (2009) with permission from Elsevier. 
 
Figure 3.2 Examples of rTMS protocols 
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For both safety and efficacy reasons, current guidelines suggest LF rTMS should 
be applied in a continuous train, whilst the pulses of rTMS in HF protocols 
should be administered in ‘trains’ of stimulation separated by adequate ‘inter-
train intervals’ of no stimulation (see last example in Figure 3.2). This is done 
for a number of reasons, but primarily to ensure safety, as the accumulation of 
rTMS pulses in the brain increases risk of seizure. Also, the electrical pulses 
cause heating of the TMS device and the inter-train interval allows time for both 
the TMS device and coil to cool in between trains.  
Physiological effects 
Despite significant advances in the development of rTMS devices and protocols, 
our understanding of the neurophysiological mechanisms underlying its effects 
is limited. Short-term effects are proposed to reflect changes in neural 
excitability caused by shifts in the ionic balance in populations of active 
neurones (Ridding & Rothwell, 2007). Long-term effects of rTMS on neural 
activity have been proposed to result from a number of mechanisms. Following 
rTMS, changes in cerebral blood flow (CBF) (Loo et al., 2003) and the release of 
dopamine (Cho & Strafella, 2009), serotonin (Baeken et al., 2011) and glutamate 
(Michael et al., 2003) in both local and remote areas to the brain region 
targeted, have been reported. However, the most current hypothesis underlying 
the therapeutic mechanisms of rTMS within neuro-circuit based disorders 
relates to changes in the ‘effectiveness’ and functional remodelling of neuronal 
synapses, referred to as neuroplasticity (Medina & Tunez, 2013). For example, 
there is a growing understanding of the association between rTMS and the 
expression of BDNF, a neurotrophin essential for synaptic and learning 
plasticity (Gersner et al., 2011; Medina & Tunez, 2013) along with reported 
increases in glutamatergic synaptic strength inducing structural plasticity and 
functional network connectivity following HF rTMS (Esslinger et al., 2014; 
Vlachos et al., 2012). Thus, the enhancement or reduction of synaptic 
transmission that characterises long-term potentiation (LTP) and long-term 
depression (LTD) respectively, have been proposed to underlie the effects of 
rTMS (Hoogendam, Ramakers, & Di Lazzaro, 2010). 
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Excitatory and inhibitory effects of rTMS 
The LTP/LTD effects of rTMS depend on the protocol used; HF rTMS typically 
excites neural activity whilst LF inhibits (Houdayer et al., 2008). For example, 
increases and decreases in rCBF of the PFC in depressed patients have been 
reported following HF and LF rTMS respectively (Loo et al., 2003). In healthy 
individuals, HF rTMS reportedly increases concentration of dopamine (Cho & 
Strafella, 2009; Strafella, Paus, Fraraccio, & Dagher, 2003) and serotonin 
concentrations in depressed patients (Baeken et al., 2011). Moreover, animal 
studies suggest that levels of BDNF are increased following HF rTMS, yet remain 
unchanged following LF rTMS (Gersner et al., 2011). Such findings underscore 
the notion that HF and LF rTMS have opposite effects on neural activity 
(Houdayer et al., 2008). However, frequency is not the only determinant of the 
neural effects of rTMS, as longer stimulation duration and inter-individual 
variability are also relevant when considering the neural excitatory, inhibitory 
or neuroplasticity effects of rTMS (Hoogendam et al., 2010).  
Stimulation site and their localisation 
The site of stimulation in rTMS research depends on the condition and/or 
symptom of interest. The primary area targeted in psychiatric research has been 
the DLPFC. Specially, the DLPFC has been targeted with rTMS in depression for 
a number of reasons including suggested dysfunction (specifically an 
underactive left DLPFC), frontal asymmetry, the DLPFC being highly connected 
with other key mood regulation regions, but also because of it’s accessibility for 
rTMS (Cummings, 1993; Wassermann & Lisanby, 2001).  
A large number of studies have located the DLPFC using the ‘5cm anterior 
method’ in which it is located by measuring and positioning the coil 5cm 
anterior from the optimal point/’hot-spot’ for determining MT. However, recent 
evidence suggests that more specific stereotaxic localisation methods based on 
individual neuroimaging should be used. This type of MRI-guided rTMS, termed 
‘neuronavigation’, has been suggested to be superior in accurately and reliably 
(both between and within individuals) locating the DLPFC when compared to 
the 5cm anterior method (Ahdab, Ayache, Goujon, & Lefaucheur, 2010; 
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Bradfield, Reutens, Chen, & Wood, 2012; Herwig, Padberg, Unger, Spitzer, & 
Schönfeldt-Lecuona, 2001; Herwig, Schönfeldt-Lecuona, et al., 2001; Rusjan et 
al., 2010). Moreover, preliminary evidence suggests that, compared to rTMS 
applied via the 5cm anterior method, neuronavigated rTMS elicits greater 
therapeutic response in depression (Fitzgerald et al., 2009), but more studies 
are required to confirm this important finding.  
The use of repetitive transcranial magnetic stimulation within 
psychiatry 
As has been discussed, the ability of rTMS to induce long-lasting neural changes 
that influence cognitions and behaviours has enabled investigations in 
psychiatric disorders. The literature surrounding the use of rTMS in depression 
is the most abundant, with comprehensive meta-analyses supporting its 
therapeutic efficacy in treatment resistant patients (Gaynes et al., 2014; Slotema 
et al., 2010). Similarly, recent meta-analyses also support the efficacy of rTMS in 
schizophrenia (Hovington, McGirr, Lepage, & Berlim, 2013) and obsessive 
compulsive disorder (Berlim, Neufeld, & Van den Eynde, 2013). There is also 
increasing interest in the use of rTMS in treating drug and alcohol addiction 
(Bellamoli et al., 2014), and on its effects on eating behaviours and/or body 
weight as these have and implications for the treatment of eating disorders (see 
Chapter 2 or McClelland, Bozhilova, Campbell, & Schmidt, 2013; Van den Eynde 
& Guillaume, 2013). Undoubtedly, a better understanding of the physiological 
effects of rTMS and the neural underpinnings of the conditions treated with 
rTMS will facilitate establishing its therapeutic potential within psychiatry 
(Ridding & Rothwell, 2007; Wassermann & Lisanby, 2001).  
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Chapter 3.2 Outline of the study 
This chapter describes the first part of the research involving rTMS in AN (in 
this thesis) and consists of a proof-of-concept, single-session RCT of real versus 
sham HF neuronavigated rTMS to the left DLPFC. It follows the recent 
recommendations of Brunoni and Fregni (2011) for clinical trials involving non-
invasive neuromodulation, namely, a priori sample size estimation, definition of 
primary outcomes and statistical analysis prior to the start of the study, strict 
eligibility criteria, a stratified randomisation procedure and the exploration of 
potential biomarkers of response.  
The primary aim was to examine the short-term effects of rTMS on core 
symptoms of AN (Chapter 3.3). Additionally, the effects of rTMS on food 
preferences and food consumption in AN were investigated (Chapter 3.4), along 
with the physiological effects of rTMS on salivary cortisol (Chapter 3.5). Cortical 
excitability in AN is discussed (Chapter 3.6) together with the safety, tolerability 
and acceptability of rTMS in AN (Chapter 3.7). Individual hypotheses, results, 
limitations and implications of the research are discussed in each section and 
then a summary of the effects of rTMS in AN is provided (Chapter 3.8). 
Participants  
A sample size calculation based on previous studies (Uher, Yoganathan, et al., 
2005; Van den Eynde et al., 2010) and including a 5% drop out rate, indicated 
that 32 individuals per group were needed to detect an effect size of d = 0.90 
with 80% power using two-sided t-tests with p = 0.05. Therefore, a total of 64 
participants were needed. 68 participants (1 male) were recruited who were 
over 18 years of age and who had a current DSM-5 diagnosis of AN. This was 
achieved via recruitment from the Eating Disorders outpatients department at 
the Maudsley Hospital (South London and Maudsley NHS Foundation Trust), by 
email advertisement throughout King’s College London and via the national 
eating disorder charity website (www.b-eat.co.uk).  
Diagnosis was established via the referring clinician and/or the Eating Disorder 
Diagnostic Scale (EDDS) (Stice, Telch, & Rizvi, 2000). Principal inclusion criteria 
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were a BMI of 14 – 18.5 kg/m2. Contra-indications to both the MRI scan and the 
rTMS were checked with the King’s College London, Centre for Neuroimaging 
Sciences standard MRI Safety Questionnaire (Appendix E.4) and the TMS Adult 
Safety Screen Questionnaire (Appendix E.5) (Keel, Smith, & Wassermann, 2001) 
respectively. Exclusion criteria were: left-handedness, a BMI less than 14, or 
more than 18.5 kg/m2, being on a dose of psychotropic medication that had not 
been stable for at least 14 days prior to enrolment, pregnancy, personal/family 
history of seizures and/or epilepsy and excessive alcohol consumption 
(drinking >3 units per day on a daily basis) (NHS, 2013) and/or excessive 
nicotine use (>15 cigarettes/day). Local ethical committee approval was 
obtained (ref: 12/LO/1525) and the trial was registered prior to 
commencement (www.controlled-trials.com registration number: 
IRCTN22851337). Written informed consent was obtained from all participants. 
The participant information sheet and consent form are included in Appendices 
C.1 and D.1 respectively. 
Randomisation and blinding  
A CONSORT diagram (Schulz, Altman, & Moher, 2010) of the recruitment and 
randomisation procedure is presented in Figure 3.3. The randomisation was set 
up and conducted by an independent researcher to ensure allocation 
concealment. The computer programme Stata (version 11.0 for Windows) was 
used to randomise participants, stratified by AN subtype diagnosis (restrictive 
or binge/purge), in a random block size design using block sizes of 2, 4, 6, 8. 
Following screening/baseline(1) assessments, once participants were deemed 
eligible and consented to taking part, they were randomised. Due to a small 
delay between baseline(1) and booking the MRI scan/testing session, several 
participants (n = 9) withdrew post-randomisation for various reasons e.g. 
feeling unwell. Therefore, a total of 51 female participants attended, intending 
to complete the full protocol. 
Three researchers were involved in the experiments: one who delivered the 
rTMS (the candidate), one who helped with the rTMS and neuronavigation 
equipment, and the other who administered the pre- and post-rTMS tasks. The 
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latter researcher was blind to the experimental condition (real or sham rTMS). 
Participants were not informed about which condition they were randomised to 
until after their data collection was complete, which was at the end of their 24 
hour follow-up phone call.  
 
 
Figure 3.3 CONSORT diagram of recruitment and randomisation procedures 
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Protocol 
A standard operating procedure was developed for the RCT of rTMS in AN and 
applies to Chapters 3 and 4. Table 3.1 provides a schematic presentation of the 
procedures followed. 
Following baseline(1) and randomisation, study procedures were typically 
completed in one day; however, some participants had their MRI scan and the 
rTMS session split over two days. To use neuronavigated (MRI-guided) rTMS, 
participants initially underwent a structural MRI scan. This was used with 
Brainsight® to neuronavigate the rTMS coil to the left DLPFC (more details of 
this procedure to follow). When procedures were done on the same day, 
participants had a 2 hour break between the scan and testing (to allow the MRI 
to be uploaded on neuronavigation software). Participants were instructed to 
refrain from eating for at least 1 hour prior to the testing session.  
The various data collection time points (TP) are illustrated in Table 3.1. At the 
start of the testing session (Baseline 2 or TP1) information on ED symptoms and 
mood was collected using the Eating Disorder Examination Questionnaire (EDE-
Q version 16) (Fairburn, 2009) and the Depression Anxiety and Stress scale 
(DASS-21) (Lovibond & Lovibond, 1995a) which are included in appendices F1 
and F.2. The first of five saliva samples (S1) collected via Salivettes® was 
obtained, along with baseline blood pressure (BP) and pulse. ‘Initial’ 10cm 
visual analogue scales (VAS) on urge to restrict, levels of feeling full, feeling fat, 
urge to exercise, levels of stress and anxiety were administered (Appendix G.1). 
A monetary temporal discounting (TD) task (TDpre) was then completed (see 
Chapter 4 for more details). 
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EDDS: eating disorder diagnostic scale; SCID: structure clinical interview for 
diagnosis of DSM-IV disorders; MRI, magnetic resonance imaging; EDE-Q: eating 
disorder examination questionnaire; DASS-21: depression, anxiety and stress scale 
(21 item); VAS; visual analogue scale.  
                                                        
2 The TD task requires detailed introduction and explanation. Therefore, it is 
reported in the subsequent chapter (Chapter 4), however, the study design and 





































Inclusion/exclusion criteria, TMS safety 




MRI MRI safety questionnaire, MRI scan 
~2hr BREAK (no eating 1 hour prior to next stage of testing) 
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EDE-Q & DASS-21 
Saliva (S1)  




Temporal discounting task (TDpre)2 
Food Challenge Task (FCTpre) 
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Food, initial & additional VAS 
Saliva (S2) 
Standard rTMS description read by participants 
Motor Threshold (MT), BP & pulse 
REAL/SHAM rTMS 





Temporal discounting task (TDpost) 
 
Blinded 
 Food Challenge Task (FCTpost) 
TP3 





Initial VAS, Saliva (S5) 
Smoothie task 
BP & pulse 




Acceptability as a treatment 
Blinding assessment 
Table 3.1 Study protocol for the RCT of rTMS in AN.  
 99 
The first delivery of our food challenge task (FCTpre) (Van den Eynde, 
Guillaume, et al., 2013) was then administered: this task required participants 
to watch a 2 minute film of people eating highly palatable foods (chocolate, nuts, 
crisps, biscuits) while the same foods were in the room. At this point (TP2), 
‘food-related’ VAS regarding the perceived smell, taste, appearance and urge to 
eat each food type were completed (Appendix G.3), along with the initial VAS 
and ‘additional’ VAS regarding related psychopathologies (mood, calmness, 
hunger, urge to eat, urge to binge eat and urge to be sick or purge; Appendix 
G.2). A second saliva sample (S2) was also collected.   
Following the above, a standardised information sheet about the rTMS 
procedure (though no information which could reveal their sham/real 
allocation) was given to participants to read immediately before the rTMS 
component of the session (this is provided in Appendix I.1). Participants were 
allowed to ask any questions they might have at that point. A real rTMS figure-
of-eight coil and the Brainsight® neuronavigation equipment were then 
calibrated to the individual. The Magstim® Rapid device (Magstim®, UK) was 
used to establish each participant’s MT. Following MT measurement, BP and 
pulse were recorded. The rTMS coil was then changed to either a real/sham 
rTMS coil and recalibrated with Brainsight®. This was then used with the 
Magstim® device to administer real/sham rTMS3. Immediately after the final, 
twentieth rTMS train, BP and pulse were recorded and a third saliva sample was 
collected (S3). Participants also completed a 10cm VAS on the ‘discomfort’ they 
experienced during the rTMS session. 
After real/sham rTMS the TD task was re-administered (TDpost), followed by 
the FCTpost. Food related, initial and additional VAS were then collected (TP3), 
followed by a fourth saliva sample (S4). Any current pain/discomfort were then 
assessed and discussed. Towards the end of the session, the initial VAS were 
repeated (TP4) and a final saliva sample (S5) was collected. At this point, 
participants were asked to choose one of three smoothie flavours and to drink 
as much as possible. Following this, BP and pulse were recorded and 
                                                        
3 More details on the methods used to establish MT and the delivery of rTMS is 
given in the ‘Procedures’ section of this chapter.  
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measurements of height and weight were taken. Participants were telephoned 
the next day for a 24 hour follow-up (TP5) during which the initial VAS were 
repeated, adverse events were discussed and participants were asked, if rTMS 
proved efficacious in AN, whether they would consider it as a treatment (a 
session each week day for four weeks). Finally, allocation concealment/blinding 
was assessed, and then revealed.   
Procedures 
Apart from the structural MRI scan, which was done in the Centre for 
Neuroimaging Sciences, all the study procedures took place in the TMS lab at the 
Institute of Psychiatry, Psychology and Neuroscience, King’s College London. 
MRI and neuronavigation 
All participants underwent a structural MRI scan, which was used with 
Brainsight® to neuronavigate the TMS coil to the left DLPFC. The imaging 
protocol included a high-resolution sagittal 3D T1-weighted Magnetisation 
Prepared Rapid Gradient Echo (MPRAGE) volume (voxel size 1.1 x 1.1 x 1.2 
mm3) which was obtained using a customised pulse sequence (Jack et al., 2008). 
Full brain and skull coverage was required and detailed quality control was 
carried out on all MRI data according to a previously described quality control 
procedure (Simmons et al., 2009, 2011).  
Following the MRI scan and prior to the main rTMS session, MRI images were 
uploaded to Brainsight®. This involved calibrating the structural MRI scan to the 
Brainsight software (personal instructions for this procedure are included in 
Appendix I.2). The site for the left DLPFC was obtained by inputting pre-
determined Talairach co-ordinates of x = -45, y = 45, z = 35. These values were 
adopted from Fitzgerald et al. (2009) who demonstrated a greater therapeutic 
effect in depressed patients using these co-ordinates (in comparison to the 5cm 
anterior method).  
Following importation of the MRI scan into Brainsight, the software was 
calibrated to the TMS coil in use and to the individual. This was done after the 
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pre-rTMS assessments and immediately before the MT/rTMS component of the 
protocol. The TMS coil was calibrated to the software using a ‘calibration block’. 
To calibrate participants to the Brainsight software, individuals wore a 
headband, termed ‘subject tracker’, whilst a calibrated ‘pointer’ was held against 
four landmarks; the nasion, nose tip and left and right tragus.    
Motor threshold 
Following calibration, the Magstim Rapid device (Magstim, Whitland, Wales, 
United Kingdom), using a real rTMS figure-of-eight coil, was used to establish 
participants’ resting MT. The left M1 and optimum spot in the left M1 to activate 
the first dorsal interosseous (FDI) muscle was located on the Brainsight 
software (by eye, i.e. not using imaging co-ordinates) and the participant’s MT 
was defined as the minimum stimulus required to evoke 5 out of 10 MEP 
greater than 50μV. This was conducted according to the ‘lower threshold’ 
method – starting at 40% of stimulator output and increasing in increments of 5 
until 5 out of 10 responses were greater than 50μV (Rossini et al., 1994; 
Rothwell et al., 1999) and was identical across both groups (real and sham 
rTMS), that is, all participants’ MT were determined using a real TMS coil.  
Repetitive transcranial magnetic stimulation procedure 
After MT was determined, the real rTMS coil used to establish MT was changed 
in both groups. The same Magstim Rapid device with either a real or sham 
figure-of-eight coil was used for the rTMS. The device used to administer rTMS 
had a peak discharge current of 7000 Amps and peak discharge voltage of 2000 
Volts, producing a sine wave magnetic field with a peak strength of 2 Tesla in a 
250 s pulse.  
The real or sham rTMS was delivered according to our previous protocols (Van 
den Eynde, Guillaume, et al., 2013); 20 x 5 second trains with 55 second 
inter-train intervals, at a frequency of 10 Hz and intensity of 110% of the 
individuals MT, providing 1000 pulses over 20 minutes. Sham stimulation 
was given at the same location and using the same protocol. These parameters 
(frequency, intensity, duration of the trains, inter-train time, and total number 
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of pulses delivered) are in accordance with the current rTMS safety guidelines 
(Rossi et al., 2009). The researcher (PhD candidate) who delivered the rTMS, 
was trained in delivery of both rTMS and tDCS at the Berenson-Allen centre of 
non-invasive brain stimulation, Harvard Medical School, Boston, USA. 
Food challenge task 
Evidence supports the importance of context-dependent neural activity on 
outcome of rTMS (Gersner et al., 2011). Therefore, rTMS was combined with a 
food-cue exposure task in order to provoke and induce ED related 
psychopathology and thus bolster the effects of rTMS on these symptoms. The 
exposure FCT task, was completed both immediately before (FCTpre) and after 
(FCTpost) either real/sham rTMS. Participants were shown a 2-minute video of 
people eating highly palatable foods (chocolates, crisps, biscuits and nuts). 
Instructions for this task and screen shots of the video are presented in 
illustrated in Appendix H.1. These same foods were simultaneously present in 
the room. They were asked to watch the video and then rate these foods on their 
perceived smell, taste, appearance and desire to eat these foods using 10cm VAS 
(included in Appendix G.3). They were not required to eat or touch the foods.  
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Chapter 3.3 The effect of repetitive transcranial magnetic 
stimulation on symptoms of anorexia nervosa 
As described in Chapter 1, AN is a severe and life-threatening mental illness. In 
adults, the best available psychotherapies have limited remission rates (Zipfel et 
al., 2000) whilst the use of pharmacotherapy in AN is not empirically supported 
and has low acceptability (Mitchell et al., 2013). Emerging neuroimaging data 
implicate altered ‘bottom-up’ processing in limbic structures (such as the insula 
and amygdala), in conjunction with aberrant ‘top-down’ cognitive control 
mechanisms (involving the PFC), suggesting a neuro-circuitry underpinning to 
AN (Kaye et al., 2009; Park et al., 2014; van Kuyck et al., 2009). Given the 
somewhat limited efficacy of existing talking psychotherapies and the emerging 
knowledge of neural underpinnings of AN, a strong case can be made for 
developing brain-directed treatments (Schmidt & Campbell, 2013). This is in 
accordance with recommendations by the NIMH for progressing the 
understanding and treatment of psychiatric disorders via the use of 
neuroscience technologies (Insel & Gogtay, 2014).  
The neuromodulation technique rTMS non-invasively alters neural activity and 
has demonstrated therapeutic effects in psychiatric disorders such as 
depression and addiction (Gaynes et al., 2014; Jansen et al., 2013; Slotema et al., 
2010). More specifically, neurocircuit-based models of addictive disorders 
implicate specific brain networks at different stages of addiction. Thus, the 
ventral tegmental area (VTA) and ventral striatum are proposed to be involved 
in initial binge/intoxication periods, whilst the amygdala is proposed to 
underlie the withdrawal/negative affect stage and prefrontal regions are 
implicated in the preoccupation and anticipation stages of addiction (Koob & 
Volkow, 2010). A number of mechanisms have been proposed to support the 
use of rTMS in addictive disorders. Given interconnections between the DLPFC 
and VTA, rTMS may increase dopamine transmission, and this notion has been 
supported in both human and animal studies (Diana, 2011; Keck et al., 2002; 
Strafella et al., 2003). Additionally, given altered activity in prefrontal regions 
(Goldstein & Volkow, 2011) and poor inhibitory control (Perry & Carroll, 2008) 
often reported in relation to addictive disorders, rTMS applied to the DLPFC 
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may improve cognitive control mechanisms. Given such models and mechanistic 
hypotheses, a number of studies have explored the utility of rTMS applied to the 
DLPFC within addictive disorders and a recent meta-analysis demonstrated 
moderate effects for the reduction of cravings (Jansen et al., 2013). Given that 
there are some shared neural underpinnings in responses to drug and food cues 
(Tang, Fellows, Small, & Dagher, 2012), our group initiated research on the 
effects of rTMS on food cravings. In frequent food cravers, real rTMS was shown 
to prevent cravings during food-cue exposure and sham rTMS increased 
cravings (Uher, Yoganathan, et al., 2005). Whilst another study involving a more 
sophisticated sham rTMS technique suggested no effects of rTMS on food 
cravings (Barth et al., 2011), other studies investigated the potential of tDCS (a 
similar form of non-invasive neuromodulation) and have reported reductions in 
food cravings (Fregni et al., 2008; Goldman et al., 2011; Kekic et al., 2014).  
Given that food cravings and consequential binge-eating episodes are a 
characteristic of BN, interest in the effects of rTMS on BN symptoms arose. 
Individual case reports support the therapeutic potential of rTMS in BN 
(Downar et al., 2012; Hausmann et al., 2004). However, whilst the only multiple 
session (5 daily sessions a week for 3 weeks) RCT of real/sham rTMS in an ED 
sample reported improvements in BN symptoms (i.e. bingeing and vomiting 
behaviours), there were no significant differences between real/sham groups 
(Walpoth et al., 2008). This study may have been underpowered (n = 14) or, 
given the typical 20 rTMS session protocols used in the treatment of depression, 
it may have administered too few rTMS sessions. Since then, our group 
conducted a single-session RCT and demonstrated that real versus sham rTMS 
temporarily reduced the urge to eat and subsequent binge eating episodes in 
patients with BN (Van den Eynde et al., 2010).  
Along with the growing understanding of the neuro-circuitry associated with 
AN (Kaye et al., 2009; van Kuyck et al., 2009), these aforementioned 
improvements in ED related symptoms following rTMS and findings of 
improved symptoms and weight gain following 20 sessions of rTMS in an 
individual with AN (Kamolz et al., 2008) increased our interest in the 
therapeutic potential of rTMS in AN. Our group conducted a single-session pilot 
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study of rTMS in 10 individuals with AN and demonstrated that, following a 
food-cue exposure task, rTMS temporarily reduced levels of anxiety, feeling full 
and feeling fat, i.e. some of the core symptoms of AN (Van den Eynde, Guillaume, 
et al., 2013). Following this, we reported two cases of enduring AN (Chapter 5) 
which demonstrated sustained improvements in ED psychopathology and mood 
following 20 sessions of rTMS (McClelland, Bozhilova, Nestler, et al., 2013). 
Moreover, a recent pilot study in seven individuals with AN using a similar 
neuromodulation paradigm – ten sessions of left DLPFC tDCS – reported 
reductions in ED and depressive symptoms (Khedr, Elfetoh, Ali, & Noamany, 
2014). Whilst the preliminary data regarding the therapeutic effects of non-
invasive neuromodulation such as tDCS and rTMS in AN are encouraging, the 
small numbers and the lack of comparison control conditions limit findings. 
Thus, there is a need for an adequately powered RCT which compares the 
effects of real and sham rTMS on the symptoms of AN.  
Moreover, an important aspect of rTMS study designs that is seldom reported is 
‘blinding’ success. The placebo response to rTMS in depression is reportedly 
comparable to that found in pharmacological interventions (Brunoni, Lopes, 
Kaptchuk, & Fregni, 2009) and therefore the success of allocation concealment 
in an RCT of rTMS is crucial for interpreting results and generalising findings. 
Recently, reviews and meta-analyses have highlighted that most studies fail to 
report blinding success (Broadbent et al., 2011). In those that do, participants in 
real/sham groups do not significantly differ in their ability to correctly guess 
their intervention allocation (Berlim, Broadbent, et al., 2013): however, trends 
towards participants in the real group more often guessing correctly have been 
identified. Therefore, reporting and evaluating blinding success in RCT of rTMS 
is essential to provide a fair representation and interpretation of results.  
The aim of the research reported in this chapter is to establish the short-term 
(up to 24 hours) effects of rTMS on symptoms of AN. Additionally, as this is a 
double-blind study, there is a responsibility to assess and report the success of 
allocation concealment in both participants and researchers. We hypothesised 
that real versus sham rTMS would temporarily reduce the core symptoms of AN.  
We also hypothesised that secondary outcomes regarding related 
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psychopathology (e.g. urge to eat, mood etc.) would also be improved following 
real rTMS. Finally, we predicted that both participants and researchers would 
be unable to guess correctly their intervention allocation at a rate better than 
chance (i.e. 50%). 
Methods 
Participants 
Recruitment and randomisation procedure are described in Chapter 3.2. 
Procedure 
A description of the procedures is provided in Chapter 3.2.  
Measures 
Baseline measures 
Eating disorder pathology 
Eating Disorders Examination – Questionnaire version 6 (EDE-Q; see Appendix 
F.1): Based on the clinical interview version (Eating Disorder Examination; 
EDE) the Eating Disorders Examination Questionnaire (EDE-Q; Fairburn & 
Beglin, 1994) is a self-report measure assessing ED symptoms over the past 
month. Version 6 of the EDE-Q (Fairburn, 2009) was used in this study to 
provide information on core ED constructs and the frequency of ED behaviours 
(e.g. bingeing/purging). Questions relate to the past 28 days and are measured 
on a 7-point Likert scale ranging from zero (no days) to six (every day). The 
items represent various ED experiences which, when averaged, reflect the 
following constructs and subscales; restraint, eating concern, shape concern and 
weight concern. The mean of these four subscales provides a global EDE-Q 
score. High subscale and global scores indicate greater ED psychopathology, 
with a proposed clinical cut-off score of ≥4 (Carter, Stewart, & Fairburn, 2001; 
Luce, Crowther, & Pole, 2008; Mond, Hay, Rodgers, Owen, & Beumont, 2004). 
The frequency of ED behaviours (e.g. bingeing, vomiting, laxative use etc.) can 
also be established via answers/estimates of incidence over the past 28 days. 
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The EDE-Q has good reliability, validity and clinical utility (Berg, Peterson, 
Frazier, & Crow, 2012; Luce et al., 2008; Mond et al., 2004).  
Other psychopathology 
Depression, Anxiety and Stress Scale – short version (DASS-21; see Appendix 
F.2) (Lovibond & Lovibond, 1995a): The DASS-21 is a short version of a 42 item 
self-report measure (Lovibond & Lovibond, 1995a). The DASS-21 is comprised 
of items measured on a 4-point Likert scale ranging from 0 (did not apply to me 
at all) to 3 (applied to me very much, or most of the time) and assesses mood 
state over the past seven days. Each item loads on to one of three subscales, 
which when totalled provide scores for depression, anxiety and stress. High 
scores indicate worse symptomatology; severity ranges from normal-mild-
moderate-severe-extremely severe are indicated by scores of 0-4, 5-6, 7-10, 11-
13, 14+ for depression, 0-3, 4-5, 6-7, 8-9, 10+ for anxiety, and 0-7, 8-9, 10-12, 
13-16, 17+ for stress subscales respectively. The addition of the three subscales 
into a total DASS-21 score gives an indication of general distress. This measure 
has good reliability and validity (Henry & Crawford, 2005; Lovibond & 
Lovibond, 1995a, 1995b; Sinclair et al., 2012). 
Eating disorder related experiences 
The main ‘initial’ VAS were completed at baseline (2)/TP1 to assess the salience 
of the FCT from TP1 to TP2. These scales included an assessment of ‘levels of 
stress’, ‘urge to restrict’, ‘urge to exercise’, ‘levels of anxiety’, ‘feeling full’ and 
‘feeling fat’ (Appendix G.1). Following the first FCT these VAS were 
administered throughout the RCT (i.e. from TP2 – TP5) and used within primary 
and secondary outcomes.  
Outcome measures 
Primary outcome  
The primary outcome variable was a composite ‘core AN symptoms’ computed 
by the summation of VAS scores on urge to restrict (0-10), levels of feeling full 
(0-10) and fat (0-10) with a total possible score of 30. The urge to exercise VAS 
was not included in this composite outcome as it was deemed as a highly 
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heterogeneous symptom of AN, which varies between individuals and sub-types 
of AN (i.e. excessive exercise is present in some people with AN, but not others). 
To assess the effects of rTMS on the primary outcome, VAS were collected at 
TP2 (pre rTMS), TP3 (immediately after rTMS), TP4 (the end/20 minutes 
following the rTMS session) and TP5 (24 hours following). 
Secondary outcomes 
Secondary outcomes included a composite ‘anxiety and stress’ outcome, 
computed by summation of the stress (0-10) and anxiety (0-10) VAS, with a 
total possible score of 20. The six individual 10cm VAS were also analysed 
separately, along with the additional VAS that were included in the FCT relating 
to calmness/tension, mood, hunger, urge to eat, urge to binge eat and urge to be 
sick or purge (Appendix G.2). The secondary composite anxiety and stress 
outcome, and the six individual VAS were collected at TP2 (pre rTMS), TP3 
(immediately after rTMS), TP4 (the end/20 minutes following the rTMS 
session) and TP5 (24 hours following). At TP5 the VAS information was 
collected over the phone, therefore participants had to respond by giving a 
number between 1 and 10. The additional VAS were administered during the 
two FCT (i.e. pre and post rTMS), therefore were only completed twice (at TP2 
and TP3). 
‘Blinding’ success 
At the end of the 24 hour follow-up phone call participants were asked to guess 
which stimulation type (real/sham) they thought they had received and then 
asked to indicate how sure they were of this decision by giving a number 
between 0 (completely unsure) and 10 (completely sure).  
Similarly, after the session, researchers were asked to guess which stimulation 
type (real/sham) they thought the participant had received and then asked to 
indicate on a VAS how sure they were of their decision (0 = completely unsure 
and 10 = completely sure). The choice of real/sham rTMS for researchers was 
not titrated according to their previous choices or against upcoming allocations. 
This meant that they could feasibly guess all real or all sham, i.e. they could 
guess a stimulation type more regularly than what was actually delivered.  
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Statistical analyses 
Statistical analyses were performed using IBM® SPSS® software (Version 22). 
Following consultation with a statistician, when normality or the ANOVA 
homogeneity of variance assumption was violated (assessed via Kolmogorov-
Smirnov and Levene’s test statistics respectively) log transformations or other 
non-parametric alternatives were used and post-hoc bootstrapping methods 
with Bonferroni corrections were employed. Where Mauchly’s test of sphericity 
was violated Greenhouse-Geisser corrections are reported. All tests were two-
tailed and the level of significance was set at α = 0.05.  
Baseline(2) data regarding demographic information and psychopathology 
were normally distributed. Therefore, independent t-tests and Pearson’s chi-
squared tests ( 2) were used to compare characteristics of the real/sham 
groups. Also, paired t-tests were used to assess the salience of the FCT.   
Data regarding the primary and secondary outcomes were normally distributed. 
Therefore, the effects of real versus sham rTMS were evaluated using a mixed 
ANOVA (group: real/sham rTMS x time: TP3, TP4 and TP5) controlling for 
scores at TP2 (this was used as baseline scores as it was immediately prior to 
the real/sham rTMS intervention). The effects of real versus sham rTMS on the 
additional FCT VAS were evaluated using a mixed ANOVA (group: real/sham 
rTMS x time: TP2, TP3). 
Pearson’s chi-square ( 2) was used to assess whether or not participants and 
researchers correctly guessed experimental condition (real/sham rTMS) better 
than chance (i.e. 50%). Also, 2 was used to compare the ability of participants 
within real/sham groups, and the ability of researchers, to correctly guess 
stimulation type. Additionally, t-tests were used to compare levels of certainty 
in both participants and researchers on how sure they were of their decision 
regarding which intervention they received. 
Partial eta squared (η2) and Cohen’s d effect sizes are reported for mixed 
ANOVAs and t-tests respectively. Partial eta squared is automatically computed 
within SPSS by dividing the sums of squares for the effect of interest by the total 
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sums of squares i.e. η2 = SSbetween/SStotal (Levine & Hullett, 2002). Cohen’s d was 
computed by dividing the difference in means by the pooled standard deviation 
i.e. d = M1 – M2/√(SD12+ SD22 /2). Interpretation of the magnitude of η2 is 0.01-
0.06 = small; 0.06-0.14 = medium and > 0.14 = large; and for Cohen’s d effect 
sizes 0.15-0.40 = small; 0.4-0.75 = medium and > 0.75: large (Cohen, 1988). 
Results 
Two participants randomised to real rTMS withdrew following the first few 
trains of rTMS (due to discomfort) and were excluded from statistical analyses. 
Therefore, 49 female (by chance), right-handed individuals, randomised to real 
(n = 21, restrictive = 13, binge/purge = 8) and sham (n = 28, restrictive = 15, 
binge/purge = 13) were included in the analyses.  
Baseline characteristics 
Table 3.2 presents demographic characteristics, ED and psychiatric history and 
psychopathology scores for the entire sample and for each of the real/sham 
rTMS groups. There were no significant group differences between real/sham 
groups on demographic information at baseline (2). In regards to 
psychopathology, groups differed on the EDE-Q weight [t(47) = -2.05, p = 0.046, 
d = 0.60] and shape concern [t(47) = -2.06, p = 0.045, d = 0.60] subscales, where 
the sham group demonstrated significantly greater ED psychopathology. Both 
groups had moderate/severe levels of depression, anxiety and stress.  
Given the uneven proportion of subtypes between real/sham groups (real: 62% 
restrictive, 38% binge/purge; sham: 54% restrictive, 46% binge/purge) and the 
differences in ED psychopathology reported between the groups, we compared 
psychopathology between AN subtypes. Those with a binge/purge diagnosis 
scored significantly higher across the EDE-Q global scale [t(47) = -2.06, p = 
0.045, d = 0.60] (restrictive: M = 3.91, SD = 1.24; binge/purge: M = 4.59, SD = 
0.98), restraint [t(46.76) = -2.36, p = 0.022, d = 0.69] (restrictive: M = 3.93, SD = 
1.56; binge/purge: M = 4.82, SD = 1.08) and eating concern subscales [t(47) = -
2.24, p = 0.030, d = 0.65] (restrictive: M = 3.51, SD = 1.30; binge/purge: M = 4.29, 
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SD = 1.07) and the DASS-21 depression sub-scale [t(47) = -2.54, p = 0.014, d = 
0.74] (restrictive: M = 9.43, SD = 5.54; binge/purge: M = 13.57, SD = 5.77). 
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Table 3.2 Baseline characteristics; demographic information, psychiatric 
history and current psychopathology. Mean ± SD reported  
 Entire sample 
(N = 49) 
Real rTMS 
(n = 21) 
Sham rTMS 
(n = 28) 
Demographic information 
Age   26.65 ± 8.73 25.29 ± 6.88 27.68 ± 9.89 
Weight 44.57 ± 5.83 45.57 ± 6.11 43.86 ± 5.62 
Ethnicity 
White (n = 44) 
Asian (n = 1) 
Other (n = 4) 
White (n = 19) 
- 
Other (n = 2) 
White (n = 25) 
Asian (n = 1) 
Other (n = 2) 
Marital status 
Single (n= 45) 
Married (n= 4) 
Single (n = 20) 
Married (n = 1) 
Single (n = 25) 
Married (n = 3) 
Non-smokers: 
smokers 
34:15 15:6 19:9 
Highest level of 
education 
obtained 
GCSE (n = 2) 
AS levels (n = 1) 
A levels (n = 24) 
Degree (n = 20) 
Masters (n = 2) 
GCSE (n= 1) 
- 
A levels (n = 7) 
Degree (n = 11) 
Masters (n = 2) 
GCSE (n = 1) 
AS levels (n = 1) 
A levels (n = 17) 






2.59 ± 2.17 
4.10 ± 3.42  
2.55 ± 2.43 
2.90 ± 2.85 
2.04 ± 1.60 
3.80 ± 3.01 
Eating disorder history 
Anorexia sub-
type 
R (n = 28) 
B/P (n = 21) 
R (n = 13) 
B/P (n = 8) 
R (n = 15) 
B/P (n = 13) 




13.34 ± 1.73 13.76 ± 1.28 13.04 ± 1.95 
Illness duration  10.32 ± 7.61 9.05 ± 7.02 11.27 ± 8.01 
Number of 
meals per day  
2.18 ± 0.95 2.05 ± 0.93 2.29 ± 0.97 
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Table 3.2 (continued). Baseline characteristics; demographic information, 
psychiatric history and current psychopathology. Mean ± SD reported. 
 Entire sample 
(N = 49) 
Real rTMS 
(n = 21) 
Sham rTMS 






Yes (n = 36) 
No (n = 13) 
Yes (n = 13) 
No (n = 8) 
Yes (n = 23) 
No (n = 5) 
Diagnosed co-
morbidities 
Depression(n = 22) 
Anxiety (n = 1) 
OCD (n = 4) 
Depression (n = 8) 
- 
- 
Depression(n = 14) 
Anxiety (n = 1) 




Fluoxetine (n = 20) 
Venlafaxine (n = 2) 
Citalopram (n = 3) 
Olanzapine (n= 1) 
Mirtazapine (n = 3) 
Diazepam (n = 2) 
Sertraline (n = 3) 
> 2 meds (n = 5) 
12/21 (57%) 
Fluoxetine (n = 8) 
Venlafaxine (n = 1) 
Citalopram (n = 1) 
Olanzapine (n = 1) 
- 
Diazepam (n = 2) 
Sertraline (n = 1) 
> 2 meds (n = 2) 
22/28 (79%) 
Fluoxetine (n = 12) 
Venlafaxine (n = 1) 
Citalopram (n = 2) 
- 
Mirtazapine (n = 3) 
- 
Sertraline (n = 2) 
> 2 meds (n = 3) 
Eating disorder examination questionnaire (EDE-Q)  
Global score  4.20 ± 1.17 3.90 ± 1.26 4.43 ± 1.07 
Restraint  4.31 ± 1.43 4.17 ± 1.68 4.41 ± 1.23 
Eating concern 3.85 ± 1.26 3.63 ± 1.16 4.01 ± 1.32 
Weight concern  3.97 ± 1.50 3.48 ± 1.66 4.33 ± 1.28 
Shape concern  4.69 ± 1.13 4.31 ± 1.22 4.96 ± 0.98 
Depression, anxiety and stress scale (DASS-21) 
Total score  32.10 ± 12.94 29.67 ± 13.65 33.93 ± 12.31 
Depression 11.20 ± 5. 95 10.14 ± 5.98 12.00 ± 5.92 
Anxiety  7.88 ± 4.36 7.05 ± 4.29 8.50 ± 4.37 
Stress 13.02 ± 4.61 12.48 ± 5.00 13.43 ± 4.36 
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Salience of the food challenge task 
Table 3.3 shows the descriptive statistics for the entire sample and for the 
real/sham groups separately of the composite outcomes and individual VAS 
scores before and after the first delivery of the FCT. By chance, at the beginning 
of the testing session, i.e. baseline(2)/TP1, the sham group scored significantly 
higher on core AN symptoms [t(31.97) = -2.22, p = 0.034, d = 0.78] and levels of 
feeling fat [t(36.21) = -2.62, p = 0.013, d = 0.87] than the real group, however 
these differences were not significant following the FCTpre (TP2). There were 
no differences between AN subtypes across measures at baseline(2)/TP1.  
The salience of the FCT (TP1 to TP2) was assessed for the entire sample and 
separately within each of the real/sham rTMS groups. As a whole, the FCT 
significantly increased scores on the composite anxiety and stress outcome 
[t(48) = -2.08, p = 0.043, d = 0.60] and the individual VAS regarding levels of 
anxiety [t(48) = -2.19, p = 0.034, d = 0.63]. There was also a trend indicating that 
the FCT increased participants’ urge to restrict [t(48) = -1.70, p = 0.095, d = 
0.49].  
When assessing the effects of the FCT separately for each group, the FCT did not 
significantly increase scores on the primary core AN symptom outcome, the 
secondary composite anxiety and stress outcome, or individual VAS in either 
group. However, there was a trend for an increase in scores on the composite 
anxiety and stress outcome in the sham group [t(27) = -1.85, p = 0.075, d = 
0.34], and across the individual VAS regarding levels of anxiety [t(20) = -1.87, p 
= 0.076, d = 0.20] and levels of stress [t(27) = -1.76, p = 0.090, d = 0.29] in the 
real and sham group respectively. 
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The individual outcomes were measured on 10cm visual analogue scales (VAS) and scores ranged between 0 (not stressed/no urge to 
restrict/not anxious/no urge to exercise/not feeling full or fat at all) to 10 (extremely stressed/strong urge to restrict/anxious/strong urge 
to exercise/feeling extremely full or fat). The composite ‘core AN symptom’ outcome was computed by adding scores on the three VAS urge to 
restrict, levels of feeling full and levels of feeling fat, therefore ‘core AN symptom’ scores could range from 0 to 30. The composite ‘anxiety & 
stress’ outcome was computed by adding scores on the two anxiety and stress VAS and could therefore range from 0 to 20. 
Table 3.3 Composite outcomes and individual VAS before and after the first FCT.  Mean ± SD reported.  
 Entire sample (N = 49) Real rTMS (n = 21) Sham rTMS (n = 28) 
 TP1 TP2 TP1 TP2 TP1 TP2 
Composite outcomes 
Core AN symptoms 18.75 ± 6.05 19.40 ± 6.59 16.49 ± 7.11  17.63 ± 7.35 20.43 ± 4.56 20.72 ± 5.75 
Anxiety & Stress 10.45 ± 5.82 11.74 ± 5.87 9.90 ± 6.54 10.48 ± 6.28 10.86 ± 5.31 12.69 ± 5.47 
Individual visual analogue scales 
Levels of stress  5.03 ± 3.04 5.45 ± 2.99 4.72 ± 3.23  4.61 ± 3.21 5.27 ± 2.90 6.08 ± 2.70 
Urge to restrict 6.63 ± 2.73 7.24 ± 2.62 6.24 ± 3.06 7.05 ± 2.19 6.92 ± 2.47 7.38 ± 2.94 
Levels of anxiety 5.42 ± 3.12 6.29 ± 3.14 5.18 ± 3.61 5.87 ± 3.32 5.60 ± 2.75 6.61 ± 3.02 
Urge to exercise  4.74 ± 3.50  4.23 ± 3.40 3.71 ± 3.57 2.99 ± 3.27 5.50 ± 3.30 5.16 ± 3.24 
Levels of feeling full 5.59 ± 2.97 5.63 ± 3.39 4.89 ± 2.89 5.03 ± 3.39  6.11 ± 2.97 6.08 ± 3.38 
Levels of feeling fat 6.53 ± 2.75 6.53 ± 2.99 5.37 ± 2.96 5.55 ± 3.23 7.40 ± 2.26 7.27 ± 2.61 
 116 
Primary outcome 
Mixed ANOVA analyses controlling for pre-rTMS (TP2) scores showed no 
significant interaction between stimulation type and time. There was however, 
an effect of time and a trend toward group differences (Table 3.4); those who 
had real rTMS reported reduced AN symptoms. Post hoc, bootstrapped 
comparisons suggested these group differences were significant at each of the 
three time points; TP3 [t(47) = -2.31, p = 0.030, d = 0.67], TP4 [t(47) = -2.24, p = 
0.035, d = 0.65] and TP5 [t(47) = -2.51, p = 0.021, d = 0.73]. However, these 
differences were no longer significant following Bonferroni corrections for 
multiple comparisons (p = 0.017).  
Secondary outcomes 
Mixed ANOVA analyses, controlling for pre-rTMS (TP2) scores, regarding the 
composite anxiety and stress outcome, showed no significant interaction or 
group differences. There was, however, an effect of time (Table 3.4).  
Across the individual VAS, mixed ANOVA analyses controlling for pre-rTMS 
(TP2) scores demonstrated no interaction effects (Table 3.5). There was an 
effect of time on levels of stress, anxiety, levels of feeling full and levels of feeling 
fat. There was also a trend for between group differences on levels of feeling fat; 
those who had real rTMS reported reduced levels of feeling fat. Post hoc, 
bootstrapped comparisons suggested that these group differences were 
significant at each of the three time points; TP3 [t(47) = -2.50, p = 0.030, d = 
0.73 ], TP4 [t(47) = -2.82, p = 0.015, d = 0.82] and TP5 [t(47) = -2.27, p = 0.036, d 
= 0.66]. However, following Bonferroni corrections for multiple comparisons (p 
= 0.017) only differences at TP4 (end of the testing session) remained 
significant. There were no significant interaction effects across any of the 
additional VAS administered during the FCT (Table 3.6). There was a significant 
effect of time and a trend for group differences on reported levels of 
calmness/tension, in addition to an effect of time (but no group differences) on 
reported mood, hunger, urge to eat, and urge to be sick or purge. There was no 
effect of time or group on participants urge to binge eat. 
 117 
 Time point 
Real rTMS 
(n = 21) 
Sham rTMS 


















s Post rTMS & FCTpost (TP3) 13.70 ± 7.29 17.75 ± 5.01 
F (1.35) = 13.58  
p < 0.001 
η2 = 0.23 
F (1) = 3.86  
p = 0.056 
η2 = 0.08 
F (1.35) = 0.14  
p = 0.780 
η2 = 0.00 
End of session (TP4) 12.58 ± 7.44 16.73 ± 5.49 











 Post rTMS & FCTpost (TP3) 8.12 ± 6.23 9.52 ± 5.79 
F (1.60) = 8.26 
p = 0.001 
η2 = 0.15 
F (1) = 0.01  
p = 0.929 
η2 = 0.00 
F (1.60) = 0.77  
p = 0.441 
η2 = 0.02 
End of session (TP4) 7.25 ± 6.51 8.88 ± 5.72 
24 hours follow-up (TP5) 8.62 ± 4.32 10.68 ± 4.72 
The composite ‘core AN symptom’ outcome was computed by adding scores across the three 10cm visual analogue scales (VAS) relating to 
the urge to restrict, levels of feeling full and levels of feeling fat and therefore scores could range from 0 to 30. The composite ‘anxiety & 
stress’ outcome was computed by adding scores across the two 10cm anxiety and stress VAS and could therefore range from 0 to 20. 
Table 3.4 Mixed ANOVA results of the composite outcomes following real/sham rTMS. Mean ± SD reported. 
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 Time point 
Real rTMS 
(n = 21) 
Sham rTMS 


















Post rTMS & FCTpost (TP3) 3.87 ± 3.15 4.52 ± 2.87 
F (1.55) = 8.40  
p = 0.001 
η2 = 0.15 
F (1) = 0.34  
p = 0.565 
η2 = 0.01 
F (1.55) = 0.95  
p = 0.370 
η2 = 0.02 
End of session (TP4) 3.65 ± 3.26 4.43 ± 2.90 












Post rTMS & FCTpost (TP3) 5.62 ± 3.01 6.17 ± 2.39 
F (1.49) = 2.21  
p = 0.130 
η2 = 0.05 
F (1) = 1.26  
p = 0.268 
η2 = 0.03 
F (1.49) = 0.88  
p = 0.393 
η2 = 0.02 
End of session (TP4) 5.18 ± 3.04 5.76 ± 2.52 














Post rTMS & FCTpost (TP3) 4.25 ± 3.18 5.00 ± 3.10 
F (1.72) = 4.93  
p = 0.013 
η2 = 0.10 
F (1) = 0.74  
p = 0.395 
η2 = 0.02 
F (1.72) = 0.37  
p = 0.657 
η2 = 0.01 
End of session (TP4) 3.60 ± 3.27 4.45 ± 2.94 
24 hours follow-up (TP5) 4.38 ± 2.33  5.46 ± 2.63 
These were measured on 10cm visual analogue scales (VAS); scores could range from 0 (not stressed/no urge to restrict/not anxious at all) 
to 10 (extremely stressed/strong urge to restrict/anxious).  
Table 3.5 Mixed ANOVA results of the ‘initial’ VAS following real/sham rTMS. Mean ± SD reported. 
 119 
These were measured on 10cm visual analogue scales (VAS); scores could range from 0 (no urge to exercise/not feeling full or fat at all) to 
10 (extremely strong urge to exercise/feeling extremely full or fat).  
Table 3.5 (continued) Mixed ANOVA results of the ‘initial’ VAS following real/sham rTMS. Mean ± SD reported. 
 Time Point 
Real rTMS   
(n = 21) 
Sham rTMS 



















 Post rTMS & FCTpost (TP3) 2.51 ± 3.26 4.47 ± 3.22 
F (1.35) = 9.50  
p = 0.001 
η2 = 0.17 
F (1) = 0.33  
p = 0.566 
η2 = 0.01 
F (1.35) = 0.96 
p = 0.358 
η2 = 0.20 
End of session (TP4) 2.59 ± 3.40  4.28 ± 3.30 

















Post rTMS & FCTpost (TP3) 3.53 ± 2.80 4.91 ± 3.18 
F (1.23) = 21.89  
p < 0.001 
η2 = 0.32 
F (1) = 1.24  
p = 0.272 
η2 = 0.03 
F (1.23) = 0.07  
p = 0.851 
η2 = 0.00 
End of session (TP4) 3.33 ± 2.73 4.44 ± 3.22 
















Post rTMS & FCTpost (TP3) 4.55 ± 3.19 6.68 ± 2.76 
F (1.44) = 11.40  
p < 0.001 
η2 = 0.20 
F (1) = 3.01  
p = 0.089 
η2 = 0.06 
F (1.44) = 0.43  
p = 0.587 
η2 = 0.01 
End of session (TP4) 4.07 ± 3.41 6.52 ± 2.68 
24 hours follow-up (TP5) 5.19 ± 2.56 6.86 ± 2.53 
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These were measured on 10cm visual analogue scales (VAS); scores could range from 0 (extremely calm/extremely low/not hungry at all) to 
10 (extremely tense/extremely high/extremely hungry).  




(n = 21) 
Sham rTMS 













 Post FCTpre/pre rTMS (TP2) 5.61 ± 3.16 6.79 ± 2.14 F (1) = 26.75   
p < 0.001 
η2 = 0.36 
F (1) = 2.91   
p = 0.095 
η2 = 0.06 
F (1) = 0.00   
p = 0.982 





 Post FCTpre/pre rTMS (TP2) 4.12 ± 1.88 3.79 ± 1.58 F (1) = 13.32    
p = 0.001 
η2 = 0.22 
F (1) = 0.46   
p = 0.499 
η2 = 0.01 
F (1) = 0.00 
p = 0.972 






r Post FCTpre/pre rTMS (TP2) 2.88 ± 2.68  3.42 ± 3.54 F (1) = 15.29   
p < 0.001  
η2 = 0.25 
F (1) = 0.57   
p = 0.455 
η2 = 0.01 
F (1) = 0.07   
p = 0.793 
η2 = 0.00 Post rTMS & FCTpost (TP3) 4.27 ± 3.06 5.02 ± 3.07 
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These were measured on 10cm visual analogue scales (VAS); scores could range from 0 (no urge to eat/binge eat/be sick or purge) to 10 
(extremely strong urge to eat/binge/eat/be sick or purge).  
Table 3.6 (continued) Mixed ANOVA results of the ‘additional’ VAS following real/sham rTMS.  Mean ± SD reported. 
 Time Point 
Real rTMS 
(n = 21) 
Sham rTMS 















Post FCTpre/pre rTMS (TP2) 2.38 ± 2.60  2.97 ± 3.37 F (1) = 13.11   
p < 0.001  
η2 = 0.22 
F (1) = 0.51 
p = 0.478 
η2 = 0.01 
F (1) = 0.01   
p = 0.917 














Post FCTpre/pre rTMS (TP2) 0.99 ± 1.95 2.22 ± 3.24 F (1) = 0.05   
p = 0.827 
η2 = 0.00 
F (1) = 2.36   
p = 0.131 
η2 = 0.05 
F (1) = 0.31   
p = 0.579 

















Post FCTpre/pre rTMS (TP2) 2.27 ± 3.14 3.26 ± 3.68 F (1) = 7.65   
p = 0.008  
η2 = 0.14 
F (1) = 2.19   
p = 0.145 
η2 = 0.04 
F (1) = 0.58   
p = 0.450 
η2 = 0.01 Post rTMS & FCTpost (TP3) 1.10 ± 2.03  2.60 ± 3.20 
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Blinding success 
Participants guessed stimulation type better than chance [ 2(1) = 4.59, p = 
0.032, N = 49] as only 35% of participants incorrectly guessed stimulation type. 
However, there were no significant differences between real/sham groups in 
their ability to correctly guess stimulation type [ 2(1) = 1.08, p = 0.299, N = 49]; 
43% who had real rTMS thought they had sham, while 29% who had sham 
rTMS thought they received real (see Figure 3.4). Both groups had similar rates 
of certainty regarding how sure they were of which rTMS they had [t(47) = -
0.03 , p = 0.975, d = 0.01]; real (M = 4.67, SD = 2.32), sham (M = 4.79, SD = 2.78).  
In contrast, researchers were not able to guess stimulation type better than 
chance [ 2(1) = 0.51, p = 0.475, N = 49] as researchers incorrectly guessed in 
45% of cases. However, between real/sham groups there were significant 
differences in the ability of researchers to correctly guess stimulation type 
[ 2(1) = 9.93, p = 0.002, N = 49]; researchers were incorrect 19% of the time for 
those who had real and 64% for those who had sham (see Figure 3.5). Rates of 
certainty in researchers were similar across groups [t(47) = -0.29 , p = 0.776, d = 
0.08]; real (M = 2.24, SD = 2.32), sham (M = 2.43, SD = 2.30). Compared to 
participants, researchers were less sure about their guess of rTMS allocation 
[t(48) = -5.06 , p < 0.001, d = 1.46]; researchers (M = 2.35, SD = 2.29), 
participants (M = 4.78, SD = 2.57). 
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In the real group 12 participants guessed correctly and 9 guessed incorrectly. In 
the sham group, 20 participants guessed correctly and 8 guessed incorrectly.   
Researchers correctly guessed allocation on 17 and 10 occasions (therefore 
incorrectly guessing 4 and 18 times) in the real and sham groups respectively.  
  
 
Figure 3.4 Number of participants who correctly or incorrectly guessed 
stimulation type 
 
Figure 3.5 The frequency of researchers correctly or incorrectly guessing 







































Guessed correctly Guessed incorrectly
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Discussion 
The results of this RCT of rTMS in AN support our primary hypothesis; 
individuals who received real rTMS (compared to sham) reported reduced AN 
symptoms. However, there were no significant interaction effects as core AN 
symptoms were also reduced following sham rTMS. Therefore, there is some 
indication of an rTMS placebo effect.  
In relation to our secondary outcomes, levels of feeling fat showed a similar 
trend, in that those who received real rTMS reported reduced levels of feeling 
fat. Compared to sham, real rTMS did not significantly reduce levels of stress 
and anxiety, or individual scores across ED related experiences, such as the urge 
to restrict or exercise. Moreover, there were no interaction or group effects on 
other symptoms assessed during the food cue-exposure task (e.g. mood, hunger, 
urge to eat etc.). Whilst broad improvements over time across secondary 
outcomes were reported in both real/sham groups, there were no between 
group differences. Finally, participants (but not researchers) correctly guessed 
stimulation type more so than chance. However, in participants, there were no 
group differences in the ability to correctly guess stimulation type. Therefore, 
blinding was partially successful.  
Our data are in partial agreement with the existing literature. Our pilot study 
found that a single session of rTMS reduced anxiety, levels of feeling full and 
feeling fat (Van den Eynde, Guillaume, et al., 2013) and our 20 rTMS session 
case studies also demonstrate within-session reductions across these measures 
(see Chapter 5 or McClelland, Bozhilova, Nestler, et al., 2013). However, these 
studies lack a control condition and whilst our current data replicate short-term 
reductions in AN symptoms following rTMS, generally this was not significantly 
more so than sham. Combining the individual measures of AN symptoms into 
the composite, primary core AN symptom outcome differentiated real and sham 
rTMS groups and this suggests that the current study is underpowered. 
Importantly, our findings of reduced AN symptoms following real rTMS were 
not accompanied by similar improvements in mood. This is in agreement with 
existing literature that shows no improvements in mood following a single 
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session of rTMS (Baeken et al., 2009; Baeken et al., 2014) and indicates that the 
improvements in AN symptoms following rTMS reported here are independent 
of effects on comorbid symptoms.  
With regards to blinding success, our results are similar to those previously 
reported in BN (Van den Eynde et al., 2010). However, participants guessed 
stimulation type better than chance and researchers were significantly more 
able to guess allocation to real rather than sham rTMS. This is likely to be a 
result of not titrating choices for researchers based on previous/upcoming 
guesses and their chance inclination to choose real rTMS more often than it was 
actually delivered. Also, researchers were less sure about their choice of rTMS 
allocation. Given that the researchers who carried out pre/post rTMS 
experimental tasks were not in the room when people had rTMS, this indicates 
that the rTMS procedure itself impacts the certainty regarding decision making 
as to which intervention was delivered.  
Study sample 
The sample of AN in the current research had particularly severe and enduring 
forms of AN, indicated by their long illness duration, lowest reported BMI since 
illness onset and ED psychopathology. This is likely to have impeded the effects 
of just a single-session of rTMS; arguably less severe symptoms in participants 
who have not had AN for as long may be more susceptible to brief rTMS 
exposure.  
By chance, baseline ED and general psychopathology scores across all primary 
and secondary outcome scores were consistently, and at times significantly, 
higher within the sham group. This is likely to be due to uneven proportions of 
subtypes between groups; the sham group had more individuals with a 
binge/purge AN subtype, who demonstrated higher symptomatology than those 
with a restrictive subtype. Whilst the differences between real/sham groups at 
baseline became non-significant following the first food exposure task, these 
initial group differences are likely to have confounded group effects and must be 
considered in the interpretation of results. It is possible that the reduced AN 
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symptoms and levels of feeling fat following real rTMS reflect a natural 
progression towards the group differences that existed initially.  
Moreover, in the current sample the food exposure task was not as salient as 
reported in our previous AN rTMS pilot study (Van den Eynde, Guillaume, et al., 
2013). Whilst significance was reached when looking at the effects of the task on 
the entire sample as a whole, these did not remain significant when the 
real/sham groups were considered separately. This further suggests that this 
study is somewhat underpowered. Additionally, given literature suggesting the 
importance of state-related neural activity on the effects of rTMS (Gersner et al., 
2011) and the concurrent use of exposure techniques with rTMS (Baek et al., 
2012), the fact that our food exposure task was not as salient as we had hoped, 
i.e. it did not significantly increase ED related experiences, may have diminished 
rTMS effects on AN symptoms in this group.  
Whilst a higher proportion of individuals in the sham group were on 
medication, over half of the participants in both groups were medicated. 
Increases in facilitatory plasticity have been reported following selective 
serotonin reuptake inhibitor (SSRI) intake (Normann, Schmitz, Furmaier, Doing, 
& Bach, 2007) and similarly, citalopram has been shown to enhance the 
facilitatory plasticity reported to be induced by tDCS (Nitsche, Kuo, et al., 2009). 
Therefore, it is possible that the patients who were on such medications had an 
enhanced response to rTMS, which may have confounded results.  
An additional complication of studying AN (which was relevant in this sample) 
is symptom heterogeneity between and within AN subtypes. The symptoms that 
characterise AN sub-types are often argued to have different underlying neural 
mechanisms (Brooks et al., 2012). Therefore, they may need to be studied with 
separate and tailored neuromodulation protocols in order to elicit symptom-
specific improvements. Whilst the current study aimed to overcome this by 
stratified randomisation procedures, larger numbers are needed in order make 
further comparisons of rTMS effects on particular ED symptoms and between 
AN subtypes.  
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Physiological mechanisms  
A number of potential mechanistic hypotheses may explain the effects of rTMS 
in AN reported here. Short-term improvements in ED symptoms may be due to 
direct, focal modulation of the DLPFC and dorsal neural circuitry responsible for 
regulation of emotion, appetite and cognitive control. Alternatively, recent 
evidence suggests that rTMS applied to the PFC induces effects on remote, 
subcortical areas (George et al., 1999) and therefore, neural modulation of the 
DLPFC with rTMS in AN may remotely effect mesolimbic responses to food and 
other ED salient stimuli.  
Also, rTMS induced changes in neural circuitry may occur in a number of ways. 
Changes to neuroplasticity markers have been reported following rTMS 
(Esslinger et al., 2014; Gersner et al., 2011; Medina & Tunez, 2013; Ridding & 
Rothwell, 2007; Vlachos et al., 2012) and may underlie the effects reported here. 
Specifically, BDNF is a proposed biomarker of response to rTMS (Fidalgo et al., 
2014) and is increased following HF rTMS (Gersner et al., 2011; Zanardini et al., 
2006). Given that alterations in BDNF levels have been reported across different 
stages of AN, rTMS may induce neuroplasticity via the modulation of BDNF 
expression (Brandys, Kas, van Elburg, Campbell, & Adan, 2011; Zwipp et al., 
2014). Additionally, modulation of dopamine (Cho & Strafella, 2009) and 
serotonin concentrations (Baeken et al., 2011; Kanno, Matsumoto, Togashi, 
Yoshioka, & Mano, 2003) has been reported following HF rTMS to the PFC. As 
alterations in these neurotransmitters have been reported in AN (Bailer et al., 
2013; Frank et al., 2005; Frank et al., 2002) rTMS may exert therapeutic effects 
in AN via modulation of their expression.  
Strengths 
This study is the first neuromodulation protocol in AN with an active control 
condition (Khedr, Elfetoh, et al., 2014; McClelland, Bozhilova, Nestler, et al., 
2013; Van den Eynde, Guillaume, et al., 2013). The MEP method of estimating 
MT is more accurate, conservative and safer than other methods. However, 
while it is recommended (Rossi et al., 2009), it typically results in lower 
estimates of MT and, as rTMS intensity is based on MT, this may have resulted in 
 128 
weaker rTMS protocols than used previously. Finally, neuronavigation provides 
a more individualised, accurate and effective method of targeting the left DLPFC 
than the previously employed 5cm anterior method (Fitzgerald et al., 2009; 
Herwig, Padberg, et al., 2001; Rossi et al., 2009).  
Limitations 
The main limitation of this study is its lack of power. It was short of the required 
sample size and therefore, we may have had more significant effects of rTMS on 
both primary and secondary outcomes and also would have been better 
positioned to control for additional covariates if participant numbers were 
larger. Additionally, whilst the use of VAS has demonstrated utility in clinical 
research (McCormack, de L Horne, & Sheather, 1988), the effects of rTMS on 
implicit, sub-conscious measures of AN symptoms i.e. attentional bias tasks may 
be more informative (Renwick, Campbell, & Schmidt, 2013). Moreover, previous 
rTMS studies in ED have looked at the effects of rTMS on food cravings, which 
could be argued as an ED symptom that fluctuates more than others. Therefore, 
the core symptoms of AN assessed here (urge to restrict, feeling full and fat) 
may not be as susceptible to short-term modulation with rTMS as symptoms 
such as food cravings. The additional VAS, e.g. regarding mood were only 
administered as part of the FCT, therefore we could not control for baseline 
levels across these measures and finally, in terms of blinding success, we did not 
titrate choices for the researcher based on previous answers and this led to 
results indicating that researcher blinding was not effective. 
Future directions 
In elucidating the therapeutic potential of rTMS in AN, particularly in relation to 
severe cases, repeated session designs may be more informative than single-
session, exploratory studies. Given the persistent nature of AN symptoms and 
the accumulative, neuroplasticity effects proposed to underlie rTMS, single-
session studies provide limited information on the long-term benefits of such 
techniques and their potential as treatment adjuncts for ED. However, the 
findings reported here pave the way for future, therapeutic RCT of rTMS in AN.  
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Given the range of neuromodulation techniques that are available, and the large 
degree of protocol variability within each, there is a great deal of scope for more 
neuromodulation research in AN. For example, whilst we targeted the left 
DLPFC with HF rTMS to alter core AN symptoms, others have suggested 
alternative protocols; left-sided tDCS protocols have been proposed in an 
attempt to restore a hypothesised inter-hemispheric imbalance in AN (Hecht, 
2010) and preliminary findings are promising (Khedr, Elfetoh, et al., 2014). 
Equally so, LF rTMS to the right DLPFC may more directly modulate right-sided 
hyperactivity often proposed to underlie AN (Grunwald, Weiss, Assmann, & 
Ettrich, 2004; Seeger, Braus, Ruf, Goldberger, & Schmidt, 2002; Uher et al., 
2003). In addition, targeting right parietal regions with rTMS has been 
suggested as a way of modulating body dysmorphia in AN (Bainbridge & Brown, 
2014). Moreover, despite being a more invasive procedure, DBS to areas such as 
the cingulate cortex and nucleus accumbens has shown promising results in 
improving AN symptoms (Lipsman et al., 2013; McLaughlin et al., 2013; 
Treasure & Schmidt, 2013; Wu et al., 2013).  
Optimising neuromodulation devices, stimulation targets, the dose and duration 
of neuromodulation protocols in the treatment of all ED require further 
clarification (Tsai, 2005). Moreover, there is a need to identify biomarkers in 
order to understand disease mechanisms, guide future neuromodulation 
research and explore the mechanisms underlying brain-directed interventions. 
This is most likely to arise from protocols that incorporate neuroimaging 
modalities (Fidalgo et al., 2014).  
Summary 
These findings suggest that compared to sham, participants who received a 
single-session of neuronavigated real rTMS report reduced AN symptoms. 
These effects were not accompanied by similar improvements in mood and 
anxiety. Importantly, the blinding procedure within participants, i.e. the 
concealment of intervention allocation, was only partially successful. 
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Chapter 3.4 The effects of repetitive transcranial magnetic 
stimulation on food preference and consumption in anorexia 
nervosa 
People with AN demonstrate altered food preferences and often display strong 
emotional aversions in response to food and eating. Compared to their healthy 
counterparts, they both explicitly and implicitly report reduced ‘liking’ 
(hedonic/pleasure) and ‘wanting’ (incentive/motivation) of food which 
unsurprisingly, is most pronounced in relation to high-calorie foods (Cowdrey, 
Finlayson, & Park, 2013; Jiang, Soussignan, Rigaud, & Schaal, 2010; Spring & 
Bulik, 2014). Distinct brain circuitry has been reported in relation to the liking 
and wanting of food and has been implicated in the aetiology of ED (Berridge, 
2009; Castro & Berridge, 2014). Specifically, neuroimaging data suggests a 
dysfunctional response to food-related cues and other salient stimuli is 
associated with altered neural activity in mesolimbic regions such as the insula, 
amygdala and anterior cingulate cortex (Cowdrey et al., 2011; Holsen et al., 
2012) in conjunction with excessive activation of cognitive control areas such as 
the PFC (Brooks et al., 2011; Holsen et al., 2012; Park et al., 2014; Santel et al., 
2006). These differences in neural circuitry have been suggested to be both 
state and trait related and are proposed to contribute to the impaired food 
motivation and appetite regulation which are characteristic of AN (Holsen et al., 
2012; Kaye et al., 2009; Lipsman et al., 2014; van Kuyck et al., 2009).  
Similarly, altered neurocircuitry has been proposed to underlie other ED such as 
BN and BED (Brooks et al., 2011; Frank et al., 2006; Schienle et al., 2009). The 
neurobiological correlates of food craving and resulting impulse control 
difficulties in BN, BED and obesity have been likened to the neural 
underpinnings of substance dependence. Specifically, increased activity in the 
orbitofrontal cortex, amygdala and insula have been linked to food cravings 
(Tang et al., 2012; Wang et al., 2004), whilst reduced prefrontal activation has 
been reported in reaction to both food cues and during inhibitory control tasks 
in BN (Joos, Saum, Zeeck, et al., 2011), BED (Hege et al., 2014) and obese 
individuals (Kishinevsky et al., 2012).  
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Neuromodulation techniques have the ability to alter neural activity and thus 
offer potential for modulating the neural circuitry that underlies salience 
attribution and motivational processes towards food and eating. For example, in 
healthy individuals, LF rTMS to the right DLPFC decreased the value assigned to 
food (Camus et al., 2009), whilst in people who report frequent food cravings, 
HF rTMS to the left DLPFC, prevented cravings during a food exposure task 
(Uher, Yoganathan, et al., 2005). Barth et al. (2011), however, did not to 
replicate these results using improved sham rTMS in a crossover design, but 
several other studies have reported reduced food cravings following 
anodal/excitatory tDCS to the right DLPFC and this is most pronounced in 
relation to sweet foods (Fregni et al., 2008; Goldman et al., 2011; Kekic et al., 
2014). Similar findings with HF rTMS to the left DLPFC extend to clinical 
populations; reductions in the desire to eat were reported following tDCS in 
obese individuals (Montenegro et al., 2012) and rTMS in BN (Van den Eynde et 
al., 2010).  
Food cravings and resulting binge-eating episodes are core components of ED 
such as binge/purge AN, BN and BED, however they fluctuate diurnally (van der 
Ster Wallin, Norring, & Holmgren, 1994) and often depend on factors such as 
mood (Hill, Weaver, & Blundell, 1991) and menstrual cycle (Cohen, Sherwin, & 
Fleming, 1987). In contrast, core AN symptoms, such as extreme food restriction 
and pathological fear of weight gain, are stubborn and arguably less resistant to 
quotidian change. Whilst evidence for short-term effects of neuromodulation on 
such AN symptoms exists (see Chapter 3.3 and Van den Eynde, Guillaume, et al., 
2013), it could be argued that these pathologies are unlikely to alter markedly 
without intense and repeated neuromodulation exposure which has been 
reported in other therapeutic designs (Kamolz et al., 2008; Khedr, Elfetoh, et al., 
2014; McClelland, Bozhilova, Nestler, et al., 2013). However, since the 
neurocircuitry underlying hedonic and motivational processes towards food 
have been reported to be altered by neuromodulation, it may be possible to 
temporarily alter the characteristic food aversions seen in AN.  
Whilst neuromodulation research in relation to both food and drugs has shown 
potential in reducing cravings (Jansen et al., 2013), the variety of 
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neuromodulation protocols and techniques available are also likely to be able to 
induce the opposite effects, i.e. increase the preference towards such 
substances. For example, increases in cravings for methamphetamine have been 
reported following LF rTMS to the left DLPFC (Li, Malcolm, et al., 2013), whilst 
HF rTMS to the superior frontal gyrus increased cravings for cigarettes/nicotine 
in smokers (Rose et al., 2011). Moreover, increases in eating-related outcomes 
have been demonstrated following neuromodulation; specifically, DBS to the 
sub-thalamic nucleus in people with Parkinson’s disease and DBS to various 
areas of both the hypothalamus and nucleus accumbens in animals, has led to 
significant increases in body weight and food intake respectively (see Chapter 2 
or McClelland, Bozhilova, Campbell, et al., 2013).  
In summary, individuals with AN exhibit dysfunctional neural activity that is 
likely to underlie reduced hedonic experiences and motivation towards food 
and eating. Neuromodulation has reported effects on the value attributed to 
food cues and food cravings and therefore may offer potential in subliminally 
improving attitudes and preferences towards food in people with AN. 
Importantly, hedonic hunger has been shown to predict weight gain in AN (Witt 
& Lowe, 2014) and therefore implicitly altering food preference may facilitate 
food intake in AN and have implications for treatment.  
The aim of the research reported in this chapter is to examine whether 
following a food-cue exposure task, real rTMS affects food preferences and food 
consumption in AN. We hypothesised that real rTMS, compared to sham, would 
temporarily increase the liking of food in individuals with AN and subsequently 
lead to increased food consumption.  
Methods 
Participants 
Recruitment and randomisation procedure are described in Chapter 3.2. 
Procedures 





The baseline measures are described in Chapter 3.3. 
Outcome measures 
Preference for each of the food types (chocolate, crisps, nuts, biscuits) was 
measured with 10cm VAS pre (TP2) and post-rTMS (TP3) across four domains – 
perceived smell, taste, appearance and urge to eat (see Appendix G.3). Scores 
were combined into an overall ‘liking’ variable for each food type, with a total 
possible score of 40. Scores across the individual VAS (perceived smell, taste, 
appearance and urge to eat) for each food type were also examined. 
Two measures were used to assess the effects of rTMS on food consumption in 
AN; the amount of smoothie consumed immediately after real/sham rTMS, and 
how much participants ate during the 24 hours following stimulation. With 
regards to smoothie consumption, at the end of the rTMS testing session, 
participants were asked to choose one of three flavours (mango/banana, 
strawberry/banana or kiwi fruit) of a well-known Innocent® fruit smoothie. 
Participants were then asked to ‘drink as much as you can’ of the chosen flavour 
and left alone in the room for approximately 10 minutes. The amount of 
smoothie drunk was established by measuring the weight of the smoothie (in 
grams) before and after consumption. To establish how much participants ate 
during the 24 hours after real/sham rTMS, during the follow-up call, they were 
asked to indicate how much they had eaten in the past 24 hours by giving a 
number between 1 (no meals) and 10 (all meals; 3 main meals and 3 snacks).  
Statistical analyses 
Statistical analyses were performed using IBM® SPSS® software (Version 22). 
Following consultation with a statistician, when normality or other ANOVA 
assumptions such as homogeneity of were violated (assessed via Kolmogorov-
Smirnov and Levene’s test statistics respectively) log transformations or other 
non-parametric alternatives were employed. When Mauchly’s test of sphericity 
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was violated, Greenhouse-Geisser corrections are reported. All tests were two-
tailed and the level of significance was set at α = 0.05. 
Following the first administration of the FCT, correlations regarding the whole 
sample were conducted in order to examine the relationship between the 
composite outcomes, individual and additional VAS and the food related 
outcomes (mentioned above in Chapter 3.3). 
The effect of real versus sham rTMS on the liking of each of the different foods 
(primary outcome), along with the individual food VAS listed above, was 
evaluated using a mixed ANOVA (group: real/sham rTMS x time: TP2, TP3). 
Additionally, post-hoc correlational analyses were conducted separately for 
each real/sham rTMS groups to examine associations between primary and 
secondary outcomes and changes to food ratings following real/sham rTMS. The 
effect of real versus sham rTMS on both smoothie consumption and amount of 
food eaten was evaluated using independent t-tests. 
Partial eta squared (η2) and Cohen’s d effect sizes are reported for mixed 
ANOVAs and t-tests respectively. Partial eta squared is automatically computed 
within SPSS by dividing the sums of squares for the effect of interest by the total 
sums of squares i.e. η2 = SSbetween/SStotal (Levine & Hullett, 2002). Cohen’s d was 
computed by dividing the difference in means by the pooled standard deviation 
i.e. d = M1 – M2/√(SD12+ SD22/2).  Interpretation of the magnitude of η2 is 0.01-
0.06 = small; 0.06-0.14 = medium and > 0.14; large; and for Cohen’s d effect 
sizes 0.15-0.40 = small; 0.4-0.75 = medium and > 0.75: large (Cohen, 1988).  
Results 
The same 49 right-handed, female individuals described above (Chapter 3.3), 
randomised to real (n = 21, restrictive-AN = 13, binge/purge-AN = 8) and sham 
(n = 28, restrictive-AN = 15, binge/purge-AN = 13) were included in the 
subsequent analyses.  
Baseline characteristics 




Following the first FCT, Pearson’s correlations including the entire sample 
indicated no significant correlations between the liking of different foods and 
either the composite core AN symptoms or the anxiety/stress measure. 
However, there was a positive association between the overall liking of 
chocolate and current state of hunger [r = 0.38, p = 0.009] and urge to eat [r = 
0.37, p = 0.009]. Similarly, there was a positive association between the urge to 
eat and liking of biscuits [r = 0.34, p = 0.017]. Finally, the liking of crisps was 
positively correlated with current hunger [r = 0.37, p = 0.010] and urge to eat [r 
= 0.44, p = 0.001].  
Liking of foods 
No significant interaction effects, differences across time or between groups 
were found in relation to liking of chocolate, crisps or nuts (see Table 3.8). 
There was however, a significant interaction between stimulation type and time 
in relation to liking biscuits; sham rTMS reduced the liking, while real rTMS 
increased it (Table 3.8). This was predominantly driven by a significant 
interaction for the urge to eat (Table 3.12) the biscuits and their perceived taste 
(Table 3.11), alongside an interaction trend regarding their appearance (Table 
3.9). In other words, following real rTMS, participants had a stronger urge to eat 
the biscuits, which were perceived as tastier and which looked more appetising. 
In contrast, there was an opposite effect in relation to the perceived taste of 
chocolate; real rTMS reduced the perceived taste of chocolate, i.e. participants 
rated chocolate as less tasty, more so than sham rTMS (Table 3.11). There were 
no group, time or interaction effects in relation to the perceived smell of each 
food type (Table 3.10).  
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The composite ‘liking of food’ outcome was computed by adding scores across all four 10cm visual analogue scales relating to the perceived 
appearance, smell, taste and urge to eat each food type. Therefore, scores on this composite ‘liking of food’ outcome could range from 0 to 40.   
Table 3.7  Mixed ANOVA results of the composite ‘liking of food’ outcomes following real/sham rTMS. Mean ± SD reported. 
 Time Point Real rTMS  
(n = 21) 
Sham rTMS    














Post FCTpre/pre rTMS (TP2) 14.59 ± 7.51 18.44 ± 11.60 F (1) = 0.01 
p = 0.911 
η2 = 0.00 
F (1) = 2.13  
p = 0.151 
η2 = 0.04 
F (1) = 0.15 
p = 0.703 




s Post FCTpre/pre rTMS (TP2) 12.07 ± 10.05 14.54 ± 9.78  F (1) = 0.87   
p = 0.355 
η2 = 0.02 
F (1) = 0.54 
p = 0.468 
η2 = 0.01 
F (1) = 0.13   
p = 0.716 




 Post FCTpre/pre rTMS (TP2)  14.27 ± 9.04 9.87 ± 8.61 F (1) = 0.48   
p = 0.493 
η2 = 0.01 
F (1) = 2.71   
p = 0.107 
η2 = 0.06 
F (1) = 0.07 
p = 0.787 





s Post FCTpre/pre rTMS (TP2) 15.30 ± 10.76 16.18 ± 12.43  F (1) = 0.07 
p = 0.792 
η2 = 0.00 
F (1) = 0.06 
p = 0.810 
η2 = 0.00 
F (1) = 7.63   
p = 0.008 
η2 = 0.14 Post rTMS & FCTpost (TP3) 17.16 ± 11.56 14.65 ± 12.02  
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Appearance of each food type was measured on a 10cm visual analogue scale; scores could range from 0 (not appetising at all) to 10 
(extremely appetising).  
Table 3.8 Mixed ANOVA results of the ‘appearance’ of each food type following real/sham rTMS.  Mean ± SD reported. 
 Time Point Real rTMS  
(n = 21) 
Sham rTMS  














Post FCTpre/pre rTMS (TP2) 3.63 ± 2.81 4.74 ± 3.53 F (1) = 0.15  
p = 0.701 
η2 = 0.00 
F (1) = 1.99  
p = 0.165 
η2 = 0.04 
F (1) = 0.11  
p = 0.739 




s Post FCTpre/pre rTMS (TP2) 2.72 ± 2.79 3.17 ± 2.94 F (1) = 2.94  
p = 0.093 
η2 = 0.06 
F (1) = 0.21  
p = 0.650 
η2 = 0.00 
F (1) = 0.07  
p = 0.796 




 Post FCTpre/pre rTMS (TP2) 3.75 ± 2.67 2.26 ± 2.49 F (1) = 0.00  
p = 0.975 
η2 = 0.00 
F (1) = 4.29  
p = 0.044 
η2 = 0.08 
F (1) = 0.00 
p = 0.991 





s Post FCTpre/pre rTMS (TP2) 3.87 ± 3.22 4.07 ± 3.52 F (1) = 0.04  
p = 0.835 
η2 = 0.00 
F (1) = 0.03  
p = 0.855 
η2 = 0.00 
F (1) = 3.75  
p = 0.059 
η2 = 0.07 Post rTMS & FCTpost (TP3) 4.28 ± 3.19 3.74 ± 3.24 
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The perceived smell of each food type was measured on a 10cm visual analogue scale; scores could range from 0 (not appetising at all) to 10 
(extremely appetising).  
Table 3.9 Mixed ANOVA results of the perceived ‘smell’ of each food type following real/sham rTMS.  Mean ± SD reported. 
 Time Point Real rTMS 
(n = 21) 
Sham rTMS 














Post FCTpre/pre rTMS (TP2) 3.30 ± 2.74 3.97 ± 3.61 F (1) = 0.66  
p = 0.420 
η2 = 0.01 
F (1) = 0.46  
p = 0.502 
η2 = 0.01 
F (1) = 0.06  
p = 0.808 




s Post FCTpre/pre rTMS (TP2) 3.24 ± 2.87 3.93 ± 3.02 F (1) = 0.79  
p = 0.378 
η2 = 0.02 
F (1) = 0.49  
p =0.486 
η2 = 0.01 
F (1) = 0.14  
p = 0.710 




 Post FCTpre/pre rTMS (TP2) 3.77 ± 3.05 2.50 ± 2.66 F (1) = 0.11  
p = 0.740 
η2 = 0.00 
F (1) = 1.99  
p = 0.164 
η2 = 0.04 
F (1) = 0.45  
p = 0.505 





s Post FCTpre/pre rTMS (TP2) 4.29 ± 3.30 3.88 ± 3.47 F (1) = 0.17  
p = 0.685 
η2 = 0.00 
F (1) = 0.64  
p = 0.429 
η2 = 0.01 
F (1) = 2.20  
p = 0.145 
η2 = 0.05 Post rTMS & FCTpost (TP3) 4.70 ± 3.18 3.64 ± 3.12 
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The perceived taste of each food type was measured on a 10cm visual analogue scale; scores could range from 0 (not tasty at all) to 10 
(extremely tasty).  
Table 3.10 Mixed ANOVA results of the perceived ‘taste’ of each food type following real/sham rTMS. Mean ± SD reported. 
 Time Point Real rTMS 
(n = 21) 
Sham rTMS 














Post FCTpre/pre rTMS (TP2) 5.78 ± 2.77 6.30 ± 2.97 F (1) = 7.57  
p = 0.008 
η2 = 0.14 
F (1) = 1.60  
p = 0.211 
η2 = 0.03 
F (1) = 3.87  
p = 0.055 




s Post FCTpre/pre rTMS (TP2) 4.23 ± 3.32 4.86 ± 3.11 F (1) = 0.38  
p =0.540 
η2 = 0.01 
F (1) = 0.69  
p = 0.409 
η2 = 0.01 
F (1) = 0.07  
p = 0.790 




 Post FCTpre/pre rTMS (TP2) 4.59 ± 2.93 3.43 ± 2.79 F (1) = 4.44  
p = 0.041 
η2 = 0.09 
F (1) = 2.10  
p = 0.154 
η2 = 0.04 
F (1) = 0.07  
p = 0.797 





s Post FCTpre/pre rTMS (TP2) 4.92 ± 3.20 5.23 ± 3.23 F (1) = 2.47  
p = 0.123 
η2 = 0.05 
F (1) = 0.01  
p = 0.908 
η2 = 0.00 
F (1) = 8.21  
p = 0.006 
η2 = 0.15 Post rTMS & FCTpost (TP3) 5.11 ± 3.23 4.59 ± 3.34 
 140 
The urge to eat each food type was measured on a 10cm visual analogue scale; scores could range from 0 (would not wish to eat them at all) 
to 10 (would like to eat some very much).  
Table 3.11 Mixed ANOVA results of the ‘urge to eat’ each food type following real/sham rTMS. Mean ± SD reported. 
 Time Point Real rTMS 
(n = 21) 
Sham rTMS 














Post FCTpre/pre rTMS (TP2) 1.88 ± 1.99 3.43 ± 3.59 F (1) = 0.38  
p = 0.541 
η2 = 0.01  
F (1) = 3.04  
p = 0.088 
η2 = 0.06 
F (1) = 0.34  
p = 0.564 




s Post FCTpre/pre rTMS (TP2) 1.89 ± 2.57 2.57 ± 2.95 F (1) = 0.78 
p = 0.382 
η2 = 0.02 
F (1) = 0.33  
p = 0.567 
η2 = 0.01 
F (1) = 0.60  
p = 0.443 




 Post FCTpre/pre rTMS (TP2) 1.81 ± 2.02 1.68 ± 2.21 F (1) = 0.88  
p = 0.353 
η2 = 0.02  
F (1) = 0.54  
p = 0.468 
η2 = 0.01 
F (1) = 1.26  
p = 0.267 





s Post FCTpre/pre rTMS (TP2) 2.21 ± 2.85 3.01 ± 3.23 F (1) = 0.95  
p = 0.334 
η2 = 0.02 
F (1) = 0.05  
p = 0.816 
η2 = 0.00 
F (1) = 4.85  
p = 0.033 
η2 = 0.09 Post rTMS & FCTII (TP3) 3.06 ± 3.17 2.68 ± 3.31 
 
141 
Pearson’s post-hoc correlations were conducted separately for each real/sham 
rTMS groups regarding food preferences and both composite and individual 
VAS outcomes following rTMS. Following real rTMS, level of hunger was 
associated with the liking of biscuits [r = 0.63, p = 0.002] and nuts [r = 0.64, p = 
0.002]. Similarly, current urge to eat was positively associated with the liking of 
chocolate [r = 0.44, p = 0.048] and crisps [r = 0.43, p = 0.050]. Following sham 
rTMS, the liking of nuts was positively correlated with both levels of feeling full 
[r = 0.45, p = 0.015] and core AN symptoms [r = 0.44, p = 0.018]. Negative 
correlations were observed following sham rTMS between levels of feeling fat 
and the liking of biscuits [r = -0.45, p = 0.015], and between mood and the liking 
of crisps [r = -0.47, p = 0.012]. 
Food consumption 
There were no significant differences between groups in either the amount of 
smoothie consumed [t(47) = -0.14, p = 0.887, d = 0.04] (see Figure 3.6) or the 
amount of food eaten during the 24 hours following real/sham rTMS [t(47) = -
0.21, p = 0.831, d = 0.06] (see Figure 3.7).  
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The mean ± SD values for the amount of smoothie (g) consumed in the real and 
sham groups are 40.00 ± 58.24 and 42.78 ± 73.79 respectively.   
 
Scores ranged from 1 (no meals) to 10 (all meals i.e. 3 main meals and 3 snacks) 
on a 10cm visual analogue scale (VAS). The mean ± SD values for the amount of 
food in the real and sham groups are 6.33 ± 2.61 and 6.50 ± 2.75 respectively.   
 
Figure 3.6 Amount of smoothie consumed after real/sham rTMS. Mean ± 
SD reported 
 
Figure 3.7 Amount of food eaten during the 24 hours following real/sham 
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Discussion 
The findings support our hypothesis; real rTMS increased the liking of some 
foods in AN whilst liking of food was reduced following sham rTMS. However, 
the increased preference was food-specific and only in relation the liking of 
sweet biscuits, and not chocolate, crisps or nuts. Moreover, changes in the liking 
of biscuits were positively associated with hunger, and negatively associated 
with levels of feeling fat in the real and sham groups respectively. The increased 
preference for food following real rTMS was not associated with any subsequent 
increase in food consumption.  
The data are in part agreement with existing literature that suggests the liking 
of (some) sweet foods can be modulated by neuromodulation. Reduced food 
cravings, in particular in relation to sweet foods, have been reported following 
tDCS in frequent food cravers (Fregni et al., 2008; Goldman et al., 2011; Kekic et 
al., 2014). Moreover, our findings are in line with other research that suggests 
neuromodulation can also increase the liking and wanting of substances such as 
alcohol, nicotine and food (Li, Malcolm, et al., 2013; Rose et al., 2011). Whilst 
hunger has not been reported to be altered following rTMS in AN (see Chapter 
3.3 and Van den Eynde, Guillaume, et al., 2013), it was positively correlated with 
the liking of biscuits within this sample.  
Hemispheric lateralisation 
Differences between literature demonstrating reduced food cravings, and our 
findings of increased liking of food in AN, may be due differences between the 
neuromodulation protocols used. For example, the tDCS anode right/cathode 
left studies predominantly activate the right PFC, whilst HF rTMS to the left 
DLPFC activates the left PFC. Research suggests that neuromodulation has 
opposing effects on the contralateral hemisphere to that which is stimulated 
(Fox et al., 1997) i.e. excitatory rTMS to the left DLPFC may inhibit activity in the 
right DLPFC and vice versa. If this is the case, anode right/cathode left tDCS and 
HF (excitatory) rTMS to the left DLPFC would have opposite effects on neural 
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activity and may explain the difference in the reported effects on the liking of 
food outcomes.  
Sample 
The opposing effects on food preferences might also be due to the different 
groups of individuals studied. Different neural mechanisms have been proposed 
to underlie ED related problems that involve food cravings and poor inhibitory 
control (e.g. AN binge/purge, BN, BED and obesity) and the core characteristics 
of restrictive AN (characterised by impaired hedonic appetite drives and 
excessive cognitive control over food). This is hard to disentangle in the current 
study that has both restrictive and binge/purge AN subtypes. For example, 
impaired right prefrontal activity has been implicated in over-eating syndromes 
such as obesity (Alonso-Alonso & Pascual-Leone, 2007) and therefore, anodal 
tDCS may remotely alter reward-related neural circuits (Fregni et al., 2008) and 
improve cognitive control over food cravings. In comparison, rTMS to the left 
DLPFC may remotely alter limbic, food-motivation related circuitry in AN that is 
involved in hedonic appetite (Holsen et al., 2012) e.g. by increasing reported 
prefrontal hypoperfusion in AN (Frank et al., 2004).  
Strengths 
This is the first study to utilise food exposure tasks in ED neuromodulation 
research. Hedonic hunger is reduced in AN, yet predicts weight gain (Witt & 
Lowe, 2014), therefore it is an important construct that is worth investigating in 
AN. Additionally, mentioned previously, this study followed a robust 
randomised control protocol and employs improved rTMS methodologies such 
as the MEP method of estimating MT and neuronavigation.  
Limitations 
Unlike the main outcomes measured in Chapter 3.3, the effects of rTMS on food 
preferences were only assessed immediately before and after real/sham rTMS. 
Therefore, the findings are limited by the fact that the study did not control for 
baseline levels of the liking of food. The effect of rTMS on food consumption is 
probably limited by social desirability effects – the amount of smoothie drunk 
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and reported food intake following real/sham rTMS is likely to have been 
influenced by the experimental setting. Furthermore, the limited way in which 
food intake during the 24 hours following rTMS was assessed was a blunt 
measure. Finally, whilst some of the binge/purge subtype participants 
informally reported binge-eating episodes post rTMS, this was not formally 
assessed.  
Future directions 
Given the opposing findings relating to the effects of rTMS towards different 
sweet foods (chocolate/biscuits) and existing evidence for distinct neural 
responses to chocolate and its addictive properties (Hetherington & 
MacDiarmid, 1993; Macdiarmid & Hetherington, 1995; Sokolov, Pavlova, 
Klosterhalfen, & Enck, 2013), future research may wish to explore the neural 
mechanisms underlying specific food cues in AN more thoroughly. This might 
perhaps be accomplished by comparing the effects of excitatory (HF 
rTMS/anodal tDCS) and inhibitory (LF rTMS/cathodal tDCS) neuromodulation 
on food related ratings in AN. Moreover, the use of online exposure tasks i.e. 
during neuromodulation rather than immediately before/after, that are more 
salient and realistic than those employed here, may elicit stronger effects on 
hedonic ratings of food in AN. Finally, virtual reality based food consumption 
tasks may elicit more interesting and accurate findings regarding potential food 
intake immediately after rTMS that is not as limited by unnatural experimental 
settings. Similarly, a food diary outlining the type and amount of food consumed 
in the 24 hours following rTMS may provide more informative findings 
regarding nutritional/calorie content consumed and binge/purge episodes. 
Summary 
Data suggest that real and sham rTMS have opposite effects on the liking of 
specific foods in AN; real rTMS increases whilst sham rTMS decreases the liking 
of sweet biscuits. This finding was associated with levels of hunger and feeling 
fat i.e. increased levels of hunger and feeling fat were positively and negatively 
associated with the liking of biscuits following real/sham rTMS respectively. 
However, real rTMS was not associated with increased food consumption. 
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Chapter 3.5 The effects of repetitive transcranial magnetic 
stimulation on salivary cortisol concentrations in anorexia 
nervosa 
Investigating the usefulness of neuromodulation techniques as treatment 
adjuncts in psychiatry is timely and important. However, there is an equally 
strong need to investigate the neurobiological mechanisms underlying 
neuromodulation, as a means of understanding both disease and therapeutic 
mechanisms. In their systematic review, Fidalgo et al. (2014) emphasise the 
importance of investigating the relationship between biomarkers and clinical 
response to non-invasive neuromodulation in depression. Whilst they found 
that various biomarkers investigated with neuroimaging modalities positively 
correlated with clinical improvements, peripheral levels of BDNF were the 
strongest predictor of treatment response. Other neuroendocrinological 
responses, e.g. hypothalamic-pituitary-adrenal (HPA) axis activity (cortisol 
concentrations) have been examined to explore the effects of rTMS. The HPA 
axis plays a central role in regulating the body’s response to stressful situations. 
Corticotrophin-releasing hormone from the hypothalamus causes secretion of 
the adrenocorticotrophic hormone from the pituitary gland and this in turn 
stimulates secretion of glucocorticoids, namely cortisol, from the adrenal cortex. 
This regulates the body’s physiological and behavioural response to stress 
(Charmandari, Tsigos, & Chrousos, 2005). The PFC has been implicated in HPA 
axis activity (McKlveen et al., 2013) and therefore examining the effects of 
prefrontal rTMS on cortisol concentrations may help to clarify the role of HPA 
activity in psychiatric disorders, and to determine whether alterations to the 
HPA axis underlie the therapeutic mechanisms of neuromodulation. However, 
changes in cortisol levels may not be simple to interpret as, for example, a 
change could be the result of either alterations to the PFC or the individuals 
perception of the rTMS as something unpleasant/stressful.  
Early animal studies suggest that rTMS alters HPA axis activity (Hedges et al., 
2003). More recently, in healthy but experimentally stress-induced humans, HF 
rTMS to the left DLPFC was shown to reduce salivary cortisol concentrations 
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and thus attenuate HPA activity (Baeken et al., 2014). The same group have also 
reported similar findings in depression (Baeken et al., 2009), a neuro-circuit 
based psychiatric disorder that is associated with increased HPA activity 
(Swaab, Bao, & Lucassen, 2005). The reported decrease in cortisol suggests that 
the intervention is not perceived as very stressful and hence the decrease in 
cortisol may be a direct effect of the rTMS on the PFC.  
Both BN and AN are associated with HPA hyperactivity/hypercortisolemia (for 
reviews see Licinio, Wong, & Gold, 1996; Lo Sauro, Ravaldi, Cabras, Faravelli, & 
Ricca, 2008). In relation to AN, HPA axis hyperactivity is independent of 
comorbid psychopathology and associated with weight loss and illness severity. 
Moreover, evidence suggests trait related HPA axis disturbances in AN, given 
that alterations exist following weight restoration (Lo Sauro et al., 2008). In fact, 
alterations in the HPA axis have been proposed to be causally involved in the 
development of AN (Connan et al., 2003; Connan et al., 2007). Lawson et al. 
(2013) have also reported associations between HPA hyperactivity, homeostatic 
and hedonic appetite suppression and hypoactivity of food motivation circuitry 
in AN.  
Despite evidence that cortisol concentrations are modulated following rTMS 
and ED are associated with HPA hyperactivity, only one study has examined the 
effects of rTMS on cortisol concentration in ED. Compared to sham, real HF 
rTMS, applied to the left DLPFC, was associated with reduced salivary cortisol 
levels in BN (Claudino et al., 2011). Given such findings and the well-
documented HPA hyperactivity in AN, this chapter describes an examination of 
the effects of rTMS on salivary cortisol concentrations in AN. It was 
hypothesised that compared to sham, real rTMS would reduce salivary cortisol 
concentrations in individuals with AN.  
Methods 
Participants 
Recruitment and randomisation procedure are described in Chapter 3.2. Gender 
and time of day are confounding factors in studies involving cortisol measures. 
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However, all participants in the RCT were female and underwent the rTMS 
testing session in the afternoon. Therefore, the same 51 individuals described 
previously were considered.  
Procedures 
A description of procedures is provided in Chapter 3.2.  
Measures 
Baseline 
The baseline measures are described in Chapter 3.3. 
Outcomes 
Participants were requested to refrain from eating for 1 hour prior to the visit. 
Salivette® (Sarstedt, Germany) devices were used to collect saliva samples. 
Appendix H.3 contains a leaflet by Sarstedt with guidance on how to obtain a 
saliva sample. Participants were instructed not to touch the cotton (as this may 
have an impact on the quality of the sample) and to chew for around 30 seconds. 
Participants were also not allowed to rinse their mouth with any fluid prior or 
post sample collection. This is a common adaptation that has been reported by 
other research groups (Gustafsson, Janlert, Theorell, & Hammarstrom, 2010). 
Saliva samples were collected at five time points during the experiment (see 
Table 3.1); at the start of the session (S1), following the first FCT (S2), 
immediately following real/sham rTMS (S3), after the second FCT (S4) and at 
the end of the testing session (S5). Samples were stored at -20°c where they are 
stable for several months. The frozen samples were thawed and the saliva 
separated from the swab by centrifugation (1500g, 15 min). Cortisol 
concentrations were measured by enzyme-linked immunosorbet assay ELISA 
(Salimetrics, Germany). Tracy Dew from Viapath pathology services, King’s 
College Hospital conducted these procedures of centrifugation and cortisol 
concentration measurement.  
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Statistical analysis 
Statistical analyses were performed using IBM® SPSS® software (Version 22). 
When normality or other ANOVA assumptions such as homogeneity of were 
violated (assessed via Kolmogorov-Smirnov and Levene’s test statistics 
respectively) log transformations or other non-parametric alternatives were 
employed. When Mauchly’s test of sphericity was violated, Greenhouse-Geisser 
corrections are reported. All tests were two-tailed and the level of significance 
was set at α = 0.05.  
As the data regarding salivary cortisol were skewed, non-parametric correlation 
analyses (Spearman’s rho, rs) between initial (S1) cortisol concentrations and 
psychopathology indices were used (EDEQ global, DASS-21 total and core AN 
symptoms). The non-parametric tests, Mann-Whitney U (U) and Wilcoxon 
Signed Rank (Z) tests were employed to examine whether the first FCT altered 
salivary cortisol levels for the whole sample and within real/sham rTMS groups 
respectively.  
Using transformed data, the effects of real versus sham rTMS on salivary 
cortisol over time were evaluated using a mixed ANOVA (group: real/sham 
rTMS x time: S3, S4, S5) controlling for cortisol levels at S2 as a baseline 
measure.  
Cortisol concentrations have been associated with reduced homeostatic and 
hedonic hunger in AN (Lawson et al., 2013). Therefore, correlational analyses 
were conducted for the entire group between cortisol concentrations (S2) and 
the additional VAS outcomes relating to ‘hunger’ and ‘urge to eat’ (see Chapter 
3.3) and the liking of food stimuli (see Chapter 3.4) following the first FCT.  
Partial eta squared (η2) are reported for mixed ANOVAs which is automatically 
computed within SPSS by dividing the sums of squares for the effect of interest 
by the total sums of squares i.e. η2 = SSbetween/SStotal (Levine & Hullett, 2002). 
Interpretation of the magnitude of η2 is 0.01-0.06 = small; 0.06-0.14 = medium 
and > 0.14; large. For non-parametric tests, the effect size r was calculated by 
dividing the Z statistic by the square root of the number within the sample, i.e. r 
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= Z/√N. Interpretation of the magnitude of r is 0.1 = small, 0.3 = medium and 0.5 
= large.  
Results 
The same 49 right-handed, female individuals described above (Chapter 3.3), 
randomised to real (n = 21, restrictive-AN = 13, binge/purge-AN = 8) and sham 
(n = 28, restrictive-AN = 15, binge/purge-AN = 13) were included in the 
subsequent analyses. 
Baseline characteristics 
Please see description of baseline demographic and ED characteristics above 
(Chapter 3.3) and in Table 3.2. Due to missing/invalid data, there were 45 
complete (from S1-S5) salivary cortisol data sets (real = 19, sham = 26), which 
were used in subsequent analyses. The demographic and ED/general 
psychopathology characteristics of this sub-sample are similar to those reported 
in Table 3.2: there were no significant group differences at baseline(2), except 
for on the EDE-Q shape concern subscale [t(29.83) = -2.28, p = 0.030, d = 0.83] 
where the sham group demonstrated significantly greater psychopathology.  
Given the skewed nature of the data, median and inter-quartile ranges (IQR) of 
cortisol concentrations within each real/sham group at each collection TP are 
presented in Figure 3.8.  Whilst there was a wide range of values, median scores 
were around normal ranges for afternoon/evening cortisol concentrations in 
adult females (< 9.90 nmol/L) and therefore do not suggest hypercortisolemia.  
Spearman’s rho (rs) did not indicate any significant associations between initial 
cortisol concentrations (S1) and psychopathology indices i.e. EDEQ global, 
DASS-21 total and the composite core AN symptoms.   
Salience of food challenge task 
There were no significant differences between groups in cortisol concentrations 
at baseline(2)/S1 [U = 289, p = 0.920, r = 0.01]. In the whole sample (N = 45), 
the FCT did not significantly alter salivary cortisol concentrations [Z = -0.07, p = 
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0.942, r = 0.01] nor did the FCT significantly alter concentrations within either 
group: real [Z = -0.64, p = 0.520, r = 0.14], sham [Z = -0.37, p = 0.707, r = 0.07]. 
The median ± IQR of cortisol concentrations (in nmol/L) from S1-S5 in the real 
(6.63 ± 5.46, 5.65 ± 8.51, 7.00 ± 9.20, 5.28 ± 6.23, 6.20 ± 6.58) and sham (6.58 ± 
5.01, 6.75 ± 3.25, 7.05 ± 6.39, 6.39 ± 4.31 and 6.37 ± 5.48) groups respectively. 
 
Outcome 
Log transformations were used in mixed ANOVA analyses and controlling for 
scores at TP2, there were no significant interaction effects [F (1.54) = 0.50, p = 
0.561, η2 = 0.01], or effects of time [F (1.55) = 2.75, p = 0.084, η2 = 0.06] or 
stimulation type [F(1) = 1.37, p = 0.248, η2 = 0.03] on salivary cortisol 
concentrations. To examine the relationship between cortisol and homeostatic 
and hedonic appetite, correlations were conducted for the entire sample 
following the first FCT. Cortisol concentrations (S2) were correlated with the 
additional VAS relating to ‘hunger’ and ‘urge to eat’ and the food ‘liking’ 
outcomes (see Chapter 3.3 and 3.4) at TP2. There were no significant 
correlations across any of these measures.  
 
Figure 3.8 Salivary cortisol concentrations for each of the real/sham 
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Discussion 
The current findings did not support our hypothesis: compared to sham, real 
rTMS did not significantly reduce salivary cortisol concentrations. Moreover, 
salivary cortisol concentrations were not associated with ED/general 
psychopathology, nor were there any demonstrated relationships between 
cortisol and homeostatic or hedonic appetite ratings. 
The lack of observed changes in salivary cortisol concentrations following rTMS 
replicates our previous findings in AN (Van den Eynde, Guillaume, et al., 2013). 
However, our data are not consistent with studies in both healthy individuals 
(Baeken et al., 2014) and other psychiatric disorders such as depression 
(Baeken et al., 2009) and BN (Claudino et al., 2011), which have reported 
reduced salivary cortisol concentrations following HF rTMS to the left DLPFC. 
One possible explanation is that general salivary cortisol concentrations within 
this group of individuals with AN were not indicative of hypercortisolemia. Also, 
whilst HPA axis hyperactivity is well documented in AN, it has been found in 
weight-restored AN, i.e. it may be trait related (Lo Sauro et al., 2008). Therefore, 
given its stability throughout different stages of illness, it may be less 
susceptible to the effects of neuromodulation, particularly only a single-session 
of rTMS. 
The findings of Lawson et al. (2013) regarding cortisol concentrations and 
reduced homeostatic and hedonic appetite ratings were not replicated in this 
group of individuals with AN. This may be due to protocol differences such as 
the method of cortisol collection and analysis (saliva versus serum), and the 
non-fasted versus fasted/fed state of participants.    
Limitations 
Given the rTMS methodologies employed, this research is arguably an 
improvement on existing studies of the effects of rTMS on HPA activity in ED. 
However, this study is underpowered and in addition, factors such as nicotine 
and caffeine intake may influence HPA axis activity (Gilbert, Dibb, Plath, & 
Hiyane, 2000; Hellhammer, Wust, & Kudielka, 2009). Whilst the principle 
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eligibility criteria of this study aimed to exclude individuals who smoke 
excessively, the consumption of caffeine and smoking prior to assessment was 
not monitored. Additionally, whilst all participants were tested in the afternoon, 
the exact timings of saliva sample collections were not recorded and thus 
controlled for, unlike in our previous study (Claudino et al., 2011). Finally, as 
crossover protocols with rTMS are problematic, due to the difficulty in adequate 
blinding of participants, the between-subject nature of the research is likely to 
have increased inter-individual variability and thus obscured any potential 
group differences.  
Future directions 
Given that stress response systems are predominantly regulated by the right 
PFC (Cerqueira, Almeida, & Sousa, 2008) and that right-sided hyperactivity has 
been proposed to be associated with AN (Grunwald et al., 2004; Hecht, 2010; 
Khedr, El Fetoh, El Bieh, Ali, & Karim, 2014), LF rTMS to the right DLPFC may 
reduce HPA hyper-activity and therefore it is worth investigating. However, 
given the negligible effects of rTMS on salivary cortisol concentrations in AN 
that have been reported so far, other biomarkers, e.g. the effects of rTMS on 
neurocognitive function in AN (see Chapter 4) or alterations to substrates such 
as BDNF and monoamine neurotransmitters might be more informative within 
this patient population. 
Summary 
The data suggest that in AN, HF rTMS to the left DLPFC does not result in a 
reduction in HPA activity, i.e. salivary cortisol levels are not reduced following 
rTMS. Since rTMS did not alter cortisol concentrations, this indicates that the 
rTMS protocol employed was not experienced as something that is very 
stressful to individuals with AN. Finally, cortisol concentrations were not 
associated with reduced homeostatic appetite drive in this group of individuals 
with AN.  
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Chapter 3.6 Cortical excitability in anorexia nervosa. 
As described previously, the intensity at which rTMS is applied, i.e. the strength 
of the magnetic field, should be based on levels of cortical excitability. This 
varies from person to person and therefore rTMS studies typically use MT 
estimates to quantify cortical excitability and to apply the appropriate ‘dose’ of 
rTMS for each individual. Along with being an important safety consideration, as 
cortical excitability can affect the risk of an rTMS induced seizure (Rossi et al., 
2009; Wassermann, 1998), measures such as MT also help to provide an 
understanding of neurophysiological mechanisms such as intracortical 
inhibitory and facilitatory networks, and cortico-cortical connectivity (Bunse et 
al., 2014).  
A number of TMS based methodologies can be used to investigate cortical 
excitability (Table 3.12). Resting and active MT estimations (RMT and AMT), i.e. 
the excitability of the motor cortex whilst a peripheral muscle is either relaxed 
or engaged, are commonly used (Rossini et al., 1994) and the amplitude of MEP 
also provide a measure of cortical excitability (Zaaroor, Pratt, & Starr, 2003). In 
contrast, the cortical silent period (CSP), defined as the duration between the 
onset of an MEP and the return to normal electromyography (EMG) activity, is 
often used to assess levels of cortical inhibition (Bunse et al., 2014; Cantello, 
Gianelli, Civardi, & Mutani, 1992).  
The use of paired-pulse TMS, i.e. applying a conditioning pulse prior to the test 
pulse, enables alternative measurements of cortical activity. The time of the 
inter-stimulus interval (ISI) and the magnitude of conditioning/test stimuli can 
both be varied in paired-pulse TMS designs to examine intracortical facilitation 
(ICF) or short-interval intracortical facilitation (SICF) (Kujirai et al., 1993; 
Nakamura, Kitagawa, Kawaguchi, & Tsuji, 1997; Ziemann, 2004) and short- or 
long-interval intracortical inhibition (SICI/LICI) (Kujirai et al., 1993). Finally, 
transcallosal inhibition (TCI) involves applying a conditioning TMS pulse to the 
motor cortex of one hemisphere followed by a test stimulus to the other and 
enables an assessment of interhemispheric activity (Ferbert et al., 1992).  
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μV: microvolt, EMG: electromyography; ms: millisecond; ISI: inter-stimulus interval 
Table 3.12 Techniques used to measure cortical inhibition and excitability. 
Measure Description 
Single-pulse TMS 
Motor evoked potential (MEP) 
Overall reaction of a peripheral muscle measured by EMG induced via TMS to contralateral 
motor cortex.  
Resting motor threshold (RMT) 
Defined as the minimum stimulus required to evoke a minimum of 5 out of 10 MEP > 50μV in a 
relaxed/resting muscle.  
Active motor threshold (AMT) 
Defined as the minimum stimulus required to evoke a minimum of 5 out of 10 MEP > 50μV 
whilst the target muscle is voluntary contracted.  
Cortical silent period (CSP) 
Suppression/reduction of muscle activity following TMS to the contralateral motor cortex. It is 
the time period from onset of MEP and return of EMG activity. 
Paired-pulse TMS 
Intracortical facilitation (ICF) 
Sub-threshold conditioning stimulus, long (7-20ms) ISI, supra-threshold test stimulus results 
in cortical excitability. 
Short-interval intracortical 
facilitation (SICF) 
Supra-threshold conditioning stimulus, short discrete ISI (1.1-1.5ms, 2.3-2.9ms, 4.1-4.4ms), 
sub-threshold test stimulus results in cortical facilitation. 
Short-interval intracortical 
inhibition (SICI) 
Sub-threshold conditioning stimulus, short (~2-5ms) ISI, supra-threshold test stimulus results 
in cortical inhibition.  
Long-interval intracortical 
inhibition (LICI) 
Supra-threshold conditioning and test stimulus separated by 50-200ms results in cortical 
inhibition. 
Transcallosal inhibition (TCI) 
A conditioning stimulus given to motor cortex of one hemisphere and is followed by a second 
stimulus to the other hemisphere. Used to determine interhemispheric inhibition.  
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Whilst the development and use of such techniques has led to improvements in 
our understanding of neurophysiological processes, it has also identified 
alterations in cortical inhibition and excitability within neurological and 
psychiatric disorders. A number of recent systematic reviews and meta-
analyses have examined studies that assess cortical activity within psychiatric 
conditions and have demonstrated ubiquitous inhibitory deficits proposed to 
result from impairments in GABAergic modulated inhibition (Bunse et al., 2014; 
Radhu et al., 2013; Radhu, Ravindran, Levinson, & Daskalakis, 2012). Reduced 
SICI is the most consistent finding across disorders and whilst such general 
inhibitory deficits have been proposed, Radhu et al. (2013) also suggest that 
obsessive compulsive disorder, major depression and schizophrenia 
demonstrate disease-specific alterations in cortical excitability. Moreover, 
increased RMT, particularly within the left hemisphere, has been demonstrated 
in depression (Levinson et al., 2010; Maeda, Keenan, & Pascual-Leone, 2000). 
Whilst these findings are highly relevant and important, a critical confounding 
factor is that psychiatric patients are commonly on medication, which is known 
to affect cortical excitability (Ziemann, 2004). Despite this, these, and similar 
findings in non-medicated patients (Bunse et al., 2014), suggest that measures 
of cortical excitability may complement existing diagnostic tools. Moreover, 
such findings may enable more targeted pharmacological and neuromodulatory 
interventions.  
Despite a) evidence for altered cortical excitability across psychiatric disorders, 
b) the increasing understanding of ED as brain-based problems, and c) the 
growing number of neuromodulation studies in ED, there is a lack of data on 
cortical excitability in ED such as AN. While determining MT is a standard 
procedural requirement of applying rTMS, studies of rTMS in ED to date usually 
omit data on this parameter (Downar et al., 2012; Hausmann et al., 2004; 
Kamolz et al., 2008; McClelland, Bozhilova, Nestler, et al., 2013; Van den Eynde 
et al., 2010; Van den Eynde, Guillaume, et al., 2013; Walpoth et al., 2008). In a 
recent study, however, by Khedr, El Fetoh, et al. (2014) an examination of 
cortical excitability in AN was conducted. In this, 14 individuals with AN were 
matched with HC and cortical excitability was examined via both RMT and AMT, 
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MEP, CSP, TCI and SICI (see Table 3.13). Compared to controls, individuals with 
AN demonstrated reductions in RMT in both hemispheres, MEP onset latencies 
in both left and right motor/esophageal regions and TCI duration. Also, the 
reduction in RMT and TCI duration were associated with AN (but not 
depressive) symptoms. Khedr, El Fetoh, et al. (2014) suggest that reductions in 
GABAergic inhibition along with diffuse hyperexcitability in the relaxed state, is 
a reflection of AN patients’ inability to relax and of their typically anxious 
temperament. Importantly, a high proportion (77%) of the patients were on 
medication, which is likely to have influenced the results. Nonetheless, these 
findings have implications for our understanding of the neural basis of AN and 
also have safety implications when applying rTMS to this patient population. 
Alterations in cortical excitability have been reported across psychiatric 
conditions and preliminary data suggest that individuals with AN have 
increased levels of cortical excitability which is positively associated with 
symptomatology. Whilst the use of rTMS in AN is important in understanding 
neural mechanisms and exploring novel intervention options, such research 
also provides a platform to explore cortical activity in ED. This chapter 
examines and quantifies cortical excitability in AN and we hypothesise that 
cortical excitability will be associated with AN symptoms.  
Methods 
Participants 
Recruitment and randomisation procedures are described in Chapter 3.2. 
Procedures 
A description of procedures is provided in Chapter 3.2.  
Measures 
Baseline 
Baseline measures are described in Chapter 3.3.  
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Cortical excitability 
As outlined previously (see Chapter 3.2) a Magstim Rapid device using a real 
rTMS figure-of-eight coil was used to establish each participants resting (i.e. 
RMT). EMG recordings from the FDI muscle of the right hand were acquired 
with surface electrodes place on the FDI, on the inside of the ipsilateral index 
finger and a ground electrode placed on the wrist. The left M1 was located on 
the Brainsight software (by eye, i.e. not using imaging co-ordinates) and 
participants’ MT was defined as the minimum stimulus required to evoked 5 out 
of 10 MEP greater than 50μV. This procedure was conducted according to the 
‘lower threshold’ method starting at 40% of stimulator output and increasing in 
increments of 5 until 5 out of 10 responses were greater than 50μV (Rossini et 
al., 1994; Rothwell et al., 1999). This process was identical across both 
real/sham groups, that is, all participants’ MT were determined using real TMS 
coils. A higher RMT estimation indicates reduced cortical excitability; i.e. 
reduced cortical excitability requires a higher stimulation output to meet MT 
requirements.   
Statistical analysis 
Statistical analyses were performed using IBM® SPSS® software (Version 22). All 
tests were two-tailed and the level of significance was set at α = 0.05.  
Descriptive statistics are reported for measures of cortical excitability (RMT) 
and the subsequent stimulation output parameters used. The data was normally 
distributed so independent t-tests were employed to examine any differences in 
MT estimations between AN subtypes (restrictive versus binge/purge), 
participants who were or were not taking medication and real/sham groups. 
Pearson’s correlation analyses regarding MT and psychopathology indices (i.e. 
EDEQ, DASS-21) were used.  
Cohen’s d effect sizes are reported for t-tests and were computed by dividing 
the difference in means by the pooled standard deviation i.e. d = M1 – 
M2/√(SD12+ SD22 /2). Interpretation of the magnitude of Cohen’s d effect sizes is 
0.15-0.40 = small; 0.4-0.75 = medium and > 0.75: large (Cohen, 1988).  
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Results 
The same 49 right-handed, female individuals described in Chapter 3.3, 
randomised to real (n = 21, restrictive-AN = 13, binge/purge-AN = 8) and sham 
(n = 28, restrictive-AN = 15, binge/purge-AN = 13) were included in the 
subsequent analyses.  
Baseline characteristics 
Baseline characteristics are described in Chapter 3.3 and presented in Table 3.2.  
Cortical excitability 
In this group of 49 individuals with AN, measurements of cortical excitability, as 
indexed by RMT of the left hemisphere and quantified by the output of the 
Magstim TMS machine, were higher (M = 55.20, SD = 5.92) than those reported 
previously (M = 31.60, SD = 4.10) by Khedr, Elfetoh, et al. (2014). Individuals 
with a restrictive (M = 55.11, SD = 5.53) or binge/purge (M = 55.33, SD = 6.54) 
AN diagnosis did not differ on measures of RMT [t(47) = -0.13 , p = 0.896, d = 
0.04]. Additionally, there were no significant differences between 
measurements of RMT in those who were (n = 34/49: 69%, M = 54.94, SD = 
5.80) or were not (n = 15/49: 31%, M = 55.80, SD = 6.34) taking medication 
[t(47) = -0.46 , p = 0.645, d = 0.13]. Finally, there were no significant differences 
between real/sham groups on RMT estimations [t(47) = -0.89 , p = 0.378, d = 
0.26];  (real M = 54.33, SD = 4.98; sham M = 55.86, SD = 6.55), or the intensity of 
rTMS output used [t(47) = -0.48 , p = 0.636, d = 0.14]; (real M = 59.86, SD = 5.43; 
sham M = 60.74, SD = 7.75).  
There was a trend towards an inverse relationship between RMT and BMI [r = -
0.24, p = 0.094], indicating that increased RMT (i.e. reduced cortical excitability) 
is associated with lower BMI. In line with this finding is the trend for a positive 
correlation between RMT and EDE-Q global score [r = 0.27, p = 0.062], in 
addition to RMT and EDE-Q restraint [r = 0.26, p = 0.066] and eating concern [r 
= 0.26, p = 0.075] subscale scores. These findings indicate moderate 
associations between reduced cortical excitability and worse ED 
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symptomatology. However, there were no significant correlations between RMT 
and EDE-Q weight [r = 0.22, p = 0.134] or shape [r = 0.21, p = 0.155] subscales. 
Similarly, there were no significant correlations between RMT and DASS-21 
total score [r = 0.14, p = 0.339] or depression [r = 0.14, p = 0.327], anxiety [r = 
0.14, p = 0.338] and stress [r = 0.07, p = 0.610] subscale scores.  
Discussion 
The estimations of cortical excitability, i.e. RMT, reported here were higher than 
we expected. The type of AN diagnosis (restrictive or binge/purge) or whether 
or not individuals were on medication did not affect measures of cortical 
excitability. Interestingly, there was a trend towards RMT being inversely 
correlated with BMI and positively associated with other measures of ED 
symptomatology. In other words, reduced cortical excitability was moderately 
associated with lower weight and worse ED symptoms. However, this was not 
accompanied by relationships between cortical excitability and measures of 
general psychopathology (e.g. mood).  
GABAergic, dopaminergic and glutamatergic mechanisms have been implicated 
in cortical inhibitory and facilitatory networks and are likely to underlie 
alterations in cortical excitability that have been reported in AN (Maeda et al., 
2000). Moreover, whilst some data supports the notion of right-sided prefrontal 
hyperexcitability in AN (Grunwald et al., 2004; Hecht, 2010; Seeger et al., 2002; 
Uher et al., 2003), the present findings of increased RMT and thus reduced 
cortical excitability of the left motor cortex suggest that this could be associated 
with opposing hypoactivity in the ipsilateral left hemisphere.  
The present data are not consistent with the literature regarding cortical 
excitability in AN, albeit only one study. The RMT estimates were higher than 
those reported previously in AN, and we found that reduced (rather than 
increased) cortical excitability was moderately associated with worse 
symptomatology. In contrast, Khedr, Elfetoh, et al. (2014) found that individuals 
with AN demonstrated increased motor cortical excitability (i.e. lower RMT) 
compared to controls and this was associated with ED symptoms. However, an 
increased RMT and thus reduced motor cortical excitability is a consistent 
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finding across other studies of psychiatric conditions, particularly depression 
(Bunse et al., 2014). Moreover, in individuals with major depressive disorder, 
inter-hemispheric differences in MT have been demonstrated (left > right) and 
show reduced excitability of the left hemisphere (Maeda et al., 2000). 
Additionally, reduced excitability of the frontal cortex differentiates treatment-
resistant depressed patients from non-medicated, euthymic medicated patients 
and HC (Levinson et al., 2010).  
There are substantial differences between our study and that of Khedr, El Fetoh, 
et al. (2014). Our study group was almost four times the size of Khedr, El Fetoh, 
et al. (2014) and due to our narrow inclusion criteria our sample was older and 
had a higher average BMI and these are factors that may influence cortical 
excitability (Bashir et al., 2014). Moreover, whilst Khedr, El Fetoh, et al. (2014) 
did not mention the illness duration of participants, the mean duration of illness 
in our sample was greater than 10 years. Therefore, the treatment-resistant 
nature of our participants and their reduced cortical excitability might reflect 
the similar findings reported in treatment-resistant depression (Levinson et al., 
2010). In this context, it is noted that 45% of our participants had a co-morbid 
diagnosis of depression, whilst none of the Khedr, El Fetoh, et al. (2014) group 
had other clinically relevant disorders. ED symptoms were also assessed 
differently (EDE-Q versus EDI/EAT), and although comparable (69% versus 
77%), more of the Khedr, El Fetoh, et al. (2014) participants were medicated.  
A number of procedural differences are also of note. Khedr, El Fetoh, et al. 
(2014) used six measures of cortical excitability and we only used one. Whilst 
more measurements provide a better overall assessment of cortical activity, the 
accumulative effects of TMS on neural activity influences cortical excitability, at 
least in the short term. Similarly, the accuracy of MT estimations is dependent 
on the type of equipment used, e.g. TMS machine and electrodes, the 
environment in which participants are tested in, e.g. temperature, and the 
consumption/use of substances such as caffeine, alcohol and nicotine, prior to 
assessment. Finally, given that our protocol was primarily designed to assess 
the effects of rTMS on core AN symptoms, our participants were exposed to a 
food cue exposure task prior to MT estimations and, whilst the effects of this 
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task weren’t significantly salient (see Chapter 3.3), its use may have influenced 
our results regarding cortical excitability.  
Limitations 
Whilst this is the first rTMS study to report MT and stimulation outputs used in 
ED patients, it lacks a healthy control comparison group, which is unfortunate. 
Since measures of MT were collected primarily for the application of rTMS, 
unlike Khedr, El Fetoh, et al. (2014), we did not assess any other measurements 
of cortical excitability and this is a further limitation. In addition, medication 
affects cortical excitability and over half of our participants were on medication. 
Finally, this study measures activity in the motor cortex, when the condition of 
interest, AN, is related to non-motor processes.  
Future directions 
Future studies involving rTMS in ED should report and consider cortical 
excitability. Moreover, cortical excitability of areas other than the motor cortex, 
i.e. those implicated in neural models of ED and targeted with neuromodulation, 
such as the DLPFC, should be determined using combined EEG/TMS protocols. 
Furthermore, the association between cortical excitability and symptoms of AN 
requires further clarification, as it may be a viable diagnostic tool and/or enable 
targeted neuromodulatory interventions.  
Summary 
This study describes and discusses the issues related to cortical excitability in 
AN and more widely, within neuromodulation research in ED. In this group of 
individuals with AN, there were trends demonstrating associations between 
reduced cortical excitability, lower BMI and worse AN symptomatology.  
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Chapter 3.7 Cardiac safety, tolerability and acceptability of 
repetitive transcranial magnetic stimulation in anorexia 
nervosa 
Whilst rTMS has proven to be a safe and tolerable technique in healthy 
individuals and patients with psychiatric and neurological disorders (Loo et al., 
2008), safety considerations remain important. The most severe side effect 
reported following rTMS, although relatively rare, is the induction of a seizure, 
however, other adverse events such as syncope and transient pain (e.g. 
headaches) have also been reported (Rossi et al., 2009). It is therefore 
important to use caution when delivering rTMS in patient populations that have 
never, or only in a preliminary fashion, been investigated with rTMS. 
The use of neuromodulation techniques such as rTMS in ED patients is relatively 
novel; research is limited to a few RCT in BN (Van den Eynde et al., 2010; 
Walpoth et al., 2008) and a number of case reports/studies in both BN (Downar 
et al., 2012; Hausmann et al., 2004) and AN (Kamolz et al., 2008; Khedr, Elfetoh, 
et al., 2014; McClelland, Bozhilova, Nestler, et al., 2013). Thus, there is a need to 
further investigate the suitability of rTMS in this patient population.  
ED have been associated with cardiovascular complications, including 
bradycardia, hypotension, cardiac arrhythmias and cardiac arrest (Casiero & 
Frishman, 2006; de Simone et al., 1994; Kollai, Bonyhay, Jokkel, & Szonyi, 1994). 
Non-invasive neuromodulation such as rTMS may be capable of modulating 
cardiovascular function (Cogiamanian et al., 2010; Sampaio, Fraguas, Lotufo, 
Bensenor, & Brunoni, 2012). Specifically, a reduction of blood pressure (BP) and 
heart rate was demonstrated following 10Hz rTMS (Hong et al., 2002) in rats, 
parasympathetic activity was activated following LF rTMS in healthy humans 
(Gulli et al., 2013) and modulation of heart rate variability has been shown 
following two weeks of rTMS treatment in major depression (Udupa et al., 
2007). The cardiac safety of rTMS in BN has been established (Van den Eynde et 
al., 2011) along with preliminary, pilot data on AN (Van den Eynde, Guillaume, 
et al., 2013): however, there is a need to examine and establish the cardiac 
safety of rTMS in AN, in larger controlled studies especially given the long-
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standing physical debilitation present in AN (Wentz, Gillberg, Gillberg, & 
Rastam, 2000).  
Additionally, starvation has detrimental effects on the development, structure 
and long-term functioning of the brain (Levitsky & Strupp, 1995; Winick, 1969). 
Systematic reviews on structural neuroimaging in AN consistently report 
reductions in brain volume, specifically reduced grey and white matter 
(Fonville, Giampietro, Williams, Simmons, & Tchanturia, 2014; Van den Eynde, 
Suda, et al., 2012). Whilst there is some evidence that the neural effects of rTMS 
are different in atrophic (compared to healthy) brains (Wagner, Eden, et al., 
2008), whether or not brain atrophy, and associated reductions in adipose 
tissue affects the tolerability of rTMS remains unclear.  
Finally, since the use of neuromodulation techniques in the treatment of ED is 
relatively new, it is important to establish patients’ attitudes to this type of 
brain-directed intervention and whether or not they would consider it as a 
treatment adjunct. Therefore, this chapter examines the cardiac safety, 
tolerability and acceptability of rTMS as a treatment for AN. It is hypothesised 
that in individuals with AN, real rTMS will not induce effects on cardiac safety 
measures (namely BP and pulse) and will be well tolerated (i.e. without severe 
side effects). It is hypothesised that real rTMS will be reported as more 
uncomfortable than sham. However, we hypothesise that, if rTMS proves 




Recruitment and randomisation procedures are described in Chapter 3.2. 
Procedures 




Baseline measures are described in Chapter 3.3. 
Safety 
Cardiac safety was assessed by recording BP (mmHg) and heart rate (beats per 
minute). This was measured with an A&D Medical UA-767 Plus Digital Blood 
Pressure Monitor at baseline(2), following MT, following the real/sham rTMS 
session and at the end of the testing session. Participants sat upright for this and 
it was done on the same arm for each participant.  
Tolerability 
Participants rated their level of discomfort of the real/sham rTMS immediately 
after the session. This was done using a 10cm VAS ranging from 0 ‘not painful at 
all’ to 10 ‘extremely painful’. 
At the end of the testing sessions, to assess any adverse effects or pain 
associated with the rTMS, participants were asked if they encountered any 
abnormal experiences, pain or discomfort. This was established by answering 
yes/no to questions relating to headache, nausea, dizziness/faintness or any 
discomfort at the site of stimulation or surrounding areas. These side effects 
were reassessed during the 24 hour follow-up phone call, together with 
whether or not they took pain killers following the session.  
Acceptability 
To gauge participants’ attitudes towards rTMS as a treatment for AN, during the 
24 hour follow-up phone call, they were asked to answer yes/no to the 
question: ‘If there is evidence that rTMS reduces some of the symptoms related 
to anorexia, would it be something you would consider having as a treatment, 
e.g. each day of the week for four weeks?’ 
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Statistical analyses 
Statistical analyses were performed using IBM® SPSS® software (Version 22). 
Following consultation with a statistician, when normality or other ANOVA 
assumptions such as homogeneity of were violated (assessed via Kolmogorov-
Smirnov and Levene’s test statistics respectively) log transformations or other 
non-parametric alternatives were employed. When Mauchly’s test of sphericity 
was violated, Greenhouse-Geisser corrections are reported. All tests were two-
tailed and the level of significance was set at α = 0.05.  
The data regarding BP and pulse were normally distributed. The effects of real 
versus sham rTMS on BP and pulse were evaluated using mixed ANOVAs 
(group: real/sham rTMS x time: post-MT, post-rTMS, TP4) controlling for 
BP/pulse at baseline-2/TP1. Independent t-tests were used to compare 
discomfort ratings of real and sham rTMS. Pearson’s chi-square ( 2) was used to 
assess the proportion of people reporting physical complaints and having to 
take painkillers after either real/sham rTMS.  
Partial eta squared (η2) and Cohen’s d effect sizes are reported for mixed 
ANOVAs and independent sample t-tests respectively. Partial eta squared is 
automatically computed within SPSS by dividing the sums of squares for the 
effect of interest by the total sums of squares i.e. η2 = SSbetween/SStotal (Levine & 
Hullett, 2002). Cohen’s d was computed by dividing the difference in means by 
the pooled standard deviation i.e. d = M1 – M2/√(SD12+ SD22 /2). Interpretation 
of the magnitude of η2 is 0.01-0.06 = small; 0.06-0.14 = medium and > 0.14; 
large; and for Cohen’s d effect sizes 0.15-0.40 = small; 0.4-0.75 = medium and > 
0.75: large (Cohen, 1988).  
Results 
The same 49 right-handed, female individuals described above (Chapter 3.3), 
randomised to real (n = 21, restrictive-AN = 13, binge/purge-AN = 8) and sham 
(n = 28, restrictive-AN = 15, binge/purge-AN = 13) were included in the 
subsequent analyses.  
 167 
Baseline information 
Baseline demographic and ED characteristics are described in Chapter 3.3 and 
presented in Table 3.2.  
Safety 
One participant was missing complete BP/pulse data and therefore, 48 
participants were included in analyses of cardiac safety (real = 21, sham = 27). 
Controlling for baseline (2), there were no significant interaction, time or group 





Real rTMS  
(n = 21) 
Sham rTMS 





























Post MT 102.14 ± 8.84 102.07 ± 9.59 
F (1.76) = 0.73   
p = 0.470 
η2 = 0.02 
F (1) = 0.03  
p = 0.857 
η2 = 0.00 
F (1.76) = 1.94   
p = 0.155 
η2 = 0.04 
Post rTMS (TP3)  100.62 ± 13.83 103.56 ± 10.70 























Post MT 66.85 ± 8.54 67.89 ± 8.00 
F (2) = 0.01   
p = 0.993 
η2 = 0.00 
F (1) = 1.13   
p = 0.294 
η2 = 0.02 
F (2) = 0.87 
p = 0.424 
η2 = 0.02 
Post rTMS (TP3) 67.33 ± 9.29 67.52 ± 8.91 


















Post MT 67.95 ± 14.95 70.30 ± 11.19 
F (2) =1.75 
p = 0.180 
η2 = 0.04 
F (1) = 1.22   
p = 0.275 
η2 = 0.03 
F (2) = 0.50   
p = 0.606 
η2 = 0.01 
Post rTMS (TP3) 66.24 ± 13.10 70.15 ± 11.67 
End of session (TP4) 69.86 ± 13.13 71.52 ± 12.66 
Table 3.13 Mixed ANOVA results of blood pressure and pulse following real/sham rTMS. Mean ± SD reported. 
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Tolerability  
As stated previously, 2 of the 23 participants randomised to receive real rTMS 
withdrew after the first few trains of stimulation due to discomfort. These two 
participants described rTMS as unbearably uncomfortable and felt that they 
could not sit through all of the 20 rTMS trains. Of the 49 remaining individuals, 
those who had real rTMS found it significantly more uncomfortable than those 
who had sham [t(46) = 6.33, p < 0.001, d = 1.87] (see Figure 3.9).  
***p < .001. Scores relate to a 10cm visual analogue scale and therefore range 
from 0 (no discomfort) to 10 (extreme discomfort). The mean ± SD values are real: 
5.51 ± 1.38, sham: 1.38 ± 2.04.  
 
There were no significant differences between real/sham groups in the number 
of physical complaints (typically feeling dizzy/dazed or having a headache) 
reported [ 2(1) = 0.73; p = 0.394, N = 49] (5/21 real; 4/28 sham) or whether or 
not participants had to take painkillers [ 2(1) = 0.44; p = 0.505, N = 49] (2/21 
real, 1/28 sham).  
 






























When considering having rTMS as a treatment, 83% (19/23) of people who had 
real rTMS and 93% (26/28) who had sham, said they would be interested in 
rTMS as a therapeutic intervention for AN.  
Discussion 
In line with our hypotheses, rTMS proved to be a safe, well tolerated and an 
acceptable potential therapeutic technique for AN. Measures of cardiac safety, 
BP and pulse, remained unchanged following both real and sham rTMS. Whilst 
real rTMS was reported to be more uncomfortable than sham, no severe side 
effects were reported, nor were there any differences in the reported physical 
complaints or pain-killers taken following real/sham rTMS. Finally, over 80% of 
people that had real rTMS would consider it as a treatment.  
The current findings are in accord with previous data suggesting cardiac safety 
and tolerability of rTMS in both AN (Van den Eynde, Guillaume, et al., 2013), BN 
(Van den Eynde et al., 2011) and other groups (Gulli et al., 2013; Pecuch, Evers, 
Folkerts, Michael, & Arolt, 2000). Moreover, the BP and pulse measures in the 
present group are within normal ranges and therefore do not suggest 
hyper/hypotension. These are the first data in AN to compare safety and 
tolerability outcomes of real to sham rTMS, and suggest that real rTMS is 
significantly more uncomfortable than sham for people with AN. This has 
implications for study design aspects such as the limited practicality of 
crossover rTMS designs and for ensuring adequate blinding. Importantly, rTMS 
was seen as a feasible potential treatment for AN, as demonstrated by the high 
proportion of people who would consider having it on a daily basis for four 
weeks.  
Limitations 
Cardiac safety of rTMS in AN was established via BP and pulse measurements 
but other safety measures are worth considering. For example, given brain 
atrophy in AN (Fonville et al., 2014) and preliminary evidence for increased 
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cortical excitability (Khedr, El Fetoh, et al., 2014), concurrent EEG would enable 
direct physiological monitoring of neural excitability and the ability to pre-empt 
any increased risk of seizure (Rossi et al., 2009; Wassermann, 1998). Whilst 
over 90% of people who had sham rTMS said they would consider it as a 
treatment, they had not actually experienced real rTMS and given the 
differences in discomfort reported between real/sham rTMS, fewer participants 
in the sham group might actually consider having it in a longer-term, 
therapeutic manner. Furthermore, the minimum BMI (14) and general medical 
stability required to participate in the current study, limits the generalisation of 
these findings regarding safety and tolerability to severely low weight 
individuals.  
Future directions 
The results of this study have implications for future neuromodulation research 
in AN. Since this application of HF rTMS was safe, relatively well tolerated and 
accepted in AN, more uncomfortable techniques that are arguably more 
focal/effective, such as theta-burst stimulation (TBS), may also be reasonable 
procedures for these patients. In addition, whilst individuals with AN would 
consider rTMS as a treatment, the use of neuromodulation techniques for the 
treatment of ED may not be widely favoured by clinicians. Since clinicians are 
patients’ primary point of contact, it will be important to examine clinicians’ 
views towards these types of adjunctive neuromodulatory therapies in ED.  
Summary 
In this group of individuals with AN rTMS proved to be safe and well tolerated, 
although more uncomfortable than sham rTMS. A large proportion of 




Chapter 3.8 Overall Summary  
The findings reported in this group of 51 female individuals, with relatively 
severe AN, supported our primary hypothesis; compared to sham, reduced core 
AN symptoms were reported following real rTMS (Chapter 3.3). Importantly, 
among participants, the concealment of intervention allocation was partially 
successful. The liking of sweet, shortbread biscuits was significantly increased 
following real rTMS, but reduced following sham (Chapter 3.4). Salivary cortisol 
concentrations were unchanged following rTMS, suggesting that rTMS does not 
down-regulate HPA axis activity in AN and also that the procedure is not overly 
stressful (Chapter 3.5). Reduced cortical excitability was moderately associated 
with AN symptoms (Chapter 3.6). Finally, rTMS proved to be a safe, tolerable 
and acceptable intervention within this patient population (Chapter 3.7).  
The research reported here is in partial agreement with existing literature. 
Whether or not rTMS temporarily alters AN symptoms significantly more than 
placebo responses, remains unclear as does the neurobiological mechanisms 
underlying its action. Whilst interpretation of the research reported in this 
chapter is limited by a lack of power, it is an improvement on existing studies of 
rTMS in ED, because it uses improved methodologies.  
Preliminary evidence exists for the beneficial effects of neuromodulation in AN 
when delivered in a repeated, therapeutic manner yet limited behavioural and 
physiological findings following a single-session of rTMS have been found in 
other psychiatric disorders. Future controlled trials, with multiple rTMS session 
protocols, may be more informative and appropriate if wanting to extrapolate 
findings to potential longer-term therapeutic effects and considering rTMS as an 
adjunctive treatment for AN. Moreover, given the lack of physiological effects 
reported here, investigating neurocognitive effects and employing 
neuroimaging modalities alongside rTMS may provide the best opportunity in 
exploring disease mechanisms and biomarkers of response to neuromodulation 
in AN.   
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Chapter 4. The effects of repetitive transcranial magnetic 
stimulation on temporal discounting in anorexia nervosa 
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Introduction 
The concept of delayed gratification, that is, the ability to resist immediate 
temptations in favour of a delayed reward, was first explored in the well-known 
Stanford marshmallow experiment (Mischel, Ebbesen, & Zeiss, 1972). In this 
study, children were told that if they resisted eating a marshmallow that was 
placed in front of them whilst the researcher was out of the room, they could 
have two marshmallows when the researcher returned. The ability to delay 
gratification, i.e. wait until the researcher returned in order to gain the larger 
reward, has been investigated in follow-up studies of these same children and is 
associated with academic and personal success in later life (Mischel, Shoda, & 
Rodriguez, 1989; Shoda, Mischel, & Peake, 1990) and a lower BMI up to three 
decades later (Schlam, Wilson, Shoda, Mischel, & Ayduk, 2013). Similarly, 
childhood self-control predicts physical health, substance dependence, personal 
finances and criminal outcomes, independent of intelligence and social class 
(Moffitt et al., 2011). Given these and other findings, the ability (or inability) to 
delay gratification is a widely pertinent construct and proposed to be a 
relatively stable personality trait (Kirby, 2009; Odum, 2011).  
Studies such as the ‘marshmallow test’ resemble everyday decisions involving 
conflict between pleasure seeking, impulsive drives and deliberate, prudent 
motivations. Extensive research in humans has examined such decision making 
paradigms and demonstrates that a delayed, or less probable reward is not as 
valuable as an immediately available reward (Cardinal, 2006). Based on the 
observation that the subjective value of a delayed reward decreases as a 
function of its temporal delay (Green, Myerson, & Ostaszewski, 1999), the rate 
at which a future reward is devalued is referred to as ‘delay discounting 
(DD)’ or ‘temporal discounting (TD)’.4  
Rates of discounting vary between individuals and intertemporal choice tasks 
are used to capture discounting behaviours. Typically, TD tasks involve a 
                                                        
4 For the purpose of consistency the term temporal discounting (TD) is used 
throughout, despite the fact that the literature discussed uses both terms. TD 
and DD are conceptually identical and therefore the terms are interchangeable. 
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number of binary choices, requiring participants to choose between monetary 
or consumable (e.g. food) rewards that are available immediately (smaller-
sooner; SS), and a reward of larger magnitude that is available after a variety of 
delay periods (larger-later; LL) (Estle, Green, Myerson, & Holt, 2007; Odum & 
Rainaud, 2003). For each delay period assessed, the point of subjective equality 
i.e. when the LL reward is deemed equal to the SS reward is termed the 
indifference point (IP). Using each of the IP of a number of different delay 
periods, a general measure of discounting can be estimated in two ways. A 
hyperbolic function can be fitted to the indifference points for each delay and k, 
a constant that characterises an individual’s rate of discounting is used to typify 
TD (Richards et al., 1999). The value of k can range from 0 to 1 and participants 
with larger k values (i.e. steeper slope of discounting) show greater TD and 
more choice impulsivity. Alternatively, area under the curve (AUC) 
measurements provide theoretically neutral accounts of TD (Myerson, Green, & 
Warusawitharana, 2001).  The AUC is generated by calculating the area under 
the empirical discounting function, i.e. summing the trapezoid of each IP and 
also has a value between 0 and 1. However, smaller AUC values represent 
greater rates of discounting and thus more choice impulsivity (see Figure 4.1 
and the methods section for further details).  
k is a constant within a hyperbolic function that represents an individual’s rate of 
discounting; larger k values indicate increased temporal discounting (TD). Area 
under the curve (AUC) is a theoretically neutral measure of TD; reduced AUC 
indicates increased TD.  
 
Figure 4.1 Schematic representation of temporal discounting and its 
measurement 
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Behavioural TD tasks are thought to measure different and implicit components 
of decision making that are not otherwise captured through self-report 
inventories (Reynolds, Ortengren, Richards, & de Wit, 2006). Many studies have 
used TD tasks with both monetary and disorder-specific related rewards to 
examine altered motivational behaviours that are relevant to a wide range of 
disorders. For example, individuals with conduct disorder (White et al., 2014), 
autism (Chantiluke et al., 2014), attention-deficit/hyperactivity-disorder 
(Demurie, Roeyers, Baeyens, & Sonuga-Barke, 2012), major depression (Pulcu 
et al., 2014) and schizophrenia (Heerey, Robinson, McMahon, & Gold, 2007) 
demonstrate increased rates of TD and are argued to be more impulsive than 
their healthy counterparts. Similarly, increased discounting of future monetary 
and disorder-specific rewards (e.g. cigarettes and food) has been demonstrated 
in relation to unhealthy behaviours such as smoking and disordered eating (for 
reviews see Reynolds, 2006; Story, Vlaev, Seymour, Darzi, & Dolan, 2014). These 
findings are likely to represent the conflict between immediate temptations (e.g. 
cigarettes/alcohol/food) and the pursuit of long-term goals/rewards (e.g. 
health/sobriety/weight management). Therefore, TD tasks are useful in 
exploring the construct of choice impulsivity and delayed gratification 
mechanisms within a wide range of disorders. 
Temporal discounting and disordered eating  
Choice impulsivity is highly pertinent in relation to eating behaviour. For 
example, impaired inhibitory control has been associated with overeating and 
BMI (Jasinska et al., 2012) whilst lower levels of impulsivity are associated with 
dietary success and restraint (van Koningsbruggen, Stroebe, & Aarts, 2013). A 
number of studies to date have therefore investigated TD behaviours in relation 
to disordered eating (see Table 4.1). Initially, studies suggested no difference in 
rates of TD between obese and healthy weight females (Nederkoorn, Smulders, 
Havermans, Roefs, & Jansen, 2006), however others have reported that obese 
women (but not men) demonstrate increased TD (Weller, Cook, Avsar, & Cox, 
2008). Similar findings have also been found in both adolescents (Fields, Sabet, 
& Reynolds, 2013) and clinical, BED samples (Davis, Patte, Curtis, & Reid, 2010; 
Manwaring, Green, Myerson, Strube, & Wilfley, 2011; Mole et al., 2014). 
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However, differences in levels of education have been shown to account for 
these differences (Davis et al., 2010), and whilst obese and BED groups 
demonstrate increased TD compared to controls, differences in TD between 
individuals who had BED and were obese remain unclear.  
More specifically, increased TD (i.e. increased choice impulsivity) has been 
associated with both food reward sensitivity and food intake in people with 
obesity (Appelhans et al., 2011). Three recent studies have examined 
associations between neural activity and discounting behaviours in obesity. 
During difficult TD choices (i.e. increased deviation from the point of subjective 
equality of SS/LL rewards) reduced activation in brain areas associated with 
executive functions is shown to predict weight gain (Kishinevsky et al., 2012). 
Similarly, reduced neural activity in similar regions during difficult choices was 
associated with increased TD/impulsive choices (Stoeckel, Murdaugh, Cox, 
Cook, & Weller, 2013). Moreover, reduced TD (and thus a better ability to delay 
gratification) predicted subsequent weight loss/dietary success and this was 
associated with increased activity and stronger functional connectivity in the 
ventromedial PFC (VMPFC) and DLPFC (Weygandt et al., 2013).  
Other studies have examined TD behaviour in relation to additional ED related 
concepts. Leitch, Morgan, and Yeomans (2013) reported no differences in 
performance on a TD task in women who scored higher (rather than lower) on a 
measure of uncontrolled eating, despite increased scores on other relevant 
measures such as the Barrett Impulsivity Scale. In contrast, within a group of 
heavy drinkers, reduced TD and the ability to delay gratification, predicted 
dietary restraint, weight and shape concerns (Stojek, Fischer, Murphy, & 
MacKillop, 2014). However, whilst findings in female college students suggest 
that reduced TD predicts lower body esteem (Lilienthal & Weatherly, 2013b), 
choice impulsivity (less TD of a monetary loss) was shown to predict risk for AN 
(Lilienthal & Weatherly, 2013a). This latter finding is somewhat inconsistent 
with the only data regarding TD in AN (Steinglass et al., 2012). Compared to 
controls, individuals with AN show reduced rates of the discounting of future, 
monetary rewards in a TD task, indicating an enhanced ability to delay 
gratification. Moreover, TD was particularly reduced in the restrictive AN 
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subtype. This suggests that reduced TD, rather than increased choice 
impulsivity, is also associated with psychiatric psychopathology. Specifically, 
reduced TD behaviours may underlie the extreme self-control over food that 
facilitates pathological dietary restraint in AN.  
In summary, the data so far suggests that increased discounting of future 
rewards exists in over-eating disorders such as obesity and BED. However, the 
difference between these two groups is unclear, as are the effects of gender and 
education levels/intelligence on discounting behaviours. Currently, there are 
little to no data regarding TD in other ED. Whilst choice impulsivity has been 
associated with risk of AN, the ability to delay gratification has been associated 
with dietary restraint, ED related concerns and AN.  
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HC: healthy controls; BED: binge eating disorder; TD: temporal discounting; k values represent an individual’s rate of discounting and > k 
values indicated greater TD; AUC: area under the curve is a theoretically neutral measure of discounting and < AUC indicates greater TD.  
Table 4.1 Studies investigating temporal discounting in relation to disordered eating 
 N Sample Task Outcome  Findings 
Obesity and binge eating disorder 
Nederkoorn et al 
(2006) 
59 Obese (n=31) & control 
(n=28) women 
Monetary TD task 
Immediate amount variable, 
delayed amount fixed (€1k) 
k value No differences on TD found. 
Weller et al 
(2008) 
95 Obese men (n=19) & 
women (n=29) & HC 
men (n=21) & women 
(n=26) 
2 monetary TD tasks (high $50k & 
low $1k) 
Immediate amount variable, 
delayed amount fixed (£50k or 
£1k) 
AUC Obese women showed greater TD than HC. 
Obese & HC men did not differ 
Davis et al (2010) 209 Obese women with 
BED (n=65), obese 
women without BED 
(n=73) & HC women 
(n=71) 
Monetary TD task 
Immediate amount variable, 





points (k value) 
BED & obese women displayed greater TD compared 
to HC but BED and obese groups did not differ on TD 
from each other.  
When group differences in education were 
accounted for, findings no longer significant.  
Appelhans et al 
(2011) 
62 Overweight & obese 
women 
Monetary TD task  
Immediate amount variable, 
delayed amount fixed (£100)  
AUC Greater food reward sensitivity was associated with 
increased palatable food intake only amongst those 
with increased TD/poor inhibitory control 
Manwaring et al 
(2011) 
90 Obese women with 
BED (n=30), obese 
women without BED 
(n=30) & HC women 
(n=30) 
TD with different rewards 
(money, food, sedentary activity, 
massage time) 
Immediate amount variable, 




BED group discount future rewards more steeply 
than the obese and control groups irrespective of the 
type of reward offered 
Kishinevsky et al 
(2012) 
 
24 Obese women Monetary TD task + fMRI 
Both immediate & delayed choices 
were variable 
Implied k value Greater activation during difficult TD trials in areas 
including prefrontal cortex. Less activation on 
difficult TD trials predicted greater weight gain.  
Fields et al 
(2013) 
61 Obese (n=21), 
overweight (n=20) & 
HC adolescents (n=20) 
Monetary TD task AUC Obese & overweight adolescents more impulsive on 
TD task. No difference between obese & overweight 
adolescents on TD 
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HC: healthy controls; BED: binge eating disorder; TD: temporal discounting; fMRI: functional magnetic resonance imaging; k values 
represent an individual’s rate of discounting and > k values indicated greater TD; AUC: area under the curve is a theoretically neutral 
measure of discounting and < AUC indicates greater TD. VMPFC: ventromedial prefrontal cortex; DLPFC: dorsolateral prefrontal cortex.  
Table 4.1 (continued) Studies investigating temporal discounting in relation to disordered eating. 
 N Sample Task Outcome  Findings 
Stoeckel et al 
(2013)  
24 Obese women Monetary TD task + fMRI 




Greater TD correlated with less modulation of 
activation in executive function regions in 
response to difficult (compared to easy) TD 
trials.  
Weygandt et al 
(2013) 
16 Obese men (n=3) and women 
(n=13) 
Food-specific delay gratification 
paradigm + fMRI 
k value Impulse control predicted weight loss. Brain 
activity in VMPFC & DLPFC correlated with 
weight loss & stronger functional connectivity 
associated with dietary success & impulse 
control 
Mole et al 
(2014) 
90 Obese with BED (n=30), 
obese without BED (n=30) 
and abstinent alcohol-
dependent (n=30) & HC 
(n=30) 
Monetary choice questionnaire k value All three groups greater TD than HC.  
Disordered eating/other ED related constructs 
Leitch et al 
(2013) 
80 Women with uncontrolled 
eating/ dietary restraint 
Monetary TD task 
Immediate choice variable, 
delayed fixed.  
AUC No significant differences across TD task 
between groups 
Stojek et al 
(2014) 
108 Heavy-drinkers Monetary choice questionnaire 
(Kirby, 1999) 
k value Lower TD predicted dietary restraint, weight & 
shape concerns  
Lilienthal et al 
(2013) 
146 Female college students Monetary gain/loss TD task AUC Less TD of a delayed monetary loss (impulsive 
decision) significantly predicted risk for AN 
Lilienthal et al 
(2013) 
139 Female college students Discounting task re: gain/lose 
weight or improve/worsen 
complexion. Percentage of 
lifestyle (0-100%) willing to 
alter in order to obtain outcome 
AUC Lower impulsivity predicted lower body 
esteem levels.  
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Table 4.1 (continued) Studies investigating temporal discounting in relation to disordered eating. 
 N Sample Task Outcome  Findings 
Anorexia nervosa 
Steinglass et al 
(2012) 
64 Underweight AN 
(n=36) & HC 
(n=28) 
Monetary TD task 
Accelerate set; immediate variable, delayed 
fixed ($80) & Delay set; immediate fixed ($45), 
delayed variable. 




similar to AUC 
Individuals with AN showed less TD than 
HC, in particular the restrictive AN 
subtype. Framing of choices as 
accelerate/delay affected discount factor; 
individuals discount future more asked to 
delay rather than accelerate receipt of 
reward.  
HC: healthy controls; AN: anorexia nervosa; k values represent an individual’s rate of discounting and > k values indicated greater TD; AUC: 
area under the curve is a theoretically neutral measure of discounting and < AUC indicates greater TD. 
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Neural correlates of temporal discounting 
As has been described, increased rates of TD and related clinical symptoms in 
obese individuals have been associated with reduced activation in prefrontal 
areas associated with executive function (Kishinevsky et al., 2012; Stoeckel et 
al., 2013; Weygandt et al., 2013). This is perhaps unsurprising, given the 
evidence suggesting that impulse control in relation to food-specific tasks relies, 
at least in part, on cognitive control via the DLPFC (Hare, Camerer, & Rangel, 
2009; Hare, Malmaud, & Rangel, 2011). More generally, the ability to resist 
immediate temptation and exert self-control has been proposed to rely on 
activity in the right PFC (Knoch & Fehr, 2007) and increased activation in the 
left DLPFC has been demonstrated during deliberations over delayed reward 
(i.e. more controlled) choices (Hare, Hakimi, & Rangel, 2014). However, the 
localisation of key regions in what is quite a complex behaviour is inherently 
difficult, suggesting that the neural correlates of intertemporal choice behaviour 
is probably not isolated to one specific region.  
Rather, the connectivity between the DLPFC and VMPFC has been associated 
with discounting behaviour. Whilst areas of the VMPFC have consistently been 
associated with the encoding of stimulus value and the magnitude of reward, 
the DLPFC is typically engaged to modulate value signals from the VMPFC, 
particularly during decisions regarding delayed rewards (Hare et al., 2009; Hare 
et al., 2014; Weygandt et al., 2013). Additionally, mesolimbic regions such as the 
nucleus accumbens and ventral striatum have been implicated in the encoding 
of both immediate and future reward value, whilst areas such as the posterior 
parietal cortex have been associated with delayed reward choices (Ballard & 
Knutson, 2009; Kable & Glimcher, 2010; McClure, Laibson, Loewenstein, & 
Cohen, 2004). Such findings provide evidence for the sensitivity to the 
value/magnitude of rewards in limbic, goal-directed brain regions, whilst 
consideration of temporal foresight relies on cortical, cognitive control 
mechanisms. Moreover, associations have been found between intelligence 
levels and the activity of both value-dependent and executive function networks 
during TD tasks in adolescents (Ripke et al., 2014). 
 183 
Resting state neural activity of these networks have been both associated with, 
and shown to predict discounting behaviour (Gianotti, Figner, Ebstein, & Knoch, 
2012; Li, Ma, et al., 2013). Using EEG recordings and DNA genotyping Gianotti et 
al. (2012) aimed to assess the role of both baseline neural activation and 
dopaminergic systems – via the catechol-O-methyltransferase (COMT) 
Val158Met genotype – known to modulate prefrontal dopamine on discounting 
behaviours. A higher number of Val alleles indicate greater COMT activity and 
lower dopamine levels. This study showed that COMT has a significant effect on 
baseline activity in the left DLPFC; a higher number of Val alleles (and thus 
reduced dopamine levels) was associated with lower baseline activation. 
Additionally, the number of Val alleles was positively correlated with TD rates 
whilst activity in the left DLPFC was inversely correlated with discounting rates. 
Finally, baseline activity of the left DLPFC mediated the effects of COMT on TD 
(Gianotti et al., 2012). These findings suggest that reduced activity of 
dopaminergic systems and prefrontal areas may be a neural signature for 
impaired cognitive control and choice impulsivity.  
A recent study of resting state functional connectivity (rsFC), Li, Ma, et al. 
(2013) reported correlations between TD processes and the activity of distinct 
neural networks. Within the ‘money’ network, rsFC of areas involved in the 
encoding of rewards, such as the striatum, were positively correlated with 
discounting rates and impulsivity. In contrast, the rsFC of frontoparietal areas 
implicated in the ‘time’ network, i.e. the DLPFC, were negatively correlated with 
TD. Whilst these findings echo those mentioned previously (Ballard & Knutson, 
2009; Kable & Glimcher, 2010; McClure et al., 2004), the functional connectivity 
between these two networks was inversely correlated with TD behaviour. This 
suggests that a reduced exchange of information between the two systems may 
also contribute to increased TD and choice impulsivity. Interestingly, Li, Ma, et 
al. (2013) also suggest that increased activity in a ‘choice’ network, including 
frontoparietal networks and the dorsal anterior cingulate cortex-anterior 
insular cortex, is associated with TD, suggesting that heightened evaluations of 
the emotional salience of rewards biases less cognitive demand and thus 
immediate reward choices.  
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In summary, distinct neural networks are involved in the evaluation of rewards 
and subsequent choice deliberations. Baseline activity in such regions, as well as 
the functional connectivity between relevant neural networks also influences 
rates of discounting. Taken together, these findings suggest neural network 
based biomarkers of decision making processes such as intertemporal choice 
behaviour.  
The effects of neuromodulation on temporal discounting  
Despite a broad amount of research implicating the role of distinct neural 
networks in intertemporal choice behaviour, only a limited number of studies 
have investigated the effects of neuromodulation on TD (see Table 4.2). 
Alongside neuroimaging approaches, neuromodulation techniques may enable 
causal relationships to be drawn between brain activity and implicit, decision 
making processes.  
Figner et al. (2010) reported the first data on the effects of neuromodulation on 
TD. Following LF (inhibitory) rTMS to the left (but not right) DLPFC, an increase 
in the choice of SS rewards was reported. Also, two studies by the same group 
have looked at the effects of TBS, a form of TMS that uses bursts of high 
frequency stimulation (i.e. 50Hz), on TD. Continuous TBS, which is thought to 
suppress neural activity, to the right DLPFC, reportedly reduces the discounting 
of future rewards, i.e. increasing the ability to delay gratification (Cho et al., 
2010) and is accompanied by reduced rCBF in the ipsilateral PFC (Cho et al., 
2012). Given the conflicting evidence so far, the role of hemispheric 
lateralisation and excitatory/inhibitory neuromodulation protocols on TD 
behaviour remains unclear.  
The evidence regarding the effects of HF rTMS on TD is somewhat more 
consistent. A recent study investigating TD with regards to smoking 
demonstrated no differences in discounting behaviours between smokers and 
non-smokers, however following HF rTMS to the left DLPFC both groups 
demonstrated reduced TD and an increased preference for delayed rewards, i.e. 
increased ability to delay gratification (Sheffer et al., 2013). Similarly, HF rTMS 
to the MPFC increased preference for delayed, monetary rewards, which 
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subsequent PET imaging indicated was associated with dopamine release in the 
striatum (Cho et al., 2014). The only study, which was conducted by our group, 
to investigate the effects of tDCS (anode to the right/cathode left DLPFC) on 
discounting behaviour reported no changes to TD. However, typical discounting 
behaviour of participants (who were frequent food cravers) moderated the 
effects of tDCS on the study’s primary outcome; individuals who discounted 
future rewards less (i.e. displayed less choice impulsivity) were more 
susceptible to the anti-food craving effects of tDCS (Kekic et al., 2014).  
In summary, the effect of neuromodulation on discounting behaviour is 
somewhat unclear. The importance of stimulation parameters needs to be 
established, since inhibitory neuromodulatory procedures to the PFC have 
shown to both increase and decrease discounting behaviour. Similarly, the role 
of hemispheric lateralisation, optimal stimulation protocols and sites are 
undefined – inhibitory protocols to both the left and right hemisphere have 
produced opposite effects on TD, whilst rTMS to both medial and DLPFC targets 
has reduced rates of discounting.  
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k values represent an individual’s rate of discounting and > k values indicated greater TD; AUC: area under the curve is a theoretically 
neutral measure of discounting and < AUC indicates greater TD; DLPFC: dorsolateral prefrontal cortex; MPFC: medial prefrontal cortex. 
 
 
Table 4.2 Studies investigating the effects of neuromodulation on temporal discounting 
 N Sample Design Type Protocol Area Task Findings 
Figner et 
al (2010) 
52 HS  Between 
subjects 






SS/LL task;  LF rTMS to the left (but not 
right) LPFC led to greater 
discounting. 
Cho et al 
(2010) 
7 HS Within 
subjects 
 
TBS 3 pulses at 50Hz 
i) iTBS (excitatory), ii) cTBS (inhibitory) & 




TD task; k 
value 
cTBS reduced k value/ 
impulsivity by 37% compared to 
sham.  
iTBS did not alter TD.  
Cho et al 
(2012) 
8 HS Within 
subjects 
TBS 3 pulses at 50Hz i) cTBS (inhibitory) 
continuous trains 40 secs = 600 pulses & 
ii) sham TBS (coil at angle) + PET imaging 
Right 
DLPFC 
As above cTBS reduced k value/ 
impulsivity; participants favour 
LL rewards. 
Reduced rCBF in ipsilateral 









rTMS Three HF rTMS sessions;   





TD tasks  
HF rTMS decreased TD of 
monetary gains, increased TD of 
monetary losses in both groups.  
Cho et al 
(2014) 
24 HS Within 
subject 
rTMS 10 Hz rTMS 15 trains = 150 pulses/750 




TD task; k 
value 
rTMS to MPFC reduced TD; 
preference for delayed rewards. 
DA release striatum 
Kekic et 
al (2014) 




tDCS Anode right/cathode left  
2mA for 20 minutes 
DLPFC Monetary 
TD task; k 
value 
TD moderated the effect of tDCS 
on food cravings; reduced TD 
predicted anti-craving effects of 
tDCS 
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The effects of repetitive transcranial magnetic stimulation on temporal 
discounting in anorexia nervosa 
The literature discussed above, although sparse, suggests that there are 
identifiable differences in TD behaviour across the spectrum of disordered 
eating. Specifically, people with disorders associated with over-eating, such as 
obesity and BED, display increased discounting of future rewards (see Table 
4.1) whilst data from one study suggests that individuals with AN demonstrate a 
unique ability to delay gratification (Steinglass et al., 2012). Moreover, the 
neural correlates of TD are somewhat understood, implicating limbic and 
cognitive neural networks and their functional connectivity (Gianotti et al., 
2012; Hare et al., 2014).  
As has been discussed previously (see Chapter 1), over-representation of 
interoceptive signals (Cowdrey et al., 2011; Zhu et al., 2012) in conjunction with 
heightened prefrontal activity has been reported in AN (Uher et al., 2003). 
Subsequent neuro-circuit based models implicate alterations in such ‘bottom-
up’ and ‘top-down’ processing in AN and this is schematically presented in 
Figure 4.2 taken from Kaye et al. (2009). Whilst this diagram aims to explain the 
altered neurocircuitry and resulting conflict between aversive interoceptive 
drives and heightened cognitive control mechanisms in AN, it is also relevant to 
the concept of TD. Specifically, in response to such conflict, excessive top down 
control via areas such as the DLPFC, may encourage the resistance of satisfying 
immediate short-term homeostatic urges (e.g. hunger) in favour of longer-term 
goals (e.g. staying thin). Moreover, altered functional connectivity between such 
networks has been demonstrated in AN and may contribute to the disorder’s 
aetiopathogenesis (Boehm et al., 2014; Cowdrey et al., 2014).  
Since the application of rTMS to the DLPFC has been shown to alter TD 
behaviours (see Table 4.2), rTMS may provide an opportunity to implicitly alter 
the hypothesised excessive, top-down control and/or the impaired circuitry in 
AN that leads to the pursuit of weight loss over more immediate and 
homeostatic needs. Furthermore, the effects of rTMS on TD may underlie the 
therapeutic effects of rTMS on AN symptoms that have been reported (Kamolz 
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et al., 2008; McClelland, Bozhilova, Nestler, et al., 2013; Van den Eynde, 
Guillaume, et al., 2013).  
The aim of the research reported in this chapter was to examine TD in AN and 
the effects of rTMS on this neurocognitive construct. Specifically, the 
relationship between TD and ED symptoms was explored and it was 
hypothesised that the restrictive AN subtype group would display reduced TD 
compared to individuals with a binge/purge subtype diagnoses. Given the 
symptom improvements reported previously, it was hypothesised that real (as 
opposed to sham) HF rTMS to the left DLPFC would temporarily increase TD, i.e. 
individuals would demonstrate a preference for SS rather than LL rewards. Such 
findings may indicate that a potential neurocognitive biomarker of the effects of 
rTMS on AN symptoms is the technique’s ability to transiently and implicitly 
alter intertemporal choice behaviour. 
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This describes the ‘top-down’ cognitive control exerted in response to aversive 
interoceptive ‘bottom-up’ emotive signals in anorexia nervosa (AN). This process is 
consistent with accounts of reduced TD in AN, in that the short-term homeostatic 
drives (e.g. satisfying hunger) are forgone in the pursuit of more valued, delayed 
outcomes (e.g. staying thin). Reprinted as appears in Kaye et al. (2009) with 
permission from Nature Publishing Group. 
 
Figure 4.2 Impaired interoceptive and reward processing in AN and the 




Recruitment and randomisation procedures have been described in Chapter 3.2. 
Procedures 
Description of procedures is provided in Chapter 3.2. 
Measures 
Baseline 
Baseline measures have been descried in Chapter 3.3.  
Outcomes  
 Temporal discounting 
A computerised hypothetical monetary TD task (Rubia, Halari, Christakou, & 
Taylor, 2009) that measures the degree to which a reward is discounted in 
relation to its temporal delay was used. Participants choose (by pressing the left 
or right mouse button) between a smaller amount of money available 
immediately (between £0 and £100), and a larger amount (always £100) 
available after 1 week, 1 month, 1 year, or 2 years (25 trials for each delay). 
Appendix H.2 provides the instructions for the TD task and screen-shot 
examples of TD choices. The value of the immediate reward is automatically 
adjusted in an algorithm based on previous choices; this narrows the range of 
the immediate values offered until an amount is reached that the participant 
judges as equivalent to the fixed delayed reward (Richards, Zhang, Mitchell, & 
de Wit, 1999), i.e. the IP/point of subjective equality – when, given the time 
delay, the SS reward is deemed equal to the LL (£100) reward. An IP is 
calculated for each of the four delay periods and these are then used to 
determine a general rate of discounting. 
Discounting rates are assessed in two ways, both of which were computed in the 
current study. Initially, in order to describe the relationship between the 
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subjective value of a reward as a function of the delay to its presentation, a 
hyperbolic function was fitted to the indifference points for each delay 
(Richards et al., 1999). The mathematical expression for this relationship is V = 
A/(1+kD), where V is the subjective value, A is the reward amount, D is the 
delay until receipt and k represents the slope of TD, and thus is a constant which 
characterises an individual’s rate of discounting. The value of k can range from 0 
to 1 and is often used as the dependent variable of TD tasks. Participants with 
larger k values (i.e. steeper slope of discounting) show greater TD – they 
tend to choose SS over LL rewards – and are expected to be more impulsive.  
The use of such simple hyperbola in describing TD behaviour is associated with 
interpretative and statistical difficulties. Instead, AUC measurements of 
discounting provide theoretically neutral accounts of TD and are therefore more 
appropriate for investigations with quantitative, inferential statistics (Myerson 
et al., 2001). A general measure of discounting can be produced from calculating 
the area under the empirical discounting function. Values are standardised via 
expressing both the subjective value and the time delay as a proportion of the 
total value and maximum delay respectively. The AUC is then calculated by 
plotting the standardised subjective value of rewards against the respective 
time delay and summing the trapezoids (see Figure 4.3). 
The equation used to establish the area of each trapezoid is (x2 – x1)*[(y1 + 
y2)/2] where x2 and x1 are the successive delays and y1 and y2 are the subjective 
values associated with these delays. The delay periods are expressed as the 
proportion of the maximum delay period (2 years) i.e. 1 week = 1/104, 1 month 
= 1/24, 1 year = 0.5 and 2 years = 1 and the standardised subjective values were 
used for each relevant delay period. Therefore, the AUC outcome of TD has a 
value between 0 and 1 and smaller AUC values represent greater rates of 





The indifference point (IP)/subjective value i.e. when a larger, delayed reward is 
deemed equal to a smaller, immediately available reward (expressed as a 
proportion of the maximum reward value available) is plotted against the various 
time delays (also expressed as a proportion of the maximum delay period). Smaller 
area under the curve (AUC) indicates greater temporal discounting. Reprinted as 
appears in Myerson (2001) with permission from John Wiley and Sons.  
 
Statistical analysis 
Statistical analyses were performed using IBM® SPSS® software (Version 22). 
Following consultation with a statistician, when normality or other ANOVA 
assumptions such as homogeneity of were violated (assessed via Kolmogorov-
Smirnov and Levene’s statistics respectively) log transformations or other non-
parametric alternatives were employed. When Mauchly’s test of sphericity was 
violated, Greenhouse-Geisser corrections are reported. All tests were two-tailed 
and the level of significance was set at α = 0.05.  
The k values were non-normally distributed and highly skewed, whilst the AUC 
data were normally distributed. Therefore, AUC was seen as a preferable 
alternative for the main analyses (Myerson et al., 2001). However, in order to 
assess agreement between the two measures of TD – k values and AUC – non-
parametric correlational analyses (Spearman’s rs) were conducted. 
 
Figure 4.3 Calculation of area under the curve.  
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Pearson’s correlations were used to examine associations between AUC/TD and 
both demographic information and psychopathology (e.g. EDE-Q, DASS-21, 
VAS). Additionally, independent t-tests were used to compare initial rates of TD 
(AUC of the TD task pre real/sham rTMS) between education levels (those who 
had reached primary versus tertiary education levels) and AN subtypes.  
The main effect of real versus sham rTMS on rates of TD, as indicated by AUC, 
was evaluated using a mixed ANOVA (group: real/sham rTMS x time: TDpre, 
TDpost). Paired-samples t-tests were used to examine the effects of rTMS within 
each real and sham group separately, and moreover, within the subtypes within 
each real/sham rTMS groups. Additionally, whether (or not) TD behaviour 
influences the effects of rTMS on the primary outcome of the RCT, i.e. core AN 
symptoms (see Chapter 3.3) was also examined: along with symptoms at TP2, 
the AUC of the first TD task was added as a covariate to the main analysis of 
rTMS on core AN symptoms, i.e. real/sham rTMS x time (e.g. TP3, TP4, TP5).  
Partial eta squared (η2) and Cohen’s d effect sizes are reported for mixed 
ANOVAs and independent sample t-tests respectively. Partial eta squared (η2) 
and Cohen’s d effect sizes are reported for mixed ANOVAs and t-tests 
respectively. Partial eta squared is automatically computed within SPSS by 
dividing the sums of squares for the effect of interest by the total sums of 
squares i.e. η2 = SSbetween/SStotal (Levine & Hullett, 2002). Cohen’s d was 
computed by dividing the difference in means by the pooled standard deviation 
i.e. d = M1 – M2/√(SD12+ SD22 /2). Interpretation of the magnitude of η2 is 0.01-
0.06 = small; 0.06-0.14 = medium and > 0.14; large; and for Cohen’s d effect 
sizes 0.15-0.40 = small; 0.4-0.75 = medium and > 0.75: large (Cohen, 1988).  
Results 
The same 49 right-handed, female individuals described above (Chapter 3.3), 
randomised to real (n = 21, restrictive-AN = 13, binge/purge-AN = 8) and sham 
(n = 28, restrictive-AN = 15, binge/purge-AN = 13) were included in the 
subsequent analyses.  
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Baseline characteristics 
Baseline demographic and ED characteristics are described in Chapter 3.3 and 
reported in Table 3.2.  
Outcomes 
As expected, Spearman’s correlations indicated an inverse relationship between 
k and AUC values at both time points, pre [rs = -0.78, p <0.001] and post [rs = -
0.79 p <0.001] real/sham rTMS, confirming their agreement in measuring TD.  
Temporal discounting and eating disorder symptomatology/diagnosis   
There was a significant inverse correlation between age and AUC [r = -0.34, p = 
0.018] and whilst BMI at time of assessment was not correlated with AUC, there 
was a trend for participants’ lowest reported BMI to be negatively correlated 
with AUC [r = -0.25, p = 0.080]. Therefore, since smaller AUC represents 
increased TD, younger age and lower historical BMI were associated with 
reduced rates of TD, i.e. a tendency to choose LL rewards. There were no 
significant correlations between AUC and either ED or general psychopathology. 
Independent sample t-tests indicated no initial difference in AUC between those 
who reached primary (n = 27) or tertiary (n = 22) education levels [t(47) = 0.76, 
p = 0.448, d = 0.22], or between the restrictive (n = 28) and binge/purge (n = 21) 
AN subtypes [t(47) = 0.12, p = 0.904, d = 0.03].  
The effect of repetitive transcranial magnetic stimulation on temporal 
discounting in anorexia nervosa 
When comparing the effects of real versus sham rTMS on TD within this AN 
sample, there was a trend towards a significant interaction effect [F(1) = 3.71, p 
= 0.060, η2 = 0.07] (Figure 4.4). Paired sample t-tests suggest that real rTMS 
significantly increased AUC/decreased TD [t(20) = -3.16, p = 0.005, d = 0.54] 
(Figure 4.5) whilst sham rTMS had no effect on TD [t(27) = -0.71, p = 0.485, d = 
0.08] (Figure 4.6). Moreover, paired sample t-tests for each AN subtype within 
the real rTMS groups indicated that the effect of rTMS was most significant 
within the restrictive AN subtype [t(12) = -2.91, p = 0.013, d = 0.54] but was 
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non-significant when the effects of real rTMS on the binge/purge AN subtype 
was considered alone [t(7) = -1.47, p = 0.185, d = 0.51] (Figure 4.7). The effects 
of sham rTMS on TD were non-significant within the restrictive [t(14) = -0.02, p 
= 0.986, d = 0.00] and binge/purge subtypes [t(12) = -0.88, p = 0.395, d = 0.16].  
When controlling for core AN symptom scores at TP2 and initial AUC (from the 
preTD task), there were no interaction effects between group (real/sham rTMS) 
and AN symptoms over time (TP3, TP4, TP5). However, the addition of the 
preTD AUC score as a covariate accounted for a significant amount of variance 
in core AN symptoms over time [F(1.35) = 4.06, p = 0.036, η2 = 0.08]. Moreover, 
when controlling for preTD AUC scores, the between group differences 
(real/sham rTMS) outlined in Chapter 3.3 became significant [F(1) = 4.29, p = 
0.044, η2 = 0.09]. Given this, a repeated measures ANOVA was conducted 
separately for each real/sham rTMS group. Controlling for AN symptoms scores 
at TP2 and AUC scores from the preTD task, there was a significant association 
between the initial TD covariate and core AN symptoms over time within the 
real [F(2) = 3.73, p = 0.034, η2 = 0.17], but not the sham group [F(1.20) = 1.49, p 
= 0.237, η2 = 0.06].   
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  Real (n = 21), sham (n = 28). 
 (n = 21) 
 
Figure 4.4 Area under the curve pre and post real/sham rTMS. Mean + SD 
reported.  
 
















































(n = 28) 
R: restrictive, BP: binge/purge. Real (n = 21; restrictive = 13, binge/purge = 8), 
sham (n = 28; restrictive = 15, binge/purge = 13). 
 
Figure 4.6 Subjective value of reward over time pre and post sham rTMS  
 
Figure 4.7 Area under the curve for each AN subtype pre and post 














































The results of this study, investigating TD in AN and the effects of rTMS on this 
construct, partially support our initial hypotheses. There was no association 
between TD and psychopathology; however, lowest BMI since the onset of AN 
was associated with reduced rates of TD. There were also no differences in TD 
depending on education history or between restrictive and binge/purge AN 
subtypes. However, real rTMS altered TD behaviour whilst sham rTMS did not. 
Yet, the direction of change was the opposite to what was predicted; HF rTMS to 
the left DLPFC decreased discounting behaviour and thus encouraged delayed 
gratification in AN. Moreover, this effect was most pronounced in the restrictive 
AN subtype. Finally, rates of TD prior to rTMS accounted for a significant 
amount of the variance of the effects of real (but not sham) rTMS on AN 
symptoms over time.  
Our data are somewhat inconsistent with existing literature. In this sample of 
individuals with AN, we found that age was inversely correlated with AUC, i.e. 
younger individuals discount future rewards less and therefore displayed less 
choice impulsivity. In contrast, others report that TD and impulsivity decreases 
with age related maturation of relevant neural circuitry (Christakou, Brammer, 
& Rubia, 2011; Steinberg et al., 2009). However, these studies were in younger 
samples than ours, where impulsivity was highest amongst adolescents. In 
comparison, all of our participants were adults. Whilst the discrepancies in 
findings may be due to such differences in the samples studied, they could 
equally suggest that discounting in AN does not following typical progression 
with age. 
Furthermore, unlike Steinglass et al. (2012), we failed to differentiate TD 
behaviours between AN subtypes. Additionally, our data suggest that the 
tendency to choose LL rewards (i.e. increased self-control) is associated with 
AN individuals’ lowest reported BMI, whilst Steinglass et al. (2012) reported 
that higher BMI was associated with LL reward choice. These differences may 
be partly due to variation in TD tasks and thus the measurement of TD. The way 
in which reward choices are framed and how discounting rates are computed 
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are just two parameters that vary between studies and may therefore explain 
inconsistencies in findings. Moreover, our participants had particularly 
enduring forms of AN whilst Steinglass et al. (2012) does not report data 
regarding illness duration.  
In relation to the effects of rTMS on discounting behaviour, our results are 
consistent with the existing relevant literature. Whilst Figner et al. (2010) 
increased rates of TD with LF rTMS to the left DLPFC, our findings of reduced 
TD are in accord with others who applied HF rTMS to PFC regions (Cho et al., 
2014; Sheffer et al., 2013). However, the reported decrease in discounting 
behaviour following inhibitory, cTBS to the right DLPFC is not consistent with 
the rTMS literature, which is likely to be due to differences between the two 
neuromodulatory techniques and/or samples studied. Interestingly, we also 
partially replicated our previous findings in that discounting behaviour 
explained some of the effects of real (but not sham) non-invasive 
neuromodulation on ED related symptoms (Kekic et al., 2014). Finally, to our 
knowledge, this is the first study to report rTMS induced neurocognitive 
changes within an ED sample.  
Mechanistic hypotheses 
Given the literature in relation to discounting in AN (Steinglass et al., 2012) and 
the effects of rTMS on TD (Figner et al., 2010), the hypothesis underpinning this 
study i.e. that rTMS would reduce exaggerated cognitive control in AN is 
reasonable. Whilst the findings by Figner et al. (2010) support the notion that 
LF rTMS applied to the left DLPFC may encourage choice impulsivity in AN, our 
hypothesis was based on the fact that HF rTMS led to symptom improvements, 
including reductions in the urge to restrict – which could be argued as symptom 
exemplifying excessive ‘self-control’ (Kamolz et al., 2008; McClelland, Bozhilova, 
Nestler, et al., 2013; Van den Eynde, Guillaume, et al., 2013). Moreover, the 
present study contributes further to this evidence for AN symptom reductions 
following HF rTMS to the left DLPFC, whilst at the same time demonstrating 
reductions in discounting behaviour/increases in cognitive control mechanisms 
(see Chapter 3.3). Therefore, aspects of the neural mechanisms of AN are likely 
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to be more complex than the proposed over-active prefrontal activity 
underpinning increased cognitive/self-control hypotheses. Alternatively, rTMS 
may alter the cortico-striatal circuitry proposed to underlie and thus improve 
the management of compulsive, habitual behaviours such as food restriction 
(Godier & Park, 2014; Park et al., 2014).  
Alternatively, increased right-sided prefrontal activity has differentiated 
recovered from currently ill AN individuals and has been associated with good 
outcomes (Uher et al., 2003). Similarly, increased functional connectivity 
through reward and prefrontal regions has been associated with better 
outcomes of rTMS in depression (Downar et al., 2014; Salomons et al., 2014) 
and increased functional connectivity of relevant value encoding and cognitive 
appraisal circuitry has been associated with reduced TD (Li, Ma, et al., 2013). 
Therefore, HF rTMS may facilitate connectivity and the exchange of information 
between the altered circuitry implicated in AN and may facilitate control over 
AN related symptoms/compulsive behaviours rather than reduce excessive self-
control per se.  
Strengths 
To date, the effects of rTMS on TD in AN have not been reported. As stated, this 
RCT was conducted according to strict and robust eligibility and randomisation 
procedures, and employed state-of-the-art methodologies. This is important to 
identify potential biomarkers and underlying mechanisms of therapeutic 
response to rTMS. Given the findings, this study helps to further the debate on 
the neural mechanisms of AN and the utility of brain directed treatments such 
as rTMS in this treatment resistant patient population.  
Limitations 
We could not account for differences in income on TD within this sample. Given 
the monetary nature of the TD task employed, this may have compromised our 
findings. In terms of the TD task itself, the way in which choices are framed 
(accelerate/delay, gains/losses) is suggested to affect rates of discounting, and 
may account for differences between studies (Steinglass et al., 2012). Our TD 
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task was previously used to measure impulsive behaviours/conditions 
(Richards et al., 1999; Rubia et al., 2009) and choices are only framed in one 
way. This may reduce its ability to capture TD characteristics and the effects of 
rTMS on these within individuals/conditions that display the opposite, i.e. 
increased ability to delay gratification, such as AN.  
Future directions 
Future studies that assess TD across the spectrum of ED are needed in order to 
ascertain variability in the construct across and within diagnoses. Similarly, 
studies that compare neuromodulation protocol parameters are required in 
order to more fully understand the neural correlates of discounting behaviour 
and develop tailored neuromodulation protocols. Studies comparing different 
rTMS protocols, i.e. HF versus LF, right versus left DLPFC, may shed light on 
issues that require further clarification such as neuromodulation mechanisms 
and the role of hemispheric lateralisation. Specifically, whether or not LF rTMS 
to the DLPFC alters both TD and AN symptoms in the same way to those 
reported here is worth investigating.  
Summary  
These findings suggest that in individuals with AN, real rTMS reduces the 
discounting of future rewards (i.e. reduces choice impulsivity). Therefore, the 
effects of rTMS on the neural correlates of self-control in AN may underlie 
associated improvements in symptoms.  
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Chapter 5. A therapeutic case series of repetitive transcranial 
magnetic stimulation in five cases of enduring anorexia 
nervosa 
 


















Anorexia Nervosa (AN) is a life-threatening mental illness. It is characterised by 
an intense fear of food, eating and gaining weight resulting in severe food 
restriction and extremely low body weight. Consequently, AN is associated with 
a myriad of physical and psychological co-morbidities and severely impaired 
quality of life. Mortality and disability rates are high (Arcelus et al., 2011). The 
median duration of AN is five to seven years (Zipfel et al., 2000) and given the 
typically adolescent onset, the illness blights a key developmental period. A 
quarter of sufferers have a particularly severe and enduring form of the illness 
that last longer than 10-15 years (Steinhausen, 2002). There is uncertainty 
about the management of adult patients with AN per se (Schmidt et al., 2012; 
Watson & Bulik, 2012), especially in those with a severe and enduring form of 
the illness who have typically undergone multiple psychological and 
pharmacological treatments and unsuccessful attempts to restore a healthy 
weight in in-patient treatment (Hay et al., 2012). This situation underscores the 
need to develop new treatments.  
The neurocircuitry of anorexia nervosa 
Significant advances have been made over the last decade in our understanding 
of the neural correlates of AN, with research highlighting both structural (Frank, 
Shott, Hagman, & Mittal, 2013; Mainz et al., 2012; Van den Eynde, Suda, et al., 
2012) and functional (Brooks et al., 2011; Frank & Kaye, 2012; Kim et al., 2012; 
Pietrini et al., 2011; Uher et al., 2004; Zhu et al., 2012) differences in the brains 
of AN sufferers compared to controls. Generally speaking, such neuroimaging 
studies demonstrate grey and white matter alterations, disturbances in limbic, 
frontal and parietal areas, in addition to alterations in the functioning of 
neurotransmitters including serotonin and dopamine at different stages of AN. 
Drawing from such findings, AN has been proposed in Chapter 1 and by many 
others as a neuro-circuit based disorder (Kaye et al., 2009; Kaye et al., 2011; 
Marsh, Maia, et al., 2009; van Kuyck et al., 2009). These neural models propose 
that the self-regulation difficulties of AN, in particular disturbances in emotion 
regulation, appetite and self-control, arise from alterations in the activity of 
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ventral, mesolimbic areas and dorsal, cognitive control circuitry. For example, 
alterations in reward processing and fear responses have been found in AN 
(Cowdrey et al., 2011; Holsen et al., 2012; Titova et al., 2013). These ‘bottom-up’ 
processing abnormalities may contribute to the heightened emotionality 
surrounding food, body image and other pertinent cues. In response, altered 
‘top-down’ activations from areas such as the DLPFC (Brooks et al., 2011; Uher 
et al., 2003; Uher et al., 2004) may be an attempt to modulate dysphoric mood 
and underlie the characteristic rigidity and extreme self-control of AN. 
Repetitive transcranial magnetic stimulation in psychiatry  
The DLPFC plays an important role in executive function and cognitive control 
mechanisms, such as decision making (Plassmann, O'Doherty, & Rangel, 2007) 
and emotion regulation (Ochsner & Gross, 2007). Given this, the DLPFC is a 
common target for neuromodulation interventions in other neuro-circuit based, 
psychiatric disorders. Most notably, rTMS to the left DLPFC has demonstrated 
clinical efficacy and is approved by the FDA as a second-line treatment for 
depression (Gaynes et al., 2014; O’Reardon et al., 2007). Evidence suggests that 
rTMS for depression is most effective as a monotherapy and for treatment-
resistant cases. In terms of efficacy, rTMS remains inferior to ECT, although 
rTMS is associated with far fewer side effects (Slotema et al., 2010). Preliminary 
evidence exists for the efficacy of rTMS in other neuro-circuit based disorders 
such as schizophrenia, autism, epilepsy, Parkinson’s disease and addictive 
disorders (Jansen et al., 2013; Slotema et al., 2010; Wassermann & Lisanby, 
2001). 
Repetitive transcranial magnetic stimulation in eating disorders 
Research involving rTMS in ED is in its infancy. However, existing evidence from 
animal models, human samples and a small number of studies in ED suggests 
potential for altering ED psychopathology and body weight (see Chapter 2 or 
McClelland, Bozhilova, Campbell, et al., 2013). To date, two studies investigating 
the effects of rTMS on ED related symptoms in healthy participants (e.g. food 
cravings) and five studies in BN exist. Reductions in food cravings following real 
rTMS have been demonstrated (Uher, Yoganathan, et al., 2005), whilst using an 
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improved sham method Barth et al. (2011) suggested no effects of rTMS on food 
cravings. In clinical samples, individual case reports support the therapeutic 
efficacy of rTMS in BN (Downar et al., 2012; Hausmann et al., 2004). However 
the only repeated session (15 sessions) RCT of real/sham rTMS within an ED 
sample suggests no difference between real/sham groups in improving 
symptoms of BN – both real/sham groups demonstrated equal improvements 
(Walpoth et al., 2008). Although, this study may have been underpowered 
(given its small sample size of n=14) or may not have delivered enough sessions 
(given that 20 sessions are typically in protocols for depression). Since then, our 
group demonstrated that a single session of real, as opposed to sham, rTMS 
reduced the urge to eat and subsequent binge-eating episodes in patients with 
BN (Van den Eynde et al., 2010). Therefore, data regarding the therapeutic 
efficacy for rTMS in BN is mixed but nevertheless promising.  
Support for the use of rTMS in AN comes from a successful case report where 20 
sessions of rTMS to the left DLPFC treated depression and improved co-morbid 
ED symptoms (Kamolz et al., 2008). Since then, our group has conducted a non-
controlled pilot study of a single session of real rTMS to the left DLPFC in ten AN 
individuals and demonstrated reductions in levels of anxiety, feeling full and 
feeling fat – some of the core characteristics of the illness (Van den Eynde, 
Guillaume, et al., 2013). To our knowledge Chapter 3 of this thesis is the only 
RCT of rTMS in a moderate sized sample of individuals with AN, and findings 
suggest that following real (as opposed to sham) rTMS, core symptoms of AN 
are reduced. However, extrapolating these findings into any long-term 
therapeutic benefit requires repeated session protocols and longer follow-ups.  
Moreover, there is a need to identify biomarkers of response to rTMS (Fidalgo et 
al., 2014). As is discussed in the previous chapter, individuals with AN have 
demonstrated reduced TD, specifically the ability to delay gratification, and this 
has been argued to contribute to their extreme control over food/eating 
(Steinglass et al., 2012). Following LF rTMS to the left DLPFC, Figner et al. 
(2010) reported increases in choice impulsivity (i.e. choosing smaller, 
immediately available awards). Therefore, rTMS may alter intertemporal choice 
behaviour which may contribute to symptom improvements in AN.    
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Based on the neuroscience data summarised in Chapter 1 and the ability of 
rTMS to improve ED related symptoms including preliminary evidence in AN 
(Kamolz et al., 2008; Van den Eynde, Guillaume, et al., 2013) we aimed to 
explore the therapeutic utility, i.e. the long-term benefits of repeated sessions of 
rTMS in AN. Moreover, we utilised improved investigatory techniques than used 
previously, i.e. neuronavigation (MRI-guided rTMS) and also examined 
associated changes to TD behaviour. Our primary hypotheses were that 20 
session of rTMS would i) improve ED psychopathology and mood, ii) lessen 
exaggerated cognitive-control (i.e. increase TD) and iii) encourage weight gain. 
Methods 
Participants 
Five participants with a DSM-5 (A.P.A., 2013) diagnosis of AN volunteered to 
take part in the study. Participant 1 and Participant 5 suffered from restrictive 
AN with purging (vomiting) behaviours, Participant 2 and Participant 3 met 
binge/purge AN criteria and Participant 4 had AN-restrictive type. Participants 
were recruited following their participation in the previous, single session RCT 
(Chapter 3). Contraindications to rTMS were checked with the TMS Adult Safety 
Screening Questionnaire (see Appendix E.5 or Keel et al., 2001).  Upon taking 
part in the RCT, participants met the principal eligibility criterion required of a 
BMI between 14-18.5 kg/m2 (one participants BMI rose to above 18.5 between 
taking part in the RCT and starting this therapeutic trial). Exclusion criteria 
were being on a dose of psychotropic medication that had not been stable for at 
least 14 days prior to enrolment, pregnancy, and excessive nicotine use or 
substance dependence. Local ethical committee approval was obtained (REC ref: 
12/LO/1525) and written informed consent was obtained from all participants. 
The participant information sheet and consent form for this trial are included in 
Appendices C.2 and D.2 respectively. 
Study protocol  
Initially, three sessions per week were administered (Monday, Wednesday, 
Friday) and Participants 1 and 2 attended three rTMS sessions per week for the 
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first two weeks/six sessions. However, following participants request and in 
order to adhere more closely to the therapeutic use of rTMS in other disorders 
(e.g. depression), session frequency was increased to five sessions per week 
(Monday – Friday) for all participants. Participants 3 – 5 attended five sessions 
per week throughout. The study protocol is detailed in Table 5.1 and Table 5.2.  
Procedures 
All five participants had previously undergone a structural magnetic resonance 
imaging (MRI) scan as part of their participation in the single session RCT and 
the full details of this procedure are provided in Chapter 3.2. Likewise, the MRI 
was used with Brainsight® to neuronavigate the TMS coil to the left DLPFC using 
the Talaraich co-ordinates x = -45, y = 45, z = 35, reported by Fitzgerald et al. 
(2009) to enhance response to rTMS treatment in depression.  
A Magstim Rapid device (Magstim, Whitland, Wales, United Kingdom) using a 
real TMS figure of eight coil was used to establish participants’ MT through 
peripheral EMG. The motor cortex was identified via the brain scan on the 
Brainsight software and upon mapping the M1 ‘hot-spot’, MT was defined as the 
minimum stimulus required to evoke 5 out of 10 MEP greater than 50μV. This 
procedure was repeated every Monday to ensure rTMS was delivered 
accurately. To administer the rTMS, a Magstim Rapid device and figure-eight 
coil (Magstim, UK) was also used as described previously (see Chapter 3) in 20 
x 5 second trains and 55 second intervals at a frequency of 10Hz, intensity 
of 110% MT delivering 1000 pulses over 20 minutes each session. 







MT: motor threshold; DASS-21: 21 item depression, anxiety and stress scale; EDE-
Q: eating disorder examination questionnaire; TD: temporal discounting; VAS: 
visual analogue scale; FU: follow-up. 
 
Quantitative measures 
Within session measures 
Subjective eating disorder experiences 
VAS were completed following cue exposure (i.e. a short film clip of people 
eating highly palatable foods), both immediately before and after each rTMS 
session (see Table 5.1). These six 10cm VAS assessed ‘levels of stress’, ‘urge to 
restrict’, ‘levels of anxiety’, ‘urge to exercise’, ‘levels of feeling full’ and ‘levels of 
feeling fat’ (see Appendix G.1). 
Table 5.1 Protocol for the 20 rTMS sessions and follow-ups 












 3 W 
4 T 





 6 M Weight, MT, DASS-21 
7 T 
 8 W 
9 T 





 11 M Weight, MT, DASS-21 
12 T 
 13 W 
14 T 





 16 M Weight, MT, DASS-21 
17 T 
 18 W 
19 T 
20 F Weight, EDE-Q, DASS-21, TD task 
1 month FU EDE-Q, DASS-21 
 
6 month FU EDE-Q, DASS-21 
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Between session measures 
Body mass index 
Weight was measured and body mass index (BMI) was calculated before and 
after the 20 rTMS sessions by dividing participants’ weight (kg) by the square 
root of their height (m2). Whilst BMI is reported at 1 and 6 month follow-up, this 
was typically calculated using self-reported weight.  
Eating disorder symptomatology 
The Eating Disorder Examination Questionnaire (EDE-Q, version 6) is described 
in Chapter 3.3 and included in Appendix F.1.     
General psychopathology 
The 21 item Depression, Anxiety & Stress Scale (DASS-21) is described in 
Chapter 3.3 and included in Appendix F.2. 
Temporal discounting  
The TD task is described in Chapter 4 and included in Appendix H.2. 
Qualitative information 
Feedback from patients 
Qualitative, non-structured and non-specific feedback from patients was 
recorded in an informal manner throughout and following the 20 rTMS 
sessions.  
Feedback from carers, partners, parents or friends 
In order to gain objective insight and feedback, towards the end of the 20 
sessions participants asked someone close to them to complete a form with 
questions regarding any noticeable changes in the participant. A significant 
other including a carer, partner, parent and friend commented on each 
participant’s typical ED symptoms, mood and any other relevant information 




As this is a small series of five cases, analyses is limited to descriptive 
information regarding changes in BMI, EDE-Q and DASS-21 scores and the TD 
area under the curve outcome (AUC; see Chapter 4). With the exception of the 
TD task, which was only collected pre- and post-intervention, the other 
outcomes (BMI, EDE-Q and DASS-21) were recorded at pre-, post-intervention, 
1 and 6 month follow-up. Within session VAS assessments are graphically 
presented in order to examine any patterns/trends within, and across the 
course of the 20 sessions. 
Results 
Participants 
Demographic and clinical information for participants can be found in Table 5.3. 
All participants had particularly severe and enduring forms of the illness, with 
illness duration ranging from 5 – 35 years, multiple failed attempts at other 
forms of psychological and/or pharmacological treatments and of note, one 
patient had also tried ECT to treat her AN.  
Adverse events 
All five participants were due to attend twenty sessions; Participant A, C and D 
completed all sessions. Participant B missed one of her sessions at the mid-way 
point due to her reporting a single episode of being dizzy/dazed following a 
session. Sessions were resumed once vital signs and bloods had been checked 
and returned as normal. As a result, Patient B only completed 19 sessions of the 
intended 20. Similarly, Patient E missed her final, twentieth session as a result 
of being unwell. This was primarily due to dental problems that were unrelated 
to the rTMS. Patient E also only completed 19 of the 20 intended sessions. To 
our knowledge, along with the occasional, mild headache/discomfort of rTMS, 




Within session measures 
Subjective eating disorder experiences 
Where there were missing data (e.g. incomplete answers or missed sessions) 
the average of the previous and next VAS scores was substituted, or in the case 
of missing scores on the twentieth session, the previous score was used. 
Generally speaking, scores across all six VAS measures pre-rTMS were slightly 
higher than post-rTMS within each session. This relationship is demonstrated in 
Figure 5.1 - Figure 5.6. Additionally, there was a general decrease in scores 




 July Aug Sept Oct Nov Dec Jan Feb March April May June July 
A 20 rTMS 1 FU  6 FU 
10 top-up rTMS  (1 x weekly) 
5 top up rTMS (1 x fortnightly) 
B 19 rTMS 
  1 FU 
12 top-up rTMS 
(each weekday) 
 6 FU*  
C  20 rTMS 1 FU  6 FU  
D  20 rTMS 1 FU  6 FU  
E  19 rTMS 1 FU  6 FU 
1 and 6 FU: 1 and 6 month follow-up; *at her request this patient had 12 top-up rTMS sessions between 1 and 6 month follow-ups. 
Table 5.2 Timeline for the 20 rTMS sessions and follow-ups. 
 Age Lowest 
BMI 














A 23 13.5 14.78 12 12 years R (purging) Depression Olanzapine, 
Diazepam, 
Fluoxetine 
Inpatient 12 years inpatient & ECT 
B 52 16.2 16.40 17 35  years B/P - Fluoxetine - 6 months day care, 3 years 
outpatient 
C 32 15.0 19.24 26 5  years B/P Depression - - Outpatient 
D 41 13.6 15.35 10 31  years R - - - Inpatient & outpatient 
E 30 9.8 14.54 12 19  years R (purging) - Fluoxetine - 6 years inpatient 
 




Figure 5.1 Levels of stress; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (not stressed at all) to 10 
(extremely stressed).  
 
Figure 5.2 Urge to restrict; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (no urge to restrict) to 10 


























































Figure 5.3 Levels of anxiety; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (not anxious at all) to 10 
(extremely anxious). 
 
Figure 5.4 Urge to exercise; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (no urge to exercise at all) to 10 



























































Figure 5.5 Levels of feeling full; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (not feeling full at all) to 10 
(feeling extremely full). 
 
Figure 5.6 Levels of feeling fat; mean VAS scores pre and post each rTMS 
session. 
Visual analogue scale (VAS) scores range from 0 (not feeling fat at all) to 10 

































































Between session measures 
Body Mass Index 
As Table 5.4 suggests, there were no substantial increases in weight and BMI in 
any of the participants following the rTMS sessions. There was, however, a loss 
of approximately 2kg in most participants by six-month follow-up.  
Eating disorder symptomatology  
Individual global and subscale EDE-Q scores are reported in Table 5.4 and Table 
5.6 respectively. A sustained improvement in ED psychopathology is 
demonstrated in most individuals. Average EDE-Q subscale scores across the 
five participants are presented in Figure 5.7. Mean scores across all subscales 
decreased following 20 sessions of rTMS and continued to do so at 1 and 6 
month follow-up – with the exception of the eating concern subscale which 
increased at 6 month follow-up, however still remained below baseline. 
Furthermore, by the end of the 20 rTMS sessions many individual and most 
average subscale scores fell below 4, therefore no longer meeting levels of 
clinical significance (Carter et al., 2001; Luce et al., 2008; Mond et al., 2004). 
Many remained below this at six months following the rTMS intervention. 
Despite showing a steady decline, average scores for the restraint subscale only 
fell below 4 at 6 month follow-up. Additionally, by 6 month follow-up, three 
participants’ global EDE-Q scores fell below 2.80, a more stringent and sensitive 
criteria for clinical significance proposed by Mond et al. (2008).  
Table 5.5 reports the frequency of ED behaviours, such as bingeing, vomiting 
and laxative use reported by participants (via the EDE-Q) across the course of 
the intervention and at follow-ups. Participant D, AN restrictive subtype, was 
the only individual without either bingeing or purging behaviours. Whilst 
Participant A failed to report/quantify the frequency of her vomiting behaviours 
on the EDE-Q up until her 6 month follow-up, she revealed to researchers that 
these behaviours had significantly reduced following the rTMS intervention. 
Patient B reported that the frequency of both her bingeing and vomiting 
reduced following the intervention along with her misuse of laxatives. Patient C 
reported extremely high rates of bingeing/purging with little to no changes, or 
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even increases in vomiting demonstrated. Patient E was AN-restrictive with 
purging (vomiting) and reported a steady decrease in the frequency of these 
behaviours over the course of the study.   
General psychopathology 
Total and subscale DASS-21 scores for each individual are presented in Table 
5.4 and Table 5.7 respectively. Average scores across the DASS-21 subscales are 
presented in Figure 5.8. Scores on the depression and anxiety subscales 
decreased over time, with a slight increase between 1 and 6 month follow-up, 
but still remaining below baseline. Mean scores on the stress subscale 
substantially decreased following the 20 rTMS sessions, with moderate 
increases at each follow-up, however still remaining much below baseline. 
Temporal discounting 
Pre and post the 20 sessions of rTMS, the AUC of the TD function remained 
relatively unchanged in most participants (Figure 5.9). The most substantial 
change in AUC was demonstrated in Participant C; AUC was much higher 
following the 20 sessions of rTMS. This indicated that, following the 
intervention, Participant C was more inclined to wait for larger, delayed 
rewards. A similar pattern was seen in Participant E, however the difference 
was not of the same magnitude.  
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Table 5.4 Individual weight, BMI, EDE-Q global and DASS-21 total scores. 
BMI: body mass index; EDE-Q: eating disorder examination questionnaire; DASS-21: 21 item depression anxiety and stress scale; 1 and 6 FU: 
1 and 6 month follow-up; *individual had 12 top-up rTMS sessions between 1 and 6 month follow-ups 
 
Table 5.5 Individual frequencies of eating disorder behaviours. 
Participant Bingeing Vomiting Laxative Use 









            A NA NA NA NA - - - 5 NA NA NA NA 
B 10 8 5 8* 10 8 7 8* 15 10 9 12* 
C 20 25 20 15 40 50 50 70 NA NA NA NA 
D NA NA NA NA NA NA NA NA NA NA NA NA 
E NA NA NA NA 28 22 27 10 NA NA NA NA 
1 and 6 FU: 1 and 6 month follow-up; *individual had 12 top-up rTMS sessions between 1 and 6 month follow-ups; NA: not applicable 
Participant Weight BMI EDE-Q Global DASS-21 Total 









                A 36.90 36.20 34.50 34.50 14.78 14.50 13.82 13.82 4.29 3.01 2.67 2.46 23 11 18 9 
B 47.40 47.50 46.20 45.60* 16.40 16.45 15.99 15.78* 4.12 3.46 3.36 2.75* 40 23 21 35* 
C 57.60 57.90 57.80 53.52 19.24 19.35 19.31 17.88 3.87 2.35 1.06 2.71 26 6 16 19 
D 41.80 41.80 - 38.00 15.35 15.35 - 13.96 5.55 5.55 5.50 4.88 41 14 21 19 




1 and 6 FU: 1 and 6 month follow-up, * individual had 12 top-up rTMS sessions between 1 and 6 month follow-ups 
 
Table 5.7 Individual DASS-21 subscale scores. 
 EDE-Q: eating disorder examination questionnaire; DASS-21: 21 item depression, anxiety and stress scale; 1and 6 FU: 1 and 6 month follow-
up; *individual had 12 top-up rTMS sessions between 1 and 6 month follow-ups. 
Table 5.6 Individual EDE-Q subscale scores. 
Participant Restraint Eating Weight Shape 
Pre Post 1 FU 6 FU Pre Post 1 FU 6 FU Pre Post 1 FU 6 FU Pre Post 1 FU 6 FU 
Participant 
1 
                A 4.80 4.20 4.20 2.60 2.60 2.60 2.00 2.20 4.40 2.00 1.60 1.80 5.34 3.25 2.87 3.25 
B 5.40 6.00 6.00 3.00* 3.80 1.40 1.00 4.20* 3.40 3.80 4.20 1.80* 3.87 2.62 2.25 2.00* 
C 4.80 3.20 1.60 4.20 3.80 1.80 1.40 2.80 3.40 2.40 0.00 2.00 3.50 2.00 1.25 1.87 
D 6.00 5.40 5.60 5.40 4.40 4.80 4.60 4.60 5.80 6.00 5.80 4.40 6.00 6.00 6.00 5.13 
E 5.00 4.60 4.60 3.40 6.00 4.60 3.60 2.80 3.80 3.60 2.60 3.00 6.00 5.50 5.75 5.50 
Participant Depression Anxiety Stress 
Pre Post 1 FU 6 FU Pre Post 1 FU 6 FU Pre Post 1 FU 6 FU 
Participant 
1 
            A 4 2 6 0 9 3 5 2 10 6 7 7 
B 10 11 7 13* 11 5 5 5* 19 7 9 17* 
C 6 0 6 7 6 2 2 6 14 4 8 6 
D 9 4 4 2 13 4 3 7 19 6 14 10 




Figure 5.7 Mean EDE-Q subscale scores pre and post the 20 rTMS sessions 
and at 1 and 6 month follow-up. 
EDE-Q: eating disorder examination questionnaire; mnth: month; FU: follow-up 
 
Figure 5.8 Mean DASS-21 subscale scores pre and post the 20 rTMS 
sessions and at 1 and 6 month follow-up  
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Figure 5.9 Area under the curve pre and post the 20 rTMS sessions for 
each participant. 




The most unanimous feedback from patients regarding the benefits of rTMS 
related to feeling calmer, less anxious, improvements in mood and a general 
increase in their hopes and motivation towards recovery. Participants reported 
feeling “better equipped to cope with things”, “calmer [and] having a brighter 
mood” and that “my improved mood helped me manage my life, specifically my 
anorexia, far better.” Improvements in self-esteem were also reported “I 
generally feel better and happier in myself on a daily basis” along with decision 
making abilities, being able to rationalise things, in particular in relation to 
new/changes in treatment plans, and a broader optimism that these small 
changes could lead to “bigger and better things”.  
In relation to ED symptoms specifically, almost all participants said they felt 






























administered, however a few weeks after completion was when most 
participants reported feeling noticeable differences. Participants reported 
feeling better able to manage food related difficulties, “[rTMS has] enabled me 
to tackle my anorexic habits more successfully” and that they felt more 
optimistic “I feel more hopeful and less despair in relation to my illness.” Whilst 
some participants said they noticed no change to the frequency of their 
binge/purge behaviours, others reported that “I make myself sick far, far less” 
as a result of feeling “less motivated to engage in purging behaviours” 
describing them as “less rewarding.” Additionally, one participant noticed a 
reduction in mirror checking behaviours along with improved sleep (previously 
getting 4 hours per night which increased to over 8 hours per night following 
the rTMS). 
Whilst most participants seemed to agree that although the “difference [rTMS 
makes] is small… that this was “…hugely significant”. Almost all participants 
implied that it had done more for them than any other form of treatment they 
had tried – “it is the first therapy that has had any impact on me” and all 
participants have expressed interest in having more sessions.  
From carers, partners, parents or friends 
Similarly to what was reported by participants, the main feedback from carers 
and loved ones suggested notable “improvements in mood” along with 
improvements in coping abilities and individuals being more “logical, rational, 
less resistant to change and thinking more clearly”. Likewise, changes to 
participants self-esteem and general demeanour was noted as they were “more 
confident, bolder and adventurous” or “more relaxed and smiley”. In general, “a 
more positive and energised outlook on life” was reported by most carers/loved 
ones.  
In relation to ED specific symptoms and behaviours, little to modest 
improvements in were reported. As all participants were adults who typically 
lived independently and therefore ate alone/unsupervised (with the exception 
of the inpatient, Participant A) eating behaviours were difficult for others to 
comment on. However, “periods of normal eating” and more relaxed approaches 
 223 
to foods, for example “trying new foods… outside of her routine or food type” 
were reported. Furthermore some feedback suggested a reduction in purging 
behaviours, and increased “motivation and determination” towards recovery. A 
number of carers/loved ones suggested that they thought the participants 
expressed desire for more rTMS sessions reflected them “feeling the benefit of 
rTMS”.  
Discussion 
Following approximately 20 sessions of neuronavigated rTMS in five cases of 
treatment-resistant and enduring AN, improvements in ED symptoms and 
general psychopathology were reported. Moreover, these improvements were 
sustained or even continued to improve for up to 6 months following treatment. 
However, these improvements in psychopathology were not associated with 
weight gain. The rTMS intervention was well accepted and both participants 
and carers reported positive feedback regarding the treatment. There were no 
general trends in the effects of rTMS on TD behaviour, however one individual 
demonstrated a substantial reduction in TD and thus an increase in the ability to 
delay gratification.  
It is important to highlight and consider the illness history and treatment 
resistant nature of the participants involved. The average duration of AN was 
over 20 years and all had failed other forms of psychological, pharmacological 
and/or neuromodulatory (ECT) therapy. Whilst some individuals were 
receiving concurrent psychological or pharmacological treatment, they had 
done so for a long time prior to starting the rTMS, with limited response. Prior 
resistance to pharmacotherapy in depression reportedly diminishes the 
likelihood of responding to subsequent interventions, including 
neuromodulation (Prudic et al., 1996; Sackeim et al., 2001). Similarly, resistance 
to previous treatment in AN is likely to predict poor outcomes in future 
interventions. Given this and the chronic, enduring nature of the five cases 
discussed, we believe a placebo response is unlikely and that the symptom 
improvements seen are, at least in part, a result of the rTMS treatment. This 
point is further emphasised by the maintenance and even continued 
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improvement in both ED specific and general psychopathology at up to 6 
months following the intervention. Moreover, we expected that given the 
severity and enduring nature of AN in these individuals, additional sessions, 
more intense rTMS protocols, concurrent psychotherapy and/or longer follow-
ups may be required in order to encourage weight gain.  
Potential mechanisms of therapeutic effect 
A number of potential mechanisms may explain the therapeutic effects of rTMS 
seen within these five AN cases. Improvements in symptoms and general 
psychopathology may be due to direct, focal modulation of the DLPFC and 
dorsal neural circuitry responsible for executive functions and mood regulation. 
In particular rTMS to the left DLPFC may alter the self-regulation difficulties 
seen in AN, i.e. by improving control over compulsive ED related 
behaviours/symptoms. However, this was not reflected across all individuals in 
the TD task. Alternatively, whilst the neural effects of rTMS are often thought to 
remain relatively focal, recent evidence suggests that rTMS to the PFC induces 
remote effects in deeper, thalamic structures (George et al., 1999). Therefore, 
neural modulation of the DLPFC with rTMS within this study may have remotely 
altered ventral circuitry, altering bottom up, mesolimbic emotional drives 
related to AN specific stimuli such as food and eating situations. 
Both the dorsal and ventral circuitry involved in AN may be altered with rTMS 
via a number of biological pathways. Firstly, given the argued neuro-circuit 
nature of intractable AN, the observed changes to some of the inherent and 
‘stubborn’ aspects of the illness may be a result of rTMS induced changes to 
neuroplasticity (Gersner et al., 2011; Medina & Tunez, 2013; Ridding & 
Rothwell, 2007). In particular, HF rTMS is proposed to facilitate LTP like 
changes in structural and functional synaptic connections, producing effects 
that outlast the stimulation period and thus underlying therapeutic effects 
(Esslinger et al., 2014; Vlachos et al., 2012). Whilst glutamate plays a central 
role in this process, BDNF is essential for synaptic regulation and plasticity. In 
treatment resistant depression, BDNF is inversely correlated with illness 
severity and a biomarker of response to rTMS (Fidalgo et al., 2014). Moreover, 
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levels of BDNF are increased following HF rTMS, suggesting a normalising effect 
of rTMS treatment (Gersner et al., 2011; Zanardini et al., 2006). This is 
particularly pertinent to AN, given the abnormalities in BDNF levels reported 
across different stages of the illness (Brandys et al., 2011; Zwipp et al., 2014). 
Therefore, as in other neuro-circuit based psychiatric disorders such as 
depression, rTMS is likely to induce neuroplasticity via the modulation of BDNF 
expression.  
Secondly, rTMS has demonstrated the ability to alter levels of monoamine 
neurotransmitters. Modulation of dopamine release in remote areas such as the 
anterior cingulate cortex, has been reported following HF rTMS to the left (but 
not right) DLPFC (Cho & Strafella, 2009). Given these and other similar findings 
(Pogarell et al., 2007), in conjunction with the dopaminergic alterations 
reported within AN (Frank et al., 2005), this focal and remote normalisation of 
dopamine may underlie the therapeutic effects reported within these five 
participants. Additionally, modulation of serotonin following HF rTMS to the 
PFC has been reported (Baeken et al., 2011; Kanno et al., 2003) and may also 
contribute to the therapeutic effects of rTMS in AN.  
Finally, the combination of rTMS and cue exposure included within the current 
protocol may have bolstered the reduction in ED related anxieties experienced 
by participants. Evidence supports the importance of context-dependent neural 
activity on outcome of rTMS. For example, HF rTMS increased levels of BDNF 
and glutamate in awake, alert animals. However, in anaesthetised animals, 
levels of these neuroplasticity markers were reduced (Gersner et al., 2011). 
Therefore, the therapeutic efficacy of rTMS in AN reported here might not have 
been achieved with either rTMS or exposure therapy alone.  
Strengths 
Until now, evidence for the potential therapeutic benefit of rTMS in AN has been 
limited to one other case report (Kamolz et al., 2008) and our small, 
uncontrolled pilot study demonstrating short-term effects of rTMS on AN 
symptoms (Van den Eynde, Guillaume, et al., 2013). The RCT outlined in Chapter 
3, along with the five cases reported here, add to this sparse literature by 
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providing further evidence for the feasibility, acceptability and some suggestion 
of therapeutic efficacy of rTMS in severe AN.  
Furthermore, the rTMS investigations reported within this thesis are the first 
within AN to use improved rTMS methodologies such as evaluating MT via EMG 
recordings (rather than the observed method) and using MRI-guided 
technology/neuronavigation (rather than the 5-cm anterior, scalp measurement 
method). This is a significant improvement to previous rTMS protocols as these 
techniques allow for more accurate, safer and reliable administration of rTMS, 
which is particularly important in repeated, therapeutic protocols.  
Limitations 
The lack of weight gain, and in fact slight weight loss at follow-up, cannot be 
ignored as weight gain is an obvious treatment goal in this group. However, the 
natural history of enduring AN across cases demonstrates that changes in 
weight require both time, and significant improvements to participants’ 
psychological state. Most participants reported noticeable changes to factors 
such as motivation, coping ability and affect regulation during or after the 
course of rTMS sessions – therefore, perhaps with time and concurrent 
psychotherapy these improvements could be utilized to encourage weight gain. 
A number of participants suggested that they thought psychotherapy alongside 
the rTMS intervention would be useful, in order to take full advantage of the 
psychological improvements they felt during/following the rTMS.  
The effectiveness of the food exposure videos used within this study is 
somewhat compromised by their lack of salience (within the food challenge task 
reported in Chapter 3). Moreover, the fact that participants watched these 
videos twice during each session, totalling 40 times, undoubtedly diminishes 
their potency in arousing AN related experiences. Furthermore, these videos 
depict other people eating highly palatable foods and are therefore seen by 
participants from a third person perspective. Given these considerations, our 
group has now developed a larger variety of new, food-centric videos, which 
aim to elicit stronger, temporary, ED related experiences for use alongside 
neuromodulation techniques. Similarly, as discussed in Chapter 4, the TD task 
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used within this thesis is limited. However, Chapter 4 demonstrated that 
compared to sham, real rTMS lead to short-term reductions in TD. Therefore 
this task might not be appropriate to assess changes in intertemporal choice 
behaviour over a longer duration/exposure to rTMS. Moreover, whether or not 
this construct can be permanently altered with rTMS (Figner et al., 2010) or 
rather, is a stable personality trait (Davis et al., 2010) requires further 
clarification. 
Whilst this study was intended to be an exploratory, feasibility case series the 
small sample size and lack of control condition is a limitation of this research 
and should therefore be considered when interpreting and generalising the 
findings. Whilst larger, controlled studies are needed to confirm our results, this 
study provides preliminary evidence for the therapeutic efficacy of rTMS in 
severe and enduring AN.  
Future directions 
As a next step, larger case study trials of therapeutic rTMS in AN are warranted, 
in order to explore its suitability for different target populations (e.g. restricting 
or binge-purge type AN) or target symptoms (e.g. ED symptoms or symptoms of 
comorbid disorders, such as severe depression, OCD or post-traumatic stress 
disorder, that are known to respond to rTMS treatment). In the longer term, 
large scale high quality RCT of therapeutic rTMS in participants with AN are 
needed together with research into different rTMS protocols for AN and for ED 
in general, utilising different types of stimulation (high or low frequencies, uni- 
or bilateral, or different stimulation sites). Such research will help to further 
clarify the neuro-circuitry underpinning of different symptoms, in addition to 
establishing the therapeutic potential of neuromodulation techniques in 
treating ED. Such tools, if proved beneficial, could exist as viable adjuncts to 
existing psychotherapy interventions. 
Conclusions 
Despite the small, case series style of this study, these findings provide further, 
albeit preliminary evidence for the therapeutic efficacy of rTMS in AN. The 
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therapeutic benefits on ED psychopathology and mood were maintained or 
continued to improve for up to six months. Of note, the five individuals studied 
had particularly enduring AN of a treatment-resistant nature, which may 
explain the lack of weight gain seen within this study. Further research is 
needed in larger samples, with control conditions and alongside neuroimaging 
modalities, in order to elucidate the neural mechanisms that underlie the 








Four major hypotheses were tested in this thesis:  
Hypothesis 1. Existing literature demonstrates that in human and animal 
populations, neuromodulation techniques have the ability to alter feeding and 
eating behaviour, body weight and ED related symptoms, and therefore have 
potential in the treatment of ED.  
Hypothesis 2. In patients with AN, core symptoms of AN will be reduced 
immediately and 24 hours after a single-session of real (as opposed to 
sham/placebo) HF rTMS to the left DLPFC.  
Hypothesis 3. Excessive cognitive control in AN will be reduced following real (as 
opposed to sham) HF rTMS to the left DLPFC.  
Hypothesis 4. In patients with enduring AN, ED and related psychopathology (e.g. 
mood) and weight will be improved immediately following therapeutic (20 
sessions) HF rTMS to the left DLPFC and at follow-up, up to 6 months later.  
Summary of findings 
The first hypothesis was tested in a systematic review of the literature on the 
effects of neuromodulation on feeding and eating related outcomes and body 
weight in animals and humans (healthy individuals, those with ED or other 
neurological/psychiatric conditions) (Chapter 2). The non-invasive techniques, 
rTMS and tDCS, when applied to the PFC, demonstrate potential in reducing food 
cravings. rTMS to the left DLPFC and the DMPFC has been shown to improve 
symptoms of BN. Improvements in AN symptomatology and weight gain have 
been reported following both rTMS to the left DLPFC and DBS to a variety of 
targets including the subgenual cingulate cortex, ventral striatum and nucleus 
accumbens. Also, DBS to areas such as the sub-thalamic nucleus and globus 
pallidus has been associated with weight gain in other disorders (e.g. 
Parkinson’s) and DBS to the lateral hypothalamus has been shown to increase 
food intake/body weight in animals – i.e. providing further support for its 
potential in AN. VNS has been associated with weight loss in obese people, 
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individuals with depression and epilepsy, and has consistently been shown to 
reduce food intake/body weight in animals. Despite some limitations in the 
ability to generalise from these findings, the systematic review supports the 
conduct of further research into the utility of neuromodulation treatment in ED 
and obesity.  
Hypotheses 2 and 3 were tested in a single-session, double blind RCT of real 
versus sham neuronavigated HF rTMS to the left DLPFC in patients with AN 
(Chapter 3 and 4). Compared to sham treatment, individuals who received real 
rTMS reported reduced levels of core AN symptoms, which is consistent with our 
earlier findings (Van den Eynde, Guillaume, et al., 2013). However, across most 
measures of psychopathology, there was also an indication of placebo effects 
(Chapter 3.3). Real rTMS increased the liking of specific foods (sweet biscuits) 
whilst sham decreased it; however, this was not associated with any changes in 
food intake (Chapter 3.4). Unlike findings from studies of other psychiatric 
disorders, including BN (Claudino et al., 2011), salivary cortisol concentrations 
were not altered following rTMS in AN (Chapter 3.5). In contrast to another 
report (Khedr, El Fetoh, et al., 2014), the AN participants in the present study 
demonstrated reduced levels of cortical excitability and these were associated 
with worse symptomatology (Chapter 3.6). Finally, this study provides further 
evidence that rTMS is a safe, well-tolerated and acceptable form of treatment in 
AN (Chapter 3.7). Whilst the present RCT was underpowered, it provides proof-
of-principle of the therapeutic potential of rTMS in AN.  
Since rTMS has been shown to improve symptoms in AN, we aimed to assess 
whether these effects were underpinned by the ability of rTMS to reduce 
excessive cognitive control (Figner et al., 2010) proposed to be involved in AN 
(Steinglass et al., 2012). Compared to sham, real rTMS reduced the discounting 
of future monetary rewards, i.e. encouraged more prudent decision making 
(Chapter 4). These findings were the opposite of what was hypothesised. They 
suggest that the effects of rTMS on symptoms of AN may rely on its ability to 
improve control over AN symptoms/behaviours rather than reducing excessive 
‘self-control’ specifically.  
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Hypothesis 4 concerning the therapeutic utility of rTMS in AN was tested in a 
case series of five patients with enduring AN (Chapter 5). Following 20 daily 
sessions of neuronavigated rTMS, improvements in ED and general 
psychopathology were found and these were sustained for at least 6 months. 
However, these improvements were not associated with weight gain. The 
chronicity, severity and treatment-resistance of participants’ illness are likely to 
have accounted for the lack of rTMS effects on weight gain. At the same time it 
probably also diminished the possibility of a placebo response in these 
individuals and suggests that despite the unblinded, open-label nature of the 
intervention, effects on ED symptoms are general psychopathology were ‘real’.  
Strengths 
The main strengths of the research are the improved and novel methodologies 
employed. Unlike other studies in ED, it used more accurate methods of 
delivering rTMS. This included studying MEP to estimate MT: this is argued to be 
more accurate, conservative and safer than previously employed methods (Rossi 
et al., 2009). Moreover, all rTMS was delivered using neuronavigation and 
therefore is expected to have stimulated the left DLPFC more accurately and 
effectively than studies that used the 5cm anterior DLPFC location method 
(Fitzgerald et al., 2009). Finally, this research examined novel aspects of the 
effects of neuromodulation in ED that have not previously been considered. For 
example, the study examined how rTMS alters hedonic drives such as the liking 
of food in AN. It also investigated cortical excitability. It is the first research in ED 
to report changes on a neuropsychological outcome, intertemporal choice, 
following rTMS. These elements all improve methodology and underlying theory 
and pave the way for future research.  
Limitations 
Sample 
The inclusion criteria for participants to take part in the research reported in 
this thesis were narrow and therefore limit the generalisability of findings. For 
example, the minimum BMI requirement was adopted for safety reasons 
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however, this reduces the ability to extrapolate findings to individuals with AN 
who are severely underweight.  
The participants had enduring forms of AN and had an average illness duration 
of over 10 years. This may reflect the type of individual willing to engage in the 
study; i.e. it is likely that individuals who are interested in participating in 
research on alternative and novel approaches to AN (such as rTMS) have had 
unsuccessful attempts at other, more conventional treatments. This 
compromises the generalisability of the findings to less severe/less chronic 
forms of AN. However, as rTMS is recommended as a second-line treatment for 
depression (Gaynes et al., 2014) it is likely that, if proved efficacious, this would 
also be the case for AN, i.e. it would not be used before some type of ‘talking’ 
therapy was attempted.  
Given the instability and diagnostic flux in ED (Milos et al., 2005), phenotypical 
and diagnostic considerations are important. Moreover, symptomatology such as 
binge-eating and dietary restraint have been proposed to arise from different 
neural mechanisms (Brooks et al., 2012). With regards to AN, the effects of 
neuromodulation on specific symptoms may be more effectively evaluated via 
research on isolated AN subtypes, or alternatively, studies that are adequately 
powered to compare effects within and between subtypes. This point is 
demonstrated in the current research, as the AN subtypes differed in symptom 
severity.  
Methodology 
Although a double-blind RCT design was employed, i.e. both participants and 
researchers (who administered the pre/post rTMS measures) were unaware of 
intervention allocation, it was not feasible for the researcher applying rTMS to be 
blinded. As participant blinding was only partially successful it is possible that 
implicit cues may have impacted upon blinding success. This point is emphasised 
by the data, which suggest that participants were surer than researchers (who 
were out of the room during rTMS procedures) as to which intervention they 
had. Also, a lot of individuals were recruited from the same outpatient 
department; therefore communication between participants about the study 
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may have impacted both the primary outcomes and blinding success of this 
research. Moreover, real rTMS was reported as significantly more uncomfortable 
than sham and this is likely to have impacted the ability to correctly guess 
stimulation type. The inability of current sham techniques to adequately mimic 
real rTMS is a methodological limitation in rTMS research. 
The randomisation procedure was stratified by AN diagnoses. However, 
compared to the sham group, those in the real rTMS group had reduced initial 
rates of psychopathology. This was by chance and is likely to be a reflection of 
the increased proportion of binge/purge subtypes in the sham group who (as a 
group) reported worse symptomatology. Whilst these differences between 
real/sham groups were not significant immediately prior to rTMS, they must be 
considered when interpreting the findings. Moreover, this supports the case for 
studying AN subtypes independently, given their characteristic differences in 
symptomatology.  
A recent study utilising multiple measures reported heightened excitability in 
AN, one of which was resting MT (Khedr, El Fetoh, et al., 2014). The present 
study is limited to this single measure of cortical excitability and reports reduced 
rates compared to those reported by Khedr, El Fetoh, et al. (2014) and this was 
associated with worse symptomatology (i.e. lower BMI and increased EDE-Q 
scores). No other study on the effects of rTMS on ED symptoms has reported this 
measure. In addition to providing information on cortical activity in ED, it is also 
an important safety consideration with regards to the increased 
susceptibility/risk of seizure.  
This research lacked a HC comparison group, which would have been 
particularly useful in regards to both cortical excitability and rates of TD. 
Moreover, our TD task did not differentiate the way in which it frames reward 
choices and this may have hampered its ability to thoroughly capture 
discounting behaviour in AN. For example, unlike Steinglass et al. (2012), we did 
not observe differences in TD between AN subtypes. 
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Implications of this research 
This study demonstrates the potential of neuromodulatory tools in improving ED 
related symptoms. Specifically, compared to sham, a single-session of real rTMS 
was shown to lead to reduced AN symptoms and it also demonstrated long-term, 
therapeutic potential. Moreover, real rTMS altered intertemporal choice 
behaviour in AN – increasing prudent, controlled choices – which may act as a 
neuropsychological marker of response to rTMS in AN.  
The present findings suggest that rTMS alters the neurocircuitry associated with 
AN, especially those that contribute to difficulties in self-regulatory control. 
Neuroplasticity may play a role in these therapeutic effects (Gersner et al., 2011). 
Specifically, modulation of BDNF (Fidalgo et al., 2014; Zanardini et al., 2006) 
along with alterations in the concentration of the neurotransmitters dopamine 
(Cho et al., 2014; Cho & Strafella, 2009) and serotonin (Baeken et al., 2011) have 
been reported following rTMS in depression. Given reported alterations in the 
levels of these substances in AN (Brandys et al., 2011; Phillipou et al., 2014), 
their modulation via rTMS may contribute to effects on symptomatology.  
Excessive cognitive control is often proposed to underlie AN, manifesting in ‘self-
controlled’ behaviours such as dietary restraint (Kaye et al., 2009; Steinglass et 
al., 2012). Preliminary data suggest that prudent decision making is reduced 
following rTMS in healthy people (Figner et al., 2010) and therefore we proposed 
that this might underlie the therapeutic effects of rTMS in AN. However, the 
results of the present research suggest that activating the PFC promotes 
controlled decision making in AN, whilst also improving symptoms. Therefore, 
the concept of ‘excessive cognitive control’ and its effects on symptoms in AN is 
questionable. Rather, it is possible that individuals with AN may lack control 
over what are typically perceived as ‘self-controlled’ symptoms, such as dietary 
restraint. Therefore, rTMS may alter the neurocircuitry underlying self-
regulatory control difficulties and subsequently improve control over 
compulsive, ED habitual symptoms/behaviours. This is schematically presented 
in Figure 6.1; an AN-specific amendment of the diagram described in Chapter 1 
that incorporates findings from the present research. Specifically, the altered 
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neurocircuitry hypothesised to be present in AN may not lead to extreme self-
control per se, but to an impaired ability to control ED behaviours such as food 
restriction and levels of feeling full/fat. Activating the DLPFC with rTMS may 
alter activity in this and related areas, resulting in improvements in self-
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Figure 6.1 An amended version of the figure presented in Chapter 1 that incorporates the findings from this research.  
INCREASED SENSITIVITY IN ADOLESCENCE 
(hormonal changes, stress, peer relationships, brain development) 
 
 
ALTERED FRONTOSTRIATAL CIRCUITRY 
Limbic structures (emotional salience, reward, fear) & frontoparietal regions (cognitive control) 
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ED cognitions & behaviours become learned & automatic via neuroplasticity & thus 
increasingly resistant to change. 
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rTMS improves symptomatology in AN & encourages prudent decision making  
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Directions for future research and clinical implications 
Repetitive transcranial magnetic stimulation in anorexia nervosa 
The proof-of-principle of rTMS as a potential adjunct to treatment in AN was 
demonstrated in the RCT and in the small uncontrolled case series. However, 
before rTMS is considered as either a stand-alone or adjunctive treatment 
option for adults with AN, these preliminary findings need to be consolidated, 
extended and replicated. For example, the superior short-term efficacy of real 
(as opposed to sham) rTMS in reducing AN symptoms reported here needs to be 
replicated. In addition, a sham-controlled therapeutic RCT of rTMS in AN would 
shed more definitive light on its therapeutic efficacy and clinical value. 
Future research on rTMS in AN needs to determine optimal stimulation 
protocols. For example, the importance of using excitatory (HF)/inhibitory (LF) 
rTMS, the role of hemispheric lateralisation and optimal targets remain 
undefined. Moreover, therapeutic trials with pre- and post-neuroimaging 
assessments would probe neural models of AN and enable an exploration of 
possible biomarkers of response to rTMS in AN, along with providing a clearer 
understanding of rTMS induced neural changes in AN. Finally, whether or not 
rTMS is optimal as a stand-alone or as an adjunct to other treatments needs to 
be established, as does the efficacy of rTMS in different types (binge/purge and 
restrictive) and stages (early/enduring and treatment resistant) of AN.  
Temporal discounting in eating disorders 
Differences in TD across the spectrum of ED, and the association of TD with ED 
symptomatology are poorly understood. Data are limited to a small number of 
studies in obesity, BED and AN. Therefore, future studies are needed that 
compare TD across the spectrum of ED to elucidate whether this construct is 
sensitive to diagnostic and symptom differences in ED. Similarly, the neural 
correlates of TD require further clarification as well as the effects of 
neuromodulation on TD behaviour. Further research is needed in order to 
understand the utility of TD tasks in relation to ED and the neural correlates of 
intertemporal choice in order to develop tailored neuromodulation protocols.  
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Neuromodulation in eating disorders 
Other than rTMS, there is a range of established and emerging neuromodulatory 
techniques. Within each lie a variety of protocol parameters – e.g. 
excitatory/inhibitory effects, increased depth/strength of stimulation etc. Given 
this, there is an increased need to refine brain-directed interventions for 
specific diagnoses and symptomatology in ED. Future research should be based 
on neuroimaging data. Thus, a clearer understanding of the role of specific brain 
structures and their connectivity with other key regions will contribute to the 
refinement and optimisation of neuromodulation protocols. Moreover, 
combined neuroimaging and neuromodulation protocols are needed to probe 
disease mechanisms and identify biomarkers of response (Fidalgo et al., 2014; 
Grefkes & Fink, 2009).  
Ethical and clinical considerations 
Ethical considerations regarding to the use of neuromodulation as treatments 
for ED must go beyond efficacy and safety (Synofzik & Schlaepfer, 2010). 
Although individuals with AN are open and positive about brain-directed 
treatments, questions remain regarding respect for autonomy i.e. the ability for 
informed consent, authenticity/agency i.e. self-perception and understanding 
the role of the self within the illness, and self-efficacy (Coman, 2014; Coman, 
Skarderud, Reas, & Hofmann, 2014).  
Whilst such ethical debates and the research reported in this thesis suggest that 
rTMS is viewed as an acceptable form of treatment by individuals with AN, 
earlier generations of brain-directed treatments (such as ECT or surgical 
interventions e.g. lobotomy) for psychiatric illnesses have been controversial 
because of serious side-effects and their irreversible nature (Synofzik & 
Schlaepfer, 2010). In order to progress research, it is important to further 
establish patients, carers and clinician’s views on the use of neuromodulation in 
ED. Resources/discussions which provide easily understandable information 
regarding the rationale behind the use of neuromodulation in ED may help to 
bridge the gap between scientists and clinicians/patients and thus encourage 
more high-quality research into the clinical utility of neuromodulation in ED.  
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Conclusions 
In this thesis I have reviewed the field of ED and proposed neurocircuit based 
aetiological models, which highlight the need for brain-directed interventions. 
The systematic review of the effects of neuromodulation on ED related 
outcomes supports the empirical nature of this thesis. The RCT demonstrates 
that compared to sham, real rTMS leads to reduced AN symptoms, alters food 
preferences, does not alter biological stress responses, provides a valid and 
useful measure of cortical excitability and is safe, tolerable and acceptable in 
AN. Additionally, real rTMS alters intertemporal choice behaviour, which may 
imply that rTMS leads to increased control over symptoms in AN. Finally, the 
data regarding five cases of enduring AN suggest that rTMS induces sustained 
improvements in ED and general psychopathology. As a whole, this thesis adds 
to the growing evidence supporting the need and utility of brain-directed 
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Appendix C: Participant information sheets 



























Appendix D: Participant consent forms 










Appendix E: Screening/baseline-1 documents  
Appendix E.1 Demographic information questionnaire 
1. Have you been diagnosed with an eating disorder? 
 
… what is your current diagnosis/symptomatology?  
 
 









3. Have you been diagnosed with another psychiatric disorder(s)? 





4. Have you had any significant health problems in past 6 months? 






5. Have you ever had any neurological disease (eg stroke), brain or eye 
injury or any brain surgery? 





6. Do you experience regular headaches, migraines, dizzy or fainting 
spells, double or blurred vision, numbness or tingling, or problems with 
balance?  





7. Have you had blood tests done in the past month? 






8. Do you smoke more than 10 cigarettes/day? 
 
YES NO 
9. How much alcohol do you drink?  
….. if YES what type? (eg. wine, beer, spirits) 
 
 
……..days/wk      
……..drinks/day 





11. Are you currently taking any medication? 





12. Are you currently receiving any psychological/psychiatric treatment? 
 
…if YES are you happy for us to inform them of your participation? 
 
…if YES please provide their name and contact details 
 











13. Do you have a current GP? 
 
…if YES are you happy to provide their details in case of an emergency? 
 










14. Within the past 6 months have you had any suicidal ideation? 
 











Appendix E.2 Eating Disorder Diagnostic Scale (EDDS) 
Over the past 3 months…   
  Not at all     Slightly     Moderately     Extremely 
1. Have you felt fat?    0 1 2 3 4 5 6 
2. Have you had a definite fear that you might gain weight or become fat?   
     0 1 2 3 4 5 6 
3. Has your weight influenced how you think about (judge) yourself as a person? 
     0 1 2 3 4 5 6 
4. Has your shape influenced how you think about (judge) yourself as a person?  
     0 1 2 3 4 5 6 
 
5. During the past 6 months have there been times when you felt you have eaten 
what other people would regard as an unusually large amount of food (e.g., a quart 
of ice cream) given the circumstances?  YES  NO 
 
6. During the times when you ate an unusually large amount of food, did you 
experience a loss of control (feel you couldn't stop eating or control what or how 
much you were eating)?    YES NO 
 
7. How many days per week on average over the past 6 months have you eaten an 
unusually large amount of food and experienced a loss of control?   
0 1 2 3 4 5 6 7 
 
8. How many times per week on average over the past 3 months have you eaten an 
unusually large amount of food and experienced a loss of control?  
0 1 2 3 4 5 6 7 8 9 10 11 
12 13 14 
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During these episodes of overeating and loss of control did you… 
9. Eat much more rapidly than normal?  YES  NO 
10. Eat until you felt uncomfortably full?  YES  NO 
11. Eat large amounts of food when you didn't feel physically hungry?  
       YES          NO 
12. Eat alone because you were embarrassed by how much you were eating?  
       YES   NO 
13. Feel disgusted with yourself, depressed, or very guilty after overeating?  
       YES  NO 
14. Feel very upset about your uncontrollable overeating or resulting weight gain? 
       YES  NO 
15. How many times per week on average over the past 3 months have you made 
yourself vomit to prevent weight gain or counteract the effects of eating?  
0 1 2 3 4 5 6 7 8 9 10 11 
12 13  14 
 
16. How many times per week on average over the past 3 months have you used 
laxatives or diuretics to prevent weight gain or counteract the effects of eating?  
0 1 2 3 4 5 6 7 8 9 10 11 
12 13 14 
 
17. How many times per week on average over the past 3 months have you fasted 
(skipped at least 2 meals in a row) to prevent weight gain or counteract the effects 
of eating? 0 1 2 3 4 5 6 7 8 9 
10 11 12 13 14 
 
18. How many times per week on average over the past 3 months have you 
engaged in excessive exercise specifically to counteract the effects of overeating 
episodes? 0 1 2 3 4 5 6 7 8 9 
10 11 12 13 14 
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19. How much do you weigh? If uncertain, please give your best estimate.  
     lbs. 
 
20. How tall are you? _Please specify in inches (5 ft.= 60 in.) 
     in. 
  
21. Over the past 3 months, how many menstrual periods have you missed?  
0 1 2 3 n/a 
 
22. Have you been taking birth control pills during the past 3 months? 
YES  NO 
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Appendix E.4 Centre for Neuroimaging Science MRI safety screening 
 
 




PLEASE USE BLOCK CAPITALS TO COMPLETE THE FORM 
 
Surname     …………………….…… Forenames  …………………… Mr/Mrs/Miss/Ms 
Address       …………………………………..…..  
                    .…………..………………………...….            Ward……………………… 
                    ……………………………….…….……… 
NHS number …………………………… Hospital number……………………….…... 



















Check List (please circle) 
 











Pacemaker?                                                          Y/N 
Vascular Clips?                                                             Y/N 
Metal in Eyes?                                                               Y/N 
Is Subject Pregnant?                                                      Y/N 
Is Subject Claustrophobic?                                           Y/N 
Does Subject have impaired Hearing?                         Y/N 
Does Subject have Impaired Eyesight                          Y/N 
 
For further advice on foreign bodies or other MR safety 




ICD Code (if known)…………………IQ / NART ……..                              Left School with no qualifications    
Age of onset of Current Symptoms………………………                             Left School with qualifications         
Age of onset of First Symptoms…………………………                              Left School post higher education     
Family History of Psychiatric Illness                               Y  N  DK             
Possible Dementia                                                             Y  N  DK     MMSE score……………………………. 
Past History of Head Trauma Requiring Hospitalisation  Y  N  DK      
Other disorder (please specify)…………………………………………………………………………………………………………… 
Symptoms (current or most recent episode) 
Hallucinations                                                                        Y  N  DK  
Delusions                                                                               Y  N  DK  
Thought disorder                                                                   Y  N  DK  
Thought broadcasting                                                            Y  N  DK  
                   Withdrawal                                                         Y  N  DK  
                    Insertion                                                             Y  N  DK  
 
Elevated Mood                                                                       Y  N  DK  
Negative mood                                                                       Y  N  DK  
Anxiety/Panic                                                                         Y  N  DK  
PTSD                                                                                      Y  N  DK  
 
History of Alcohol abuse    Y  N  DK  
History of Drug Abuse        Y  N  DK  
 
Autism spectrum: 
Social                                   Y  N  DK  
Repetitive                             Y  N  DK  
Communicative                   Y  N  DK  
       Symptoms……………………………. 
Learning disability               Y  N  DK  
Inattentiveness                     Y  N  DK  
Overactivity                         Y  N  DK  










P.I. on Ethics Approval  
 
 






























Appendix E.5 Transcranial magnetic stimulation adult safety screen 





Please answer the following: 
Are you right handed?      Yes     No 
Have you ever:  
Had an adverse reaction to TMS?      Yes     No 
Had a seizure?        Yes     No 
Had an electroencephalogram (EEG)?     Yes     No 
Had a stroke?         Yes     No
Had a serious head injury (include neurosurgery)?   Yes     No 
Do you have any metal in your head (outside the mouth)  
such as shrapnel, surgical clips, or fragments from welding  
or metalwork?       Yes     No 
Do you have any implanted devices such  
as cardiac pacemakers, medical pumps, or intracardiac lines?Yes     No 
Do you suffer from frequent or severe headaches?  Yes     No 
Have you ever had any other brain-related condition?   Yes     No 
Have you ever had any illness that caused brain injury?  Yes     No
Are you taking any medications?      Yes     No
If you are a woman of childbearing age, are you sexually  
active, and if so, are you not using a reliable method of birth control?
         Yes     No 
Does anyone in your family have epilepsy?    Yes     No 
Do you need further explanation of TMS and its associated risks? Yes     No 
 
If you answered yes to any of the above, please provide details (use reverse if 
necessary): 
________________________________________________________________________ 
Keel JC, July 2000 
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Appendix F: Self-report questionnaires 











Appendix F.2 Depression, anxiety and stress scale (DASS-21) 
 350 
Appendix G: Visual analogue scales (VAS) 
Appendix G.1 The ‘initial’ VAS collected throughout the randomised control 




Appendix G.2 The ‘additional’ VAS collected during FCT immediately pre and 
post rTMS in the randomised control trial 
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Appendix G.3 The ‘food related’ VAS collected during the FCT immediately 








Appendix H: Tasks and measures 
Appendix H.1 Instructions and screen shots of the food challenge task (FCT) 
Instructions: 
You will now be presented with two short video clips of people eating a variety 
of foods including crisps, chocolate, biscuits and nuts. These same foods will 
also be present in the room. After viewing the video and looking at the foods 
presented in front of you, please rate each food according to their appearance, 
smell, taste and your current urge to eat them.  



















Appendix H.2 Instructions and screen shots of the temporal discounting (TD) 
task 
Instructions: 
You will now be asked to complete a short, computerised task which requires 
you to choose between a hypothetical, smaller amount of money immediately or 
a larger amount of money at a later date. Please try to make a decision which 
would most accurately reflect how you would behave if you were presented 
with such a choice in reality. Please press the left mouse button to choose the 
immediate value of money offered, and the right mouse button to choose the 
amount offered in the future. If you have any questions at this point please don’t 
hesitate to ask one of the researchers.  








Appendix H.3 Instructions for the collection of saliva samples 
 
 358 
Appendix I: Other information 
Appendix I.1 Standard explanations of TMS given to participants in the RCT 
This is the device that generates the localised magnetic waves that are used to 
stimulate the brain. In this coil, there is an electric current that generates a 
magnetic field. It is important for you to know that you will not be in contact 
with the electric current as it runs inside the coil. To deliver the magnetic waves 
to the brain, this coil will be held against your head. TMS is a safe technique 
however, some people have found receiving rTMS to be a bit uncomfortable. It is 
important for you to know that the effects vary markedly between individuals 
and that both people who received sham (a placebo) or real rTMS have reported 
a range of experiences. These experiences range from ‘feeling nothing at all’ to a 
strong ‘tapping’ or ‘woodpecker’ sensation. Most of the people who reported 
these effects stated that it got less uncomfortable during the duration of the 
session.  
There are two part to the stimulation section of the study: 1) stimulating your 
motor cortex and 2) delivery of the rTMS. Firstly, in order to know where to 
hold the coil in relation to your brain in particular we need to register the image 
gained from the MRI scan you had previously, to where you are seated 
currently. This is somewhat like how a satnav works – we need to tell the 
computer where you and the coil are so that it can relate this information to the 
picture of your brain we gained from the MRI scan. You will be required to wear 
a headband in order to do this, please try not to move this headband once it is in 
place. 
1) Motor cortex: In the first section we will locate a part of the brain that is 
called the motor cortex. We are aiming to find the spot on the left side of your 
skull that, if we stimulate it, will activate the muscles in your right hand. When 
we are looking for this area you will hear a clicking sound from time to time. 
Every click represents a single stimulation pulse with magnetic waves. The 
reason we need to do this is because the ‘excitability’ of people’s brain differs 
between individuals. This allows us to find the lowest possible intensity on an 
individual basis with which we can stimulate your brain in the second part of 
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the session. Sometimes this process can take a little time which is completely 
normal.  
2) rTMS session: After stimulating the motor cortex, we will begin the rTMS 
session to the left frontal part of the brain. You will now hear the same clicking 
sound but in shorter more rapid bursts. These are what we call ‘trains’ of 
stimulation – they last for 5 seconds and there is a 55 second break in between 
each train. You will receive 20 trains like this, therefore this part of the session 
will last for approximately 20 minutes. We will always let you know when the 
next train is about to start by counting down from 5 seconds. Please do not close 
your eyes during the delivery of the stimulation. 
Halfway through the stimulation session we will take your blood pressure and 
pulse. There is, in our experience, no evidence that rTMS affects blood pressure 
or pulse changes. This is just an additional safety measure. One thing that may 
happen during the stimulation session is that the coil may warm up. This is 
never to a degree that it would hurt you, but there is an inbuilt safety 
mechanism in the machine that stops it from working when it gets hot. If that 
were to happen, we will need to change the coils. When we do this it is 
important for you to know that the condition (real or sham rTMS) will not be 
changed - the coil will just be replaced by a similar coil. 
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Appendix I.2 Personal instructions for Brainsight® neuronavigation set-up 
1. Find scans from dougal, put all in basket, use cyberduck 
(/data/blinded/CNSCNSA) to download onto desktop 
 
2. Select anatomical data set (participants MRI) 
o Click file chooser (green) 
o Accepts NIfTI, DICOM, PAR?REC, Analyse files 
o Mini brain scan image will appear, select one file 
 
3. Co-register with Talairach space: 
o Chose new,  manual AC-PC option 
o Find and mark AC/PC (see diagram) select next step 
o Make bounding box to include edges of brain 
o Make sure AC/PC and callosum lines up, make any adjustments 
then click finish 
 
4.  ROIs/Overlays: N/A (overlays for use with fMRI data) 
5. Reconstructions: 
o new, skin (include whole head in box, make sure nose is in 
picture), exit 
o new, curviliniear/brain reconstruction (include just brain in box, 
in order to see detailed brain anatomy/sulci use peel), exit  
 
6. Anatomical landmarks: 
o Select homologous anatomical landmarks for participants 
 new, nose bridge, set crosshairs 
 new, nose tip, set crosshairs 
 new, right ear, set crosshairs 
 new, left ear, set crosshairs (remember to account for 
earplugs with ear tragus so put slightly in front)  
 
7. Configure targets: 
o new, name leftDLPFC, use trajectory  
o Enter Talairach co-ordinates:  
 x = - 45, y = 45, z = 35 (based on Fitzgerald (2009): 
between centre BA9/border BA46) and name marker 
leftDLPFC 
o Ensure trajectory marker is lined up correctly too(green cone 
should line up on red marker), set crosshairs  
o SAVE PROJECT! (so that target is saved, set to cross hairs)  
 
